Conditions: Hypercholesterolemia Acute Coronary Syndrome
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 206
Healthy volunteers: no

Brief summary:
Primary Objective:

To compare the efficacy of alirocumab (Praluent®) with standard of care (SoC) on coronary atheroma progression (percent change in normalized total atheroma volume \[TAV\]) after 9 months of treatment in participants who had acute coronary syndrome (ACS) within 4 weeks prior to randomization, with hypercholesterolemia treated with statin.

Secondary Objectives:

* To compare the efficacy of alirocumab (Praluent®) with SoC on secondary endpoints including absolute change in percent atheroma volume and normalized TAV after 9 months of treatment.
* To evaluate the efficacy of alirocumab (Praluent®) on low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, triglycerides, non-high-density lipoprotein cholesterol and lipoprotein (a) after 9 months treatment.
* To evaluate the safety of alirocumab (Praluent®) including the occurrence of cardiovascular events (coronary heart disease death, non-fatal myocardial infarction, fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization) throughout the study.

Detailed description:
The duration of study per participant was 9 months.

Arms:
arm 1: Statin therapy (atorvastatin or rosuvastatin) will be administered with or without non-statin lipid modifying therapies (LMTs). Non-statin LMTs will be adjusted by physicians to achieve the LDL-C target level \<100 milligrams per deciliter (mg/dL). arm 2: Alirocumab will be given subcutaneously every 2 weeks on top of stable dose statin therapy (atorvastatin or rosuvastatin) with or without stable dose non-statin LMTs.

Interventions: intervention 1: Alirocumab SAR236553 intervention 2: Atorvastatin intervention 3: Rosuvastatin intervention 4: Fenofibrate intervention 5: Bezafibrate intervention 6: Ezetimibe intervention 7: Antiplatelets intervention 8: Anticoagulants
Intervention descriptions: intervention 1: Pharmaceutical form: Solution for injection

Route of administration: Subcutaneous intervention 2: Pharmaceutical form: tablet

Route of administration: oral intervention 3: Pharmaceutical form: tablet

Route of administration: oral intervention 4: Pharmaceutical form: tablet

Route of administration: oral intervention 5: Pharmaceutical form: tablet

Route of administration: oral intervention 6: Pharmaceutical form: tablet

Route of administration: oral intervention 7: Pharmaceutical form: tablet or capsule

Route of administration: oral intervention 8: Pharmaceutical form: tablet or capsule

Route of administration: oral

Protocol document:
Prot_000.pdf: 
Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of Sanofi (or any of its 
affiliated companies). The use of such confidential information must be restricted to the recipient for the agreed purpose and must not be 
disclosed, published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without the prior written 
consent of Sanofi (or the concerned affiliated company); ‘affiliated company’ means any corporation, partnership or other entity which at the date 
of communication or afterwards (i) controls directly or indirectly Sanofi, (ii) is directly or indirectly controlled by Sanofi, with ‘control’ meaning 
direct or indirect ownership of more than 50% of the capital stock or the voting rights in such corporation, partnership or other entity
According to template: QSD-002579 VERSION N°14.0 (04-FEB-2016)
Page 1
Translation of Original 
Japanese Document
AMENDED CLINICAL TRIAL PROTOCOL NO. 3
COMPOUND: Alirocumab
TITLE : A randomized, open-label, blinded intravascular ultrasound analysis, 
parallel group, multicenter study to evaluate the effect of Praluent® (alirocumab)
on coronary atheroma volume in Japanese patients hospitalized for acute 
coronary syndrome with hypercholesterolemia not adequately controlled with 
statin
STUDY NUMBER: ALIROL08069
STUDY NAME: ODYSSEY J-IVUS
VERSION DATE/ STATUS: 21-Nov-2017/ Final
Protocol Amendment 3
Version number: 1 (electronic 1.0)
Date: 21-Nov-2017
Amended Clinical Trial Protocol 2
Version number: 1 (electronic 1.0)
Date: 03-Apr-2017
Protocol Amendment 2
Version number: 1 (electronic 1.0)
Date: 03-Apr-2017
Amended Clinical Trial Protocol 1
Version number: 1 (electronic 1.0)
Date: 19-Aug-2016
Protocol Amendment 1
Version number: 1 (electronic 1.0)
Date: 19-Aug-2016
Clinical Trial Protocol
Version number: 1 (electronic 1.0)
Date: 07-Jul-2016
Version Number:
Amended 3
EudraCT 
Not applicable
IND Number(s)
Not applicable
Date:
21-Nov-2017
Total number of pages:
105
This is English translation of the original Japanese version of amended clinical trial protocol no. 3.
(electronic 1.0)
NCT Number:NCT02984982


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 2
NAMES AND ADDRESSES OF
STEERING COMMITTEE
Name:
Address:
Tel:
Fax:
E-mail:
Described in attachment
MONITORING TEAM’S 
REPRESENTATIVE
Name:
Address:
Tel:
Fax:
E-mail:
Described in attachment
SPONSOR
Company:
Address:
Described in attachment
OTHER EMERGENCY 
TELEPHONE NUMBERS
Described in attachment
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 3
CLINICAL TRIAL SUMMARY
COMPOUND: PRALUENT® (Alirocumab)
STUDY No.: ALIROL08069
STUDY NAME: ODYSSEY J-IVUS
TITLE
A randomized, open-label, blinded intravascular ultrasound analysis, 
parallel group, multicenter study to evaluate the effect of Praluent®
(alirocumab) on coronary atheroma volume in Japanese patients 
hospitalized for acute coronary syndrome with hypercholesterolemia 
not adequately controlled with statin
INVESTIGATOR/TRIAL LOCATION
JAPAN – Multicenter study
PHASE OF DEVELOPMENT
Phase 4
STUDY OBJECTIVE(S)
Primary objective:
To compare the effect of Praluent® with standard of care (SoC) on 
coronary atheroma progression (percent change in normalized total 
atheroma volume [TAV]) after 9 months of treatment in patients who 
had acute coronary syndrome (ACS) within 4 weeks prior to 
randomization, with hypercholesterolemia treated with any statin
Secondary objective(s):

To compare the effect of Praluent® with SoC on secondary 
endpoints including absolute change in percent atheroma 
volume (PAV) and normalized TAV after 9 months of
treatment

To evaluate the effect of Praluent® on low-density 
lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), 
triglycerides, non-high-density lipoprotein cholesterol 
(non-HDL-C) and Lipoprotein(a)(Lp(a)) after 9 months 
treatment

To evaluate the safety of Praluent® including the 
occurrence of cardiovascular (CV) events (coronary heart 
disease [CHD] death, non-fatal myocardial infarction [MI], 
fatal and non-fatal ischemic stroke, unstable angina 
requiring hospitalization) throughout the study
STUDY DESIGN
Open-label, 1:1 randomized, blinded intravascular ultrasound (IVUS)
analysis, 2-arm, parallel-group, multicenter study
Randomization will be stratified by on statin therapy or not on statin 
therapy at the time of ACS onset.
After randomization, patients will receive open-label study treatment 
of Praluent® 75 mg every 2 weeks (Q2W) on top of stable daily statin 
therapy for 36 weeks, or SoC. For patients randomized to 
alirocumab arm, a dose up-titration to Praluent® 150 mg Q2W may
be conducted at Week 14 based on LDL-C level at Week 12 (see 
below). For patients randomized to SoC arm, LDL-C target level 
<100 mg/dL is achieved with stable dose statin therapy (within the 
range of statin doses approved by the Health Authority) ± other lipid 
modifying therapies (LMTs) except for anti-PCSK9 monoclonal 
antibody. Concomitant non-statin LMTs will be considered if LDL-C 
target level <100 mg/dL cannot be achieved with statin monotherapy.
LDL-C is managed to achieve target level <100 mg/dL using the 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 4
above mentioned or other method.
The study consists of:

A 36-week open label treatment period (study period)

During the study period, patients randomized to 
alirocumab or SoC arm will receive treatment in an un-
blinded manner as follows.
1.
Alirocumab arm;

Praluent® (alirocumab) 75 mg Q2W subcutaneously on top 
of statin therapy (atorvastatin ≥10 mg/day or rosuvastatin 
≥5 mg/day) within the range of statin doses approved by 
the Health Authority.

Statin (atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day
within the range of statin doses approved by the Health 
Authority) and non-statin LMTs will be continued at the 
same doses after ACS diagnosis unless modifications are 
necessary. The target LDL-C level is <100 mg/dL.

At Week 14, patients randomized to alirocumab arm will, in 
an un-blinded manner, either:
-
Continue receiving Praluent® (alirocumab) 75 mg Q2W if 
the Week 12 LDL-C measured by the central laboratory is 
<100 mg/dL OR
-
Receive dose up-titrated to Praluent® (alirocumab) 150 mg 
Q2W at Week 14, if the Week 12 LDL-C measured by the 
central laboratory is ≥100 mg/dL.
Continuation of Praluent® 75 mg Q2W or dose up-titration 
to Praluent® 150 mg Q2W will occur at each study site 
based on the rules as above.

Self-injection of Praluent® (alirocumab) at home
-
Patients can choose self-injection at home any time, if they 
wish self-injection at home and the Investigator or sub-
Investigator considers it feasible.  
-
Patients are allowed to perform self-injection at home if they
successfully perform the correct self-injection of Praluent®
(alirocumab) under the direct supervision of site medical 
staff at the site once, and the Investigator or sub-
Investigator considers that they can perform self-injection at 
home correctly.
-
Regardless of the timing when the self-injection is started, 
patients must visit the study site at least every 4 weeks, and 
at Week 0, Week 4, Week 12, Week 14, Week 24 and 
Week 36.
-
Patients can discontinue self-injection at home any time. 
The Investigator or sub-Investigator must have patients
discontinue self-injection at home if the Investigator or sub-
Investigator judges that the patients are not able to perform
self-injection at home correctly. Patients who discontinue 
self-injection at home can have injections performed by 
medical staff at the study site. 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 5
2.
Standard of Care arm;

During the study period, patients randomized to the SoC
arm will, in an un-blinded manner, receive either:
-
Stable dose statin therapy of either atorvastatin ≥10 mg/day
or rosuvastatin ≥5 mg/day (within the range of statin doses
approved by the Health Authority) to achieve the LDL-C 
target level <100 mg/dL. 
-
Concomitant non-statin LMTs if LDL-C target level 
<100 mg/dL cannot be achieved with statin monotherapy. 
Adjustment of LMTs is to be performed based on, but not 
limited to, the above rule.
STUDY POPULATION 
Main selection criteria
Main inclusion criteria:
I 01.
Patients hospitalized for ACS (ST-elevation myocardial 
infarction [STEMI], non ST-elevation myocardial infarction 
[NSTEMI], unstable angina).
I 02.
LDL-C ≥100 mg/dL at ACS diagnosis (either by Friedewald 
method or direct method measured at each study site),:
a)
Patients who have already been on any statin therapy
at ACS onset. If the statin is not atorvastatin or 
rosuvastatin, statin will be changed to either 
atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day 
immediately after the ACS diagnosis based on 
Investigators' medical judgment. 
b)
If patients have not been on any statin therapy at 
ACS onset, either atorvastatin 10 mg/day or 
rosuvastatin 5 mg/day is started immediately after the 
ACS diagnosis, and LDL-C is not adequately 
controlled with statin at 2 to 4 weeks after the ACS 
diagnosis (in principle, LDL-C target level
≥100 mg/dL, but this may not apply if the responsible 
physician considers the LDL-C level inadequate on
statin. Patients who have LDL-C <70 mg/dL cannot 
be enrolled).
I 03.
Patients who has stenosis of at least 50% on coronary 
angiography within 1 week after the ACS onset, and has 
analyzable coronary IVUS image. The evaluated segment 
of IVUS is a segment where a physician considers the 
IVUS imaging is possible (regardless of culprit vessels or 
not culprit vessels) other than the culprit lesions.
I 04.
Patients aged ≥20 years old at ACS diagnosis.
I 05.
Patients who meet any of the following conditions:
-
Negative hepatitis B virus surface antigen, negative 
hepatitis B virus total core antibody, and negative hepatitis 
C virus antibody.
-
Negative hepatitis B virus surface antigen, positive hepatitis 
B virus total core antibody, negative hepatitis B virus DNA,
and negative hepatitis C virus antibody.
I 06.
Written informed consent.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 6
Main exclusion criteria:
E 01.
Patients who have been previously treated with at least one 
dose of any anti-PCSK9 monoclonal antibody.
E 02.
Uncontrolled hypertension (multiple reading with systolic 
blood pressure [SBP] > 180 mmHg or diastolic blood 
pressure [DBP] >110 mmHg) between ACS diagnosis and 
randomization visit.
E 03.
Known history of hemorrhagic stroke.
E 04.
Currently under treatment with anticancer drug.
E 05.
Patients on LDL apheresis.
E 06.
Conditions/situations such as:

Any clinically significant abnormality identified that in the 
judgment of the Investigator or any sub-Investigator would 
preclude safe completion of the study or constrain 
endpoints assessment such as major systemic diseases, 
patients with short life expectancy.

Considered by the Investigator or any sub-Investigator as 
inappropriate for this study for any reason, e.g.:
-
Those deemed unable to meet specific protocol 
requirements, such as scheduled visits.
-
Investigator or any sub-Investigator, pharmacist, study 
coordinator, other study staff or relative thereof directly 
involved in the conduct of the protocol, etc.
-
Presence of any other condition (e.g., geographic, social, 
etc.) actual or anticipated, that the Investigator or sub-
Investigator feels would restrict or limit the patient's 
participation for the duration of the study.
E 07.
Laboratory findings measured before the randomization 
visit within 4 weeks after the ACS diagnosis.

Positive serum or urine pregnancy test in women of 
childbearing potential.
Total expected number of patients
200
STUDY TREATMENT(s)
SoC (stable dose statin therapy ± other LMTs targeting LDL-C
<100 mg/dL) and combination therapy (stable dose statin therapy + 
Praluent® 75 mg Q2W subcutaneously with up-titration to 150 mg
Q2W at Week 14 if LDL-C <100 mg/dL is not achieved.)
Investigational medicinal product(s)
Praluent® (Alirocumab)
Formulation:
Alirocumab, an active ingredient of Praluent®, is a fully human 
monoclonal antibody that binds PCSK9.
Praluent® will be supplied in a 1 mL autoinjector as an injectable 
drug with pH 6.0, containing histidine, polisorbate 20, and sucrose, 
with alirocumab concentration of 75 mg/mL or 150 mg/mL.
Route(s) of administration:
Subcutaneous administration to the abdomen, thighs, or outer area 
of the upper arms
Dose regimen:
Dose regimen approved in Japan: 75 mg Q2W with up-titration to 
150 mg Q2W if LDL-C <100 mg/dL is not achieved.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 7
Noninvestigational medicinal product(s)

Atorvastatin

Rosuvastatin

Cholesterol absorption inhibitor (ezetimibe)

Fibrates (fenofibrate, bezafibrate)

Anti-platelets (aspirin, clopidogrel, etc.)

Warfarin, and other oral anticoagulants approved in Japan
Route(s) of administration:
Oral
Dose regimen:
Dose regimen approved in Japan
ENDPOINT(S)
Primary efficacy endpoint:

Percent change in normalized TAV from baseline to 
Week 36
Key secondary efficacy endpoint:

Absolute change in PAV from baseline to Week 36
Other secondary efficacy endpoint(s):

Absolute change in normalized TAV from baseline to 
Week 36  

Absolute and percent change in external elastic membrane 
(EEM) volume from baseline to Week 36

Absolute and percent change in lumen volume from 
baseline to Week 36

Absolute and percent change in calculated LDL-C from 
baseline to Week12, and Week 36

Absolute and percent change in Apo B from baseline to 
Week 36

Absolute and percent change in non-HDL-C from baseline 
to Week 36

Absolute and percent change in total cholesterol (TC) from 
baseline to Week 36

Absolute and percent change in Lp(a) from baseline to 
Week 36

Absolute and percent change in HDL-C from baseline to 
Week 36

Absolute and percent change in fasting triglycerides (TGs) 
from baseline to Week 36

Absolute and percent change in apolipoprotein A-1
(Apo A-1) from baseline to Week 36
Safety endpoints:

Safety parameters (adverse events including CV events*, 
laboratory data and vital signs) assessed throughout the 
study
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 8
*CV events: CHD death, non-fatal MI, fatal and non-fatal 
ischemic and/or haemorrhagic stroke, unstable angina 
requiring hospitalization, congestive heart failure requiring 
hospitalization, ischemia-driven coronary revascularization.
ASSESSMENT SCHEDULE
Patient’s assessments in the treatment period:
On-site visits: Week 0 (randomization visit), Week 4, Week 12, 
Week 24, Week 36
STATISTICAL CONSIDERATIONS
Sample size determination:
The study is expected to enroll approximately 200 patients.
Based on the results of ZEUS(1) and PRECISE-IVUS(2) studies, 
it is assumed that difference in percent change in normalized 
TAV from baseline between alirocumab arm and SoC arm is 8%, 
and the common standard deviation of percent change in 
normalized TAV is 15%.
Under the assumption, a sample size of 150 patients (75 in the 
alirocumab arm and 75 in the SoC arm) will have 90% power to 
detect the treatment difference with two-sided significance level 
of 5%. Assuming that proportion of non-evaluable primary 
endpoint is 25%, it is considered that 200 patients (100 in the 
alirocumab arm and 100 in the SoC arm) will be needed.
Analysis population:
Randomized population includes all patients who have been 
allocated to a randomized treatment and recorded in the 
registration center database, regardless of whether a study drug 
was used or not.
The primary efficacy analysis population will be the modified 
intent-to-treat (mITT) population, defined as the randomized 
population who takes at least one dose or part of dose of study 
drug and has an available value of normalized TAV before 
randomization and after 24 weeks of treatment.
Patients in the mITT population will be analyzed according to the 
treatment arm allocated by randomization.
The safety population consists of patients of randomized 
population who actually received at least one dose or partial dose 
of study treatment. The safety population will be analyzed 
according to the treatment actually received.
Primary analysis:
The percent change in normalized TAV will be analyzed using an 
analysis of covariance (ANCOVA) model with treatment arm and 
randomization strata as fixed effects, and the baseline normalized 
TAV as covariate.
Analysis of Key secondary efficacy endpoints:
Analysis of key secondary efficacy endpoint will be performed on 
the mITT population considering corresponding baseline value as 
covariate, in the same manner as for the primary endpoint.
Multiplicity adjustment:
A hierarchical procedure will be used to control the type I error 
and to handle multiple endpoints. If the primary endpoint analysis 
is significant at the two-sided 5% alpha level, the key secondary 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 9
efficacy endpoint will be tested at the two-sided 5% level.
The other secondary efficacy endpoints not included in key 
secondary endpoint will be analyzed for exploratory purpose only.
Safety analysis:
Safety analysis will be descriptive, based on the safety 
population. Safety analysis will focus on the Treatment Emergent 
Adverse Events (TEAE) period defined as the time from the day 
of randomization to the last administration + 21 days (3 weeks), 
or end of study, whichever comes first.
The treatment arm allocation for as-treated analysis will defined 
as follows:

Alirocumab arm if proportion of IMP injection is ≥ 50%.

SoC arm if proportion of IMP injection is <50%.
where proportion of IMP injection  (%) is defined as: 
100x (Number of IMP injection)/[(Date of end of treatment - Date
of randomization)/14 + 1].
DURATION OF STUDY PERIOD (per 
patient) 
9 months
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 10
1
FLOW CHARTS
1.1
GRAPHICAL STUDY DESIGN
Abbreviations: ACS, acute coronary syndrome; IC, informed consent; IVUS, intravascular ultrasound; LDL-C, low-density lipoprotein cholesterol; LMT, lipid modifying therapy; Q2W, every 2 weeks; R, randomization; 
SoC, standard of care.
a
If patients have not been on any statin therapy at ACS onset, either atorvastatin 10 mg/day or rosuvastatin 5 mg/day is started immediately after the ACS diagnosis. 
b
At randomization, patients should have already received stable statin therapy with either atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day for at least 2 weeks.  
c
Stable dose statin monotherapy (atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day within the range of statin doses approved by the Health Authority) will be administered to achieve the LDL-C target level 
<100 mg/dL. Concomitant non-statin LMTs will be considered if patients have already been on them on top of statin monotherapy at the time of ACS diagnosis or if LDL-C target level <100 mg/dL cannot be 
achieved by the statin monotherapy. Adjusting of LMT will occur based on above rule, but not limited.
d
Praluent® 75 mg Q2W on top of stable dose of atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day ± other LMTs, in accordance with doses approved by the Health Authority. Concomitant non-statin LMTs will be 
considered if patients have already been on them on top of statin monotherapy at the time of ACS diagnosis. Background statin and/or non-statin LMT regimens should not be changed as a principle during the 
entire study period.
e
In the alirocumab arm, if LDL-C level at Week 12 measured by the central laboratory does not reach <100 mg/dL, Praluent® dose up-titration to 150 mg Q2W will be carried out at Week 14. 
f
Patients who perform self-injection of Praluent® at home must visit the study site at least every 4 weeks, and at Week 0, Week 4, Week 12, Week 14, Week 24 and Week 36.
Open-label treatment period (36 weeks) f
ACS
   Diagnosis a
N=100 
N=100
R b
Within 4 weeks
SoC arm: Standard of care (LDL-C < 100 mg/dL c)
Alirocumab arm: Background LMT + Praluent® 75 mg Q2W d
IC
Up-titration to 150 mg Q2W
when LDL-C ≥100 mg/dL e
Baseline 
IVUS
Evaluation 
IVUS
W24
W0
W36
W12
W4
(electronic 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 11
1.2
STUDY FLOW CHART
Treatment
EOT
Week (W)
W0
W2
W4
W6
W8
W10
W12
W14
W16
W18
W20
W22
W24
W26
W28
W30
W32
W34
W36
Day (D)
D1
D15
D29
D43
D57
D71
D85
D99
D113
D127
D141
D155
D169
D183
D197
D211
D225
D239
D253
Visit Number
1a
2
3
4
5
Visit Window (D)
±7
±7
±7
±14
Design
Informed consent
Xb
On-site visit
X
X
X
X
X
Inclusion criteria/ Exclusion criteria
X
Patient demography
X
Medical / family / surgical history,
alcohol habits, smoking habits
Xc
Prior medication history
X
Physical examination
X
Body weight 
X
X
X
X
Height
X
Randomization
X
Registration center contact
X
X
Treatment
Praluent® administrationm
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
(X)d
Praluent® administration window (D)
±7
±7
±7
±7
±7
±7
±7
±7
±7
±7
±7
±7
±7
±7
±7
±7
±7
Phone-call interviewe
X
X
X
X
X
Compliance check (IMP/NIMP)e
X
X
X
X
X
X
X
X
X
X
Vital signs
Heart rate 
X
X
X
X
X
Blood pressure (sitting position）
X
X
X
X
X
Efficacy
IVUS imaging
Xf
Xg
Transfer IVUS imaging data to central  
reading laboratory
X
X
(electronic 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 12
Treatment
EOT
Week (W)
W0
W2
W4
W6
W8
W10
W12
W14
W16
W18
W20
W22
W24
W26
W28
W30
W32
W34
W36
Day (D)
D1
D15
D29
D43
D57
D71
D85
D99
D113
D127
D141
D155
D169
D183
D197
D211
D225
D239
D253
Visit Number
1a
2
3
4
5
Visit Window (D)
±7
±7
±7
±14
Safety
AE/SAE recording including CV events 
X
X
X
X
X
X
X
X
X
X
Laboratory testing - Efficacy
TC, calculated LDL-C, HDL-C, TG, 
non-HDL-C
Xh
X
X
X
X
Apo B, Apo A-1, Apo B/Apo A-1 ratio, 
Lp(a)
X
X
Laboratory testing - Safetyi
Hematology and chemistryj
X
X
X
X
X
Hepatitis B virus core antibodyn
X
Hepatitis C virus antibody
X
X
Serum pregnancy testk
X
Urine pregnancy testk
X
X
Laboratory testing - Others
HbA1c 
X
X
X
X
hs-CRP
X
X
Quality of Life Variables
EQ-5D patient questionnairel
X
X
X
X
X
Abbreviations: AE, adverse event; Apo A-1, apolipoprotein A-1, Apo B, apolipoprotein B; CV, cardiovascular; D, day(s); EOT, end of treatment; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein 
cholesterol; hs-CRP, high sensitivity C-reactive protein; IMP, investigational medicinal product; IVUS, intravascular ultrasound; LDL-C, low-density lipoprotein cholesterol; NIMP, noninvestigational medicinal 
product; non-HDL-C, non-high-density lipoprotein cholesterol; SAE, serious adverse event; TC, total cholesterol; TG, triglyceride; W, week.
a
Randomization visit (Visit 1) is conducted after the assessment of candidate patients for inclusion/exclusion criteria. 
b
Informed consent is obtained between ACS diagnosis and Visit 1.
c
Patient medical history includes lipid parameters (i.e., LDL-C used for patient selection) used for the study eligibility and HbA1c.
d
Praluent® is administered at Week 36 if the patient cannot complete the evaluation IVUS by Week 36. It should be noted that the final lipid values will be recorded at Week 36 (V5) as EOT. 
e
Phone call interview will be carried out only for the patients assigned to the SoC arm. Review of IMP / NIMP administration status includes the compliance with diet therapy recommended by the Japan 
Atherosclerosis Society Guideline or equivalent. 
f
Baseline IVUS study will be performed as following standard protocol in each site. Baseline IVUS imaging data will be transferred to the central reading laboratory.
g
Evaluation IVUS is carried out on V5 / Week 36 ± 14 days (between Week 34 and Week 38). The IVUS imaging data will be transferred immediately after the evaluation IVUS is obtained.
h
Lipid parameters will be measured at the study sites and will be used for the patient selection before randomization. The lipid parameters will be also recorded as part of the patient demography.
(electronic 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 13
i
Laboratory testing data for safety assessment except hepatitis B virus core antibody and hepatitis C virus antibody will be collected from each study site. 
j
Hematology laboratory testing includes red blood cell count, hematocrit, hemoglobin, white blood cell count with differential count, and platelet count. Chemistry laboratory testing includes glucose, sodium, 
potassium, chloride, creatinine, uric acid, lactate dehydrogenase (LDH), total protein, albumin, gamma-glutamyl transpeptidase (γGT), creatine phosphokinase (CPK), alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin. 
k
Women of childbearing potential (WOCBP) only.
l
EQ-5D patient questionnaire interview will be carried out for all patients on study treatment. For prematurely (permanently) discontinued patients, the last questionnaire interview will be carried out at the EOT
visit defined in the protocol (see Section 10.3).
m Patients can choose self-injection of Praluent® at home any time, if they wish self-injection at home and the Investigator/sub-Investigator considers it feasible.
Before starting self-injection at home, the Investigator/sub-Investigator must explain to the patients using the operation procedure for administration of IMP. If necessary, patients can use the training kits.
Patients are allowed to perform self-injection at home if they successfully perform the correct self-injection of Praluent® under the direct supervision of site medical staff at the study site once, and the 
Investigator/sub-Investigator considers that they can perform self-injection at home correctly. They can use tools to assist. 
Regardless of the timing when the self-injection is started, patients must visit the study site at least every 4 weeks, and at Week 0, Week 4, Week 12, Week 14, Week 24 and Week 36.
Patients must record self-injection at home in the diary. At each visit, they must bring the diary, and the site medical staff must check their records. If self-injection at home is performed, IMPs will be provided for 
only number of times of self-injections at home until the next visit. Patients must return used and unused IMPs to the site medical staff at the next visit.  
Patients can discontinue self-injection at home any time. The Investigator/sub-Investigator must have patients discontinue self-injection at home, if the Investigator/sub-Investigator judges that the patients are 
not able to perform self-injection at home correctly. Patients who discontinue self-injection at home can have injections performed by medical staff at the study site.
n
Hepatitis B virus DNA will be measured promptly if hepatitis B virus total core antibody comes back positive.
(electronic 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 14
2
TABLE OF CONTENTS
AMENDED CLINICAL TRIAL PROTOCOL NO. 3.........................................................................................1
1
FLOW CHARTS.............................................................................................................................10
1.1
GRAPHICAL STUDY DESIGN ......................................................................................................10
1.2
STUDY FLOW CHART ..................................................................................................................11
2
TABLE OF CONTENTS ................................................................................................................14
2.1
LIST OF TABLES...........................................................................................................................19
2.2
LIST OF FIGURES.........................................................................................................................19
3
LIST OF ABBREVIATIONS ..........................................................................................................20
4
INTRODUCTION AND RATIONALE.............................................................................................22
5
STUDY OBJECTIVES ...................................................................................................................28
5.1
PRIMARY.......................................................................................................................................28
5.2
SECONDARY ................................................................................................................................28
6
STUDY DESIGN ............................................................................................................................29
6.1
DESCRIPTION OF THE STUDY...................................................................................................29
6.2
DURATION OF STUDY PARTICIPATION ....................................................................................31
6.2.1
Duration of study participation for each patient .............................................................................31
6.2.2
Determination of end of clinical trial (all patients) ..........................................................................31
6.3
INTERIM ANALYSIS......................................................................................................................31
6.4
STUDY COMMITTEES..................................................................................................................31
7
SELECTION OF PATIENTS..........................................................................................................32
7.1
INCLUSION CRITERIA..................................................................................................................32
7.2
EXCLUSION CRITERIA ................................................................................................................33
7.2.1
Exclusion criteria related to study methodology ............................................................................33
7.2.2
Exclusion criteria related to background therapies........................................................................34
7.2.3
Exclusion criteria related to the current knowledge of Praluent®...................................................34
7.2.4
Additional exclusion criteria before randomization ........................................................................35
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 15
8
STUDY TREATMENTS .................................................................................................................36
8.1
INVESTIGATIONAL MEDICINAL PRODUCT(S): SUBCUTANEOUS INJECTION ......................36
8.2
NONINVESTIGATIONAL MEDICINAL PRODUCT(S): ORAL ADMINISTRATION.......................36
8.3
BLINDING PROCEDURES............................................................................................................37
8.3.1
Methods of blinding........................................................................................................................37
8.4
METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP ..............................................37
8.5
PACKAGING AND LABELING ......................................................................................................37
8.6
STORAGE CONDITIONS AND SHELF LIFE................................................................................38
8.7
RESPONSIBILITIES ......................................................................................................................38
8.7.1
Treatment accountability and compliance......................................................................................38
8.7.2
Return and/or destruction of treatments ........................................................................................39
8.8
CONCOMITANT MEDICATION.....................................................................................................39
9
ASSESSMENT OF INVESTIGATIONAL MEDICINAL PRODUCT ..............................................40
9.1
EFFICACY ENDPOINT..................................................................................................................40
9.1.1
Primary efficacy endpoint...............................................................................................................40
9.1.2
Secondary endpoints .....................................................................................................................40
9.1.2.1
Key secondary efficacy endpoint ...................................................................................................40
9.1.2.2
Other secondary efficacy endpoints...............................................................................................40
9.1.3
Efficacy assessment method .........................................................................................................41
9.1.3.1
IVUS parameters............................................................................................................................41
9.1.3.2
Lipid parameters ............................................................................................................................41
9.2
SAFETY ENDPOINTS ...................................................................................................................42
9.2.1
Adverse events ..............................................................................................................................42
9.2.2
Laboratory safety variables............................................................................................................43
9.2.3
Vital signs.......................................................................................................................................43
9.3
OTHER ENDPOINTS.....................................................................................................................44
9.3.1
Hemoglobin A1c.............................................................................................................................44
9.3.2
High sensitive C-reactive protein ...................................................................................................44
9.3.3
EQ-5D Patient Questionnaire ........................................................................................................44
9.4
APPROPRIATENESS OF MEASUREMENTS ..............................................................................44
10
STUDY PROCEDURES ................................................................................................................45
10.1
VISIT SCHEDULE..........................................................................................................................47
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 16
10.1.1
Open-label treatment period ..........................................................................................................48
10.1.1.1 Study site visit ................................................................................................................................48
10.1.1.2 Praluent® administration visit (alirocumab arm only) .....................................................................53
10.1.1.3 Phone-call interview (SoC arm only)..............................................................................................54
10.2
DEFINITION OF SOURCE DATA..................................................................................................55
10.3
HANDLING OF PATIENT TEMPORARY OR PERAMANENT TREATMENT
DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION.......................................56
10.3.1
Temporary treatment discontinuation ............................................................................................56
10.3.2
Permanent treatment discontinuation with investigational medicinal product(s) ...........................56
10.3.3
List of criteria for permanent treatment discontinuation (SoC or IMP)...........................................56
10.3.4
Handling of patients after permanent treatment discontinuation (SoC or IMP) .............................57
10.3.5
Procedure and consequence for patient withdrawal from study....................................................58
10.4
OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING ..........................58
10.4.1
Definitions of adverse events.........................................................................................................58
10.4.1.1 Adverse event ................................................................................................................................58
10.4.1.2 Serious adverse event ...................................................................................................................59
10.4.1.3 Adverse event of special interest...................................................................................................60
10.4.2
General guidelines for reporting adverse events ...........................................................................60
10.4.3
Instructions for reporting serious adverse events ..........................................................................60
10.4.4
Guidelines for reporting adverse events of special interest...........................................................61
10.4.4.1 Reporting of adverse events of special interest (AESI) .................................................................61
10.4.4.2 Device deficiency ...........................................................................................................................63
10.4.5
Guidelines for management of specific laboratory abnormalities ..................................................63
10.4.6
Summary of adverse event reporting instructions .........................................................................64
10.5
OBLIGATIONS OF THE SPONSOR .............................................................................................64
10.6
SAFETY INSTRUCTIONS .............................................................................................................64
10.6.1
Local tolerability (local injection site reactions)..............................................................................64
10.6.2
Allergic adverse events..................................................................................................................64
10.6.2.1 Allergic adverse events with cutaneous involvement ....................................................................65
10.6.2.2 Acute allergic reactions of IMP injection ........................................................................................65
10.6.3
Cardiovascular events and all deaths............................................................................................66
10.6.4
Laboratory alert related to calculated LDL-C <25 mg/dL (0.65 mmol/L) .......................................66
11
STATISTICAL CONSIDERATIONS..............................................................................................67
11.1
DETERMINATION OF SAMPLE SIZE...........................................................................................67
11.2
DISPOSITION OF PATIENTS .......................................................................................................67
11.3
ANALYSIS POPULATIONS...........................................................................................................67
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 17
11.3.1
Efficacy populations .......................................................................................................................68
11.3.1.1 Modified intent-to-treat population .................................................................................................68
11.3.2
Safety population ...........................................................................................................................68
11.3.3
Quality-of-life (QOL) population .....................................................................................................68
11.4
STATISTICAL METHODS .............................................................................................................68
11.4.1
Extent of study treatment exposure and compliance.....................................................................69
11.4.1.1 Extent of investigational medicinal product exposure....................................................................69
11.4.1.2 Compliance of investigational medicinal product exposure...........................................................69
11.4.2
Analyses of efficacy endpoints.......................................................................................................69
11.4.2.1 Analysis of primary efficacy endpoint.............................................................................................69
11.4.2.2 Analyses of secondary efficacy endpoints.....................................................................................70
11.4.2.3 Multiplicity considerations ..............................................................................................................71
11.4.3
Analyses of safety data..................................................................................................................71
11.4.3.1 Adverse events ..............................................................................................................................72
11.4.3.2 Laboratory data and vital signs......................................................................................................73
11.4.4
Analyses of other endpoints...........................................................................................................73
11.4.5
Analyses of quality of life/health economics variables...................................................................74
11.5
INTERIM ANALYSIS......................................................................................................................74
12
ETHICAL AND REGULATORY CONSIDERATIONS...................................................................75
12.1
ETHICAL AND REGULATORY STANDARDS ..............................................................................75
12.2
INFORMED CONSENT .................................................................................................................75
12.3
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) ..............75
13
STUDY MONITORING...................................................................................................................77
13.1
RESPONSIBILITIES OF THE INVESTIGATOR(S).......................................................................77
13.2
RESPONSIBILITIES OF THE SPONSOR.....................................................................................77
13.3
SOURCE DOCUMENT REQUIREMENTS....................................................................................77
13.4
USE AND COMPLETION OF CASE REPORT FORMS (CRFS) AND ADDITIONAL 
REQUEST......................................................................................................................................78
13.5
USE OF COMPUTERIZED SYSTEMS..........................................................................................78
14
ADDITIONAL REQUIREMENTS...................................................................................................79
14.1
CURRICULUM VITAE....................................................................................................................79
14.2
RECORD RETENTION IN STUDY SITES ....................................................................................79
14.3
CONFIDENTIALITY .......................................................................................................................79
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 18
14.4
PROPERTY RIGHTS.....................................................................................................................80
14.5
DATA PROTECTION.....................................................................................................................80
14.6
INSURANCE COMPENSATION....................................................................................................80
14.7
SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES .................................81
14.8
PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE-OUT OF 
A SITE............................................................................................................................................81
14.8.1
By the Sponsor...............................................................................................................................81
14.8.2
By the Investigator .........................................................................................................................82
14.9
CLINICAL TRIAL RESULTS ..........................................................................................................82
14.10
PUBLICATIONS AND COMMUNICATIONS .................................................................................82
15
CLINICAL TRIAL PROTOCOL AMENDMENTS ..........................................................................83
16
BIBLIOGRAPHIC REFERENCES.................................................................................................84
17
APPENDICES................................................................................................................................88
APPENDIX A.
GUIDANCE ON CONTRACEPTIVE METHODS AND COLLECTION OF 
PREGNANCY INFORMATION......................................................................................................89
APPENDIX B.
DIAGNOSTIC CRITERIA FOR THE CLINICAL DIAGNOSIS OF HETEROZYGOUS 
FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) [JAPAN ATHEROSCLEROSIS 
SOCIETY (JAS) GUIDELINES FOR PREVENTION OF ATHEROSCLEROTIC 
CARDIOVASCULAR DISEASES 2012].........................................................................................92
APPENDIX C.
SUMMARY OF DIET FOR PREVENTION OF ATHEROSCLEROTIC 
CARDIOVASCULAR DISEASE (JAS GUIDELINES FOR PREVENTION OF 
ATHEROSCLEROTIC CARDIOVASCULAR DISEASE 2912)......................................................93
APPENDIX D.
CORONARY ARTERY SEGMENTAL ANATOMY CLASSIFICATION ..............................94
APPENDIX E.
THE STAGES OF HEART FAILURE – NYHA CLASSIFICATION.....................................95
APPENDIX F.
SUMMARY OF ADVERSE EVENT REPORTING INSTRUCTIONS..................................96
APPENDIX G.
GENERAL GUIDANCE FOR FOLLOW-UP OF LABORATORY ABNORMALITIES 
BY SANOFI....................................................................................................................................98
APPENDIX H.
GUIDELINES FOR HEMOGLOBIN (HB) DECREASE ≥1.5 G/DL...................................103
APPENDIX I.
ASSESSMENT OF LOCAL INJECTION SITE REACTIONS.............................................104
APPENDIX J.
EQ-5D PATIENT QUESTIONNAIRE ................................................................................105
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 19
2.1
LIST OF TABLES
Table 1 – Heart Failure – NYHA classification ..............................................................................................95
Table 2 – Adverse Event Reporting Instructions...........................................................................................96
2.2
LIST OF FIGURES
Figure 1 – Coronary artery segmental anatomy classification ......................................................................94
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 20
3
LIST OF ABBREVIATIONS
ACS:
Acute coronary syndrome
AE:
Adverse event
AESI:
Adverse event of special interest 
ALP:
Alkaline phosphatase 
ALT:
Alanine aminotransferase 
ANCOVA:
Analysis of covariance 
Apo A-1:
Apolipoprotein A-1
Apo B:
Apolipoprotein B
AST:
Aspartate aminotransferase 
BMS:
Bare metal stent
CEC:
Clinical Event Committee
CHD:
Coronary heart disease
CPK:
Creatine phosphokinase
CRF:
Case report form
CRP:
C-reactive protein
CV:
Cardiovascular
DBP:
Diastolic blood pressure
DES:
Drug eluting stent
e-CRF:
Electronic Case Report Form
EEM:
External elastic membrane 
EOT:
End of treatment
FH:
Familial hypercholesterolemia 
HbA1c:
Hemoglobin A1c 
HDL-C:
High-density lipoprotein cholesterol
heFH:
Heterozygous familial hypercholesterolemia 
HLGT:
High level group term
HLT:
High level term
HRT:
Hormonal replacement therapy 
hs-CRP:
High sensitive C-reactive protein
IEC:
Independent ethics committee
IMP:
Investigational medicinal product
IRB:
Institutional review board 
IVUS:
Intravascular ultrasound
JAS:
Japan Atherosclerosis Society
LDH:
Lactate dehydrogenase 
LDL-C:
Low-density lipoprotein cholesterol
LDL-R:
Low-density lipoprotein receptor
LLT:
Low level term
LMT:
Lipid modifying therapy
Lp(a):
Lipoprotein (a)
LS:
Least square
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 21
MedDRA:
Medical dictionary for regulatory activities
MI:
Myocardial infarction
mITT:
Modified intent-to-treat 
MMRM:
Mixed-effect model with repeated measures 
NIMP:
Noninvestigational medicinal product
non-FH:
Nonfamilial hypercholesterolemia 
non-HDL-C:
Non-high-density lipoprotein cholesterol
NSTEMI:
Non ST-elevation myocardial infarction
OCT:
Optical coherence tomography
PAV:
Percent atheroma volume
PCI:
Percutaneous coronary intervention
PCSA:
Potentially clinically significant abnormality
PCSK9:
Proprotein convertase subtilisin kexin type 9
PT:
Preferred term
Q2W:
Every 2 weeks
SAE:
Serious adverse event
SAP:
Statistical analysis plan 
SBP:
Systolic blood pressure
SC:
Steering Committee
SE:
Standard error
SoC:
Standard of care
SOC:
System organ class
STEMI:
ST-elevation myocardial infarction
TAV:
Total atheroma volume
TC:
Total cholesterol
TEAE:
Treatment-emergent adverse event
TG:
Triglyceride
ULN:
Upper limit of normal range
WOCBP:
Women of childbearing potential
γGT:
Gamma-glutamyl transpeptidase 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 22
4
INTRODUCTION AND RATIONALE
Alirocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin 
kexin type 9 (PCSK9). 
Alirocumab has been approved for manufacturing and sales in Japan. The approved indications, 
and dosage and administration are as follows: 

Drug indications: Familial hypercholesterolemia and hypercholesterolemia nevertheless it 
is limited to cases at high cardiovascular (CV) risk and with inadequately controlled 
despite of taking HMG-CoA reductase inhibitors.

Dosage and Administration: The usual adult dosage is 75 mg of alirocumab (genetical
recombination) administered subcutaneously once every 2 weeks (Q2W). In case of an 
insufficient response, the dosage can be increased to 150 mg. 
Detailed information of alirocumab is described in the latest version of Package Insert. 
Alirocumab is also referred to as SAR236553/REGN727. However, for this study, ODYSSEY 
J-IVUS (ALIROL08069), it will be referred to as Praluent®, since alirocumab has already been 
approved in Japan.
Background on patient populations:
Patients with recent acute coronary syndrome (ACS) are at very high risk for suffering recurrent 
coronary events. In approximately 10% of patients with ACS, CV death, recurrent myocardial 
infarction (MI), or stroke, occur within 1 year (3). Driven by the results of large clinical trials, 
early intensive statin therapy has become endorsed as a treatment recommendation (4, 5) for 
patients with ACS (6) to prevent the recurrent events. The use of high-dose statins has been 
largely demonstrated to be safe and well tolerated in Western countries (7). The strong and direct 
association between achieved low-density lipoprotein cholesterol (LDL-C) levels with statins, 
HMG-CoA reductase inhibitors, and the risk of coronary heart disease (CHD), and CHD risk 
reduction by lowering LDL-C level with statins has been reported. In recognition of the benefits 
of intensive lipid-lowering therapy, the current European guidelines and the Adult Treatment 
Panel (ATP) III guidelines recommend the lowering of LDL-C levels to either below 70 mg/dL or 
to at least achieve a 50% reduction from baseline levels in patients at high CV risk (8, 9, 10).
IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) 
demonstrated an incremental benefit of adding ezetimibe to standard statin therapy to reduce CV
events (11). The benefit of further LDL-C reduction with alirocumab on top of statin therapy on 
patient CV outcomes is expected to be demonstrated in the ongoing ODYSSEY Outcomes trial 
(EFC11570). On the other hand epidemiological studies show lower CV event rates and higher 
cerebrovascular event rates in the Japanese population as compared to Western populations. In the 
REACH (Reduction of Atherothrombosis for Continued Health) registry, a correlation exists 
between being Japanese and lower CV risk at levels that are similar to that of statin use and CV 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 23
risk reduction in Western populations (12), which suggests the need to take the differences in 
ethnicity into consideration. Thus, there is a need to conduct an outcome or outcome surrogate 
marker study targeting the Japanese population to demonstrate the benefit of intensive LDL-C 
lowering in Japanese population.
Introduction to intravascular ultrasound (IVUS) coronary plaque measurements: 
Advances in arterial wall imaging have enhanced the ability to directly visualize atherosclerotic 
plaque. While angiography has been widely used to quantify the extent of obstructive disease both 
in clinical practice and trials that evaluated anti-atherosclerotic therapies, it does not image the 
artery wall, the site in which plaque accumulates. Accordingly, use of wall-based imaging 
approaches provides the potential for more precise assessments of atherosclerotic plaque. 
Intravascular ultrasound (IVUS) generates high resolution images of the full thickness of the 
artery wall and as a result currently provides the most accurate quantitation of plaque burden (13). 
Serial IVUS imaging has been employed to evaluate the effect of LDL-C lowering on plaque 
regression (14, 15, 16). Many studies have demonstrated the effectiveness of intensive statin 
therapies. The Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin 
versus Atorvastatin (SATURN) compared the effects of statin on the progression of coronary 
atherosclerosis of the highest doses of atorvastatin with those of rosuvastatin (17, 18). The 
rosuvastatin group achieved lower LDL-C levels (62.6 vs. 70.2 mg/dL) and higher high-density 
lipoprotein cholesterol (HDL-C) levels (50.4 vs. 48.6 mg/dL) compared with the atorvastatin
group. The change in percent atheroma volume as a primary endpoint decreased in both groups 
consistent with plaque regression, the difference between groups not reaching statistical 
significance. In contrast, the secondary endpoint, change in total atheroma volume (TAV), 
demonstrated greater regression in the rosuvastatin treated patients. Approximately two-thirds of 
patients in the study demonstrated regression, reinforcing the hypothesis that aggressively 
lowering LDL-C to levels of 70 mg/dL and below offered significant plaque reduction. 
Furthermore, a meta-analysis of 6 clinical IVUS trials demonstrated a direct relationship between 
the burden of coronary atherosclerosis, its progression, and adverse CV events. These data support 
the use of atherosclerosis imaging with IVUS in the evaluation of novel anti-atherosclerotic 
therapies (19).
Japanese cardiologists use IVUS imaging as part of their standard coronary intervention 
throughout the country and many IVUS trials have been conducted (1, 18, 20, 21). This universal
use of IVUS is a unique to Japanese practice, and this condition is suitable to efficiently conduct a
nation-wide study using IVUS imaging. Most recently PRECISE-IVUS (Plaque Regression with 
Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular Ultrasound) 
trial demonstrated greater plaque regression by combination therapy of ezetimibe and atorvastatin 
compared to atorvastatin monotherapy in patients with CHD (2).
The SATURN and the PRECISE-IVUS studies showed greater plaque regression in ACS patients 
when compared with non-ACS patients. Since it is suggested that patients with ACS have high 
initial clinical risk but their disease substrate is likely to be improved, they are considered as the 
patient population who can get the greatest benefit from strong lipid lowering therapy (2, 22).
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 24
Introduction to PCSK9: 
PCSK9 belongs to the subtilisin family of serine proteases and is highly expressed in the liver.  
PCSK9 is involved in regulating the levels of the low-density lipoprotein receptor (LDL-R) 
protein (23, 24). Once PCSK9 is secreted into plasma, it directly binds to the LDL-R and 
promotes its degradation. The increased degradation of LDL-Rs leads to a reduced LDL-C 
removal and, therefore higher LDL-C circulating levels. Experiments with mice have shown that 
increasing PCSK9 protein levels decreases levels of LDL-R protein in the liver, while PCSK9 
knockout mice have increased levels of LDL-R protein in the liver (25, 26). In humans, PCSK9 
mutations have been identified: the gain-of-function mutations are rare and cause an autosomal 
dominant form of severe hypercholesterolemia and premature CHD, whereas loss-of-function 
mutations are more common and are associated with reduced plasma levels of LDL-C and 
protection from developing cardiovascular disease (27, 28). One report from the Japanese 
population found the individual heterozygous for W428X mutation of PCSK9 had 70.4 mg/dL of 
plasma LDL-C, corresponding to a 44% decrease from the average LDL-C level (126.8 mg/dL) in 
the untreated population. This observation is consistent with the finding that the two African-
American nonsense mutations were associated with a 40% reduction in plasma LDL-C levels (29). 
Therefore blocking PCSK9 binding to the LDL-R can potentially benefit patients with 
hypercholesterolemia by decreasing their plasma LDL-C levels. In addition, PCSK9 messenger 
ribonucleic acid (mRNA) and protein levels are increased in response to statins, potentially 
attenuating their cholesterol-lowering effect (30). 
Introduction to Alirocumab: 
Alirocumab binds with high affinity and specificity to PCSK9, which, in turn, can no longer bind 
LDL-Rs. By inhibiting the binding of PCSK9 to LDL-Rs, alirocumab prevents the PCSK9-
induced microsomal LDL-R degradation within the hepatocytes, thus increases the density of 
LDL-Rs on hepatocytes, thereby lowering LDL-C.
Results from phase 1 and 2 overseas studies have demonstrated that treatment with alirocumab 
has a significant LDL-C lowering effect in patients with LDL-C ≥100 mg/dL (2.59 mmol/L) who 
had either nonfamilial hypercholesterolemia (non-FH) (administered alone or in combination with 
a statin) or heterozygous familial hypercholesterolemia (heFH) (administered in combination with 
a statin, with or without ezetimibe). Alirocumab was generally well tolerated. LDL-C reduction 
was associated with consistent reduction in total cholesterol (TC), apolipoprotein B (Apo B), non-
high-density lipoprotein-cholesterol (non-HDL-C) and Apo B/apolipoprotein A-1 (Apo A-1) ratio. 
A trend for an increase in HDL-C and for a decrease in lipoprotein (a) (Lp(a) ) was also seen. 
Results for triglycerides (TGs) were not conclusive due to very high variability and relatively 
small sample sizes. A dose-finding phase 2 study (DFI12361) conducted in Japanese patients 
showed similar results observed in the oversea studies.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 25
Japanese Phase 3 study (EFC13672):
In EFC13672, administration of alirocumab Q2W for 52 weeks as an add-on to stable statin 
therapy with or without other lipid modifying therapies (LMTs) was investigated in 41 patients
with heFH and 175 patients with hypercholesterolemia who have high CV risk, who had not 
achieved target LDL-C level on statin therapy. An up-titration scheme was applied, with 
alirocumab 75 mg Q2W as the initiation dose with up-titration to 150 mg Q2W from Week 12, if
LDL-C level at Week 8 is higher than the target level. Dose/dose regimens in the Japanese phase 
3 study were selected based on the results obtained in the Japanese phase 2 study (DFI12361).
EFC13672 enrolled patients with heFH with LDL-C ≥100 mg/dL (2.59 mmol/L) or patients with
non-FH with LDL-C ≥100 mg/dL (2.59 mmol/L) with a history of documented CHD, or patients
with non-FH with LDL-C ≥120 mg/dL and categorized in primary prevention category III. These 
cut-off LDL-C levels were aligned with the LDL-C target level recommended in the Japan 
Atherosclerosis Society (JAS) guidelines (31). In the JAS guidelines, the treatment goal for the 
secondary prevention is set as <100 mg/dL. Since heFH is a high risk disease for the development 
of cardiovascular disease, it can be considered as equivalent to the secondary prevention. The 
treatment goal for LDL-C in heFH is set as <100 mg/dL as well. When the goal cannot be 
achieved in heFH cases, 50% or more reduction of LDL-C from baseline can be used as the 
alternative goal. For the patients who are primary prevention category III, the treatment goal for 
LDL-C is established as <120 mg/dL. The primary prevention category III is defined as follows:

Non-FH patients who have any of 1) diabetes, 2) chronic kidney disease (CKD), 3) non-
cardiogenic ischemic stroke, or 4) peripheral artery disease (PAD)

A 10-year fatal CHD risk SCORE calculated using NIPPON DATA 80 ≥2%

A 10-year fatal CHD risk SCORE calculated using NIPPON DATA 80 ≥0.5% and <2%, 
and have 1 or more of the following criteria
-
Hypo high-density lipoprotein cholesterolemia (<40 mg/dL)
-
Family history of premature coronary artery disease (first-degree relative and male: 
<55-year-old, female: <65-year-old)
-
Impaired glucose tolerance (defined as a fasting blood glucose [FBG] <126 mg/dL 
[7.0 mmol/L], and a 2-hour post glucose challenge value ≥140 mg/dL [7.8 mmol/L] 
and <200 mg/dL [11.1 mmol/L] (oral glucose tolerance test [OGTT]).
Efficacy (EFC13672): 
In EFC13672, alirocumab or placebo were administered Q2W for 52 weeks to 216 patients with 
hypercholesterolemia (including 41 patients with heFH) who were under treatment with statin and 
had not achieved the target LDL-C level. The administration was initiated with 75 mg and dose 
was up-titrated to 150 mg at Week 12 in the patients who did not achieve the target LDL-C level 
at Week 8. Among 140 patients who received alirocumab at Week 12 in the alirocumab group, 
2 patients received up-titration. The least square (LS) mean differences versus placebo in the
percent change in LDL-C from baseline to Week 12 and Week 24 were -61.5% and -64.1% 
respectively, showing that the statistically significant decrease was observed at Week 24 (primary 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 26
efficacy endpoint, p<0.0001). The effect persisted up to Week 52 (LS mean present change from
baseline in the alirocumab group, -62.5%).  
Safety (EFC13672): 
Alirocumab was well tolerated throughout the treatment period. Treatment-emergent adverse 
events (TEAEs) were reported in 90.9% of patients in the alirocumab group and 83.3% of patients 
in the placebo group. Ten patients (7.0%) in the alirocumab group and 9 patients (12.5%) in the 
placebo group experienced at least 1 treatment-emergent serious adverse event (SAE). There were 
no deaths reported. Seven patients (4.9%) in the alirocumab group and 4 patients (5.6%) in the 
placebo group experienced at least 1 TEAE leading to permanent investigational medicinal 
product (IMP) discontinuation. 
Overall, 29 patients (20.3%) in the alirocumab group and 8 patients (11.1%) in the placebo group 
reported at least 1 TEAE that was considered by the Investigator to be related to the IMP. The 
most frequently reported TEAE considered to be related to the IMP was injection site reaction 
(18 patients [12.6%] in the alirocumab group and 3 patients [4.2%] in the placebo group). All the 
remaining TEAEs considered to be related to the IMP were reported in a single patient each.
Further details on alirocumab are provided in the Package Insert of Praluent®. 
Rationale for protocol design in this study: 
The objective of the present study is to evaluate the ability of alirocumab to progress/regress 
coronary atherosclerotic plaque in patients who experienced an ACS event and despite statin 
therapy failing to reach the goals as defined in the guidelines for these high risk patients of 
recurrence. As a phase 4 study, the dose regimen in this study has to be in line with the approved
regimen in Japan, which is starting Praluent® at 75 mg Q2W with up-titration to 150 mg Q2W if 
patients do not reach their target LDL-C level. 
For this randomized, open-label, blinded IVUS analysis, multicenter study, it is estimated that 
approximately 200 patients will be enrolled with a treatment period of 9 months and a total 
duration of 9 to 10 months. Despite stable statin therapy, hypercholesterolemia patients who 
suffer ACS events and whose LDL-C ≥100 mg/dL will be enrolled this study. Or, if patients are 
not on any statin therapy at ACS onset, either atorvastatin 10 mg/day or rosuvastatin 5 mg/day is 
started, and the patients whose LDL-C is not adequately controlled with statin (in principle, LDL-
C target level ≥100 mg/dL, but this may not apply if the responsible physician considers the LDL-
C level inadequate on statin. Patients who have LDL-C <70 mg/dL cannot be enrolled) at 2 to 
4 weeks after the ACS diagnosis will be enrolled this study. Within 4 weeks of the index ACS 
diagnosis, patients will be randomized to either alirocumab arm (atorvastatin ≥10 mg/day or 
rosuvastatin ≥5 mg/day plus Praluent® 75 mg Q2W with/without other LMTs) or standard of care
(SoC) arm (atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day with/without other LMTs). At
Week 12, if LDL-C does not reach <100 mg/dL, Praluent® will be up-titrated to 150 mg Q2W in 
the alirocumab arm, and dose up of atorvastatin or rosuvastatin or adding other LMTs will be 
considered in the SoC arm. 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 27
Treatment duration of 9 months was designed based on previous Japanese studies including 
ESTABLISH (18), JAPAN-ACS (20) and PRECISE-IVUS (2), each study duration was 6 months, 
8-12 months and 9-12 months, respectively. This is based on Japanese standard procedure for 
follow-up to coronary angiography 8-10 months after the ACS onset. Also, keeping 8-10 months 
study duration makes it feasible to align with standard Japanese IVUS studies. If the study goes 
beyond this standard duration, then a very high drop-out rate is expected. Compared to the studies 
done in Cleveland Clinic, the study duration in Japan are shorter and yet still sufficiently proved 
the benefit of LDL-C reduction on disease progression. This may be because differences in target 
population (ACS vs. non-ACS) and target vessel (culprit vessel vs. non-culprit vessel). It is also 
noted that diabetes population is also well known high risk population and studies suggest more 
benefit of intensive LDL-C lowering in diabetes population compared to the non-diabetes 
population (1, 32, 33).
The proposed primary efficacy endpoint is the effect of alirocumab arm compared to SoC arm on 
the percent change in normalized TAV measured by IVUS. Considering the differences in IVUS 
study methods of Japan with the Cleveland Clinic, sample size is more appropriately calculated 
based on Japanese IVUS study results. Percent change in TAV has been predominantly used as a 
primary endpoint in Japanese IVUS studies. Based on the results in ZEUS and PRECISE-IVUS 
studies, it is assumed that difference in percent change in normalized TAV from baseline between 
alirocumab arm and SoC arm is 8%, the common standard deviation is 15% (1, 2). Considering 
that absolute change in percent atheroma volume (PAV) has been employed in most US IVUS 
studies as a primary endpoint, comparison of change in PAV between arms will be analyzed as a 
key secondary endpoint (34). 
Based on previous Japanese IVUS studies results, IVUS parameters including primary efficacy 
endpoint, and percent change in TAV, will be assessed at Week 36 since this is considered 
sufficient to provide efficacy information of alirocumab on atherosclerosis disease 
progression/regression in this study (1, 2, 18, 20, 21). This treatment duration should also provide 
a sufficient duration of exposure to appreciate tolerability and safety profiles for alirocumab in the 
ACS setting. The effect of alirocumab on lipid parameters will also be assessed at Week 36 in this 
study. 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 28
5
STUDY OBJECTIVES
5.1
PRIMARY 
To compare the effect of Praluent® with SoC on coronary atheroma progression (percent change 
in normalized TAV) after 9 months of treatment in patients who had ACS within 4 weeks prior to 
randomization, with hypercholesterolemia treated with any statin.
5.2
SECONDARY 

To compare the effect of Praluent® with SoC on secondary endpoints including absolute 
change in PAV and normalized TAV after 9 months of treatment.

To evaluate the effect of Praluent® on LDL-C, Apo B, TGs, non-HDL-C and Lp(a) after 9 
months treatment.

To evaluate the safety of Praluent® including the occurrence of CV events (CHD death, 
non-fatal MI, fatal and non-fatal ischemic stroke, unstable angina requiring 
hospitalization) throughout the study.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 29
6
STUDY DESIGN
This is a phase 4, open-label, 1:1 randomized, blinded IVUS analysis, parallel group, multicenter
study to investigate the effect of alirocumab on coronary atheroma volume in Japanese patients 
with hypercholesterolemia, who have recently suffered from ACS and are failing to reach the 
recommended LDL-C levels as defined by JAS guidelines for very high CV disease risk in spite 
of stable statin therapy. Randomization will be stratified by ‘on statin therapy’ or ‘not on statin’
therapy at the time of ACS onset. As a phase 4 study, the dose regimen is in line with the 
approved regimen in Japan; starting dose is 75 mg Q2W with up-titration to 150 mg Q2W if 
patients do not reach their target LDL-C level. 
Approximately 200 patients from approximately 40 study sites will be enrolled and randomized 
with a treatment period of 9 months. Patients who suffer ACS events despite stable statin therapy 
and whose LDL-C is ≥100 mg/dL will be enrolled. If patients are not on any statin therapy at the 
time of ACS onset, they will start either atorvastatin 10 mg/day or rosuvastatin 5 mg/day
immediately after the ACS diagnosis, and the patients whose LDL-C is not adequately controlled 
with statin (in principle, LDL-C target level ≥100 mg/dL, but this may not apply if the responsible 
physician considers LDL-C level inadequate on statin. Patients who have LDL-C <70 mg/dL 
cannot be enrolled) at 2 to 4 weeks after the ACS diagnosis will be also enrolled. 
6.1
DESCRIPTION OF THE STUDY
The study consists of a 36-week open-label treatment period started within 4 weeks after ACS 
diagnosis and appropriate percutaneous coronary intervention (PCI) with bare metal stent (BMS) 
or drug eluting stent (DES) placement and includes post-treatment IVUS imaging (evaluation 
IVUS imaging, Week 36 [end of treatment (EOT)] ± 2 weeks). The patient who did not receive 
PCI but has undergone coronary artery bypass graft surgery or received medical therapy only can 
be included if the analyzable IVUS imaging is obtained.
A 36-week open label treatment period: Patients will be randomized to either alirocumab arm 
or SoC arm. Randomization will be stratified by on statin therapy or not on statin therapy at the 
ACS onset. While the last Praluent® administration will be performed at Week 34, evaluation 
IVUS imaging can be carried out between Week 34 and Week 38 (Week 36 ± 2 weeks)
considering potential scheduling difficulty. The Investigator/sub-Investigator is to make their best
effort to schedule the evaluation IVUS imaging within this time period. If a patient cannot 
undergo evaluation IVUS by Week 36, the last Praluent® administration will be performed at 
Week 36 and the Investigator/sub-Investigator will make their best effort to carry out evaluation 
IVUS before Week 38 while maintaining sufficient alirocumab effect at the evaluation IVUS 
imaging (see Section 1.2). Patients in the SoC arm will continue the study treatment until 
evaluation IVUS. 
-
Alirocumab arm: Praluent® 75 mg Q2W on top of statin therapy (atorvastatin 
≥10 mg/day or rosuvastatin ≥5 mg/day within the range of statin doses approved by the 
Health Authority) will be administered. 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 30
Note: At Week 14, patients whose LDL-C level measured at Week 12 by central 
laboratory remains ≥100 mg/dL in spite of 75 mg Praluent® administration, will receive 
Praluent® dose up-titrated to 150 mg Q2W. 
Note: Patients can choose self-injection of Praluent® (alirocumab) at home any time, if 
they wish self-injection at home and the Investigator/sub-Investigator considers it 
feasible.
Before starting self-injection at home, the Investigator/sub-Investigator must explain to 
the patients using the operation procedure for administration of IMP. If necessary, 
patients can use the training kits. Patients are allowed to perform self-injection at home 
if they successfully perform the correct self-injection of Praluent® under direct 
supervision of site medical staff at the study site once, and the Investigator/sub-
Investigator considers that they can perform self-injection at home correctly. They can 
use tools to assist.
Regardless of the timing when the self-injection is started, patients must visit the study 
site at least every 4 weeks, and at Week 0, Week 4, Week 12, Week 14, Week 24 and 
Week 36.
Patients must record self-injection at home in the diary. At each visit, they must bring 
the diary, and the site medical staff must check their records. 
If self-injection at home is performed, IMPs will be provided for only number of times 
of self-injections at home until the next visit. Patients must return used and unused 
IMPs to the site medical staff at the next visit.  
Patients can discontinue self-injection at home any time. The Investigator/sub-
Investigator must have patients discontinue self-injection at home, if the 
Investigator/sub-Investigator judges that the patients are not able to perform self-
injection at home correctly. Patients who discontinue self-injection at home can have 
injections performed by medical staff at the study site.
-
SoC arm: Statin (atorvastatin ≥10 mg/day or rosuvastatin ≥ 5 mg/day) and non-statin 
LMTs will be continued at the same doses determined after ACS diagnosis and PCI
unless modifications are considered necessary by Investigator/sub-Investigator. The 
target LDL-C level is set as <100 mg/dL.
Note: 1) Stable dose statin therapy (atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day
within the range of statin doses approved by the Health Authority) will be administered,
and the dose will be adjusted to achieve the LDL-C target level <100 mg/dL; 2) 
Concomitant non-statin LMTs will be considered if LDL-C target level <100 mg/dL 
cannot be achieved with statin monotherapy. Adjustment of LMTs is to be performed
based on, but not limited to, the above rule.
The evaluation IVUS imaging will be performed at the EOT (Week 36 ± 2 weeks). The detailed 
instructions of IVUS imaging procedure and the image data processing are described in the 
specific manual. This manual also includes detailed IVUS imaging procedures and image 
processing at the initial IVUS imaging performed at the time of PCI for ACS.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 31
Note: If the study site is able to perform optical coherence tomography (OCT) at the time of the 
IVUS imaging, OCT will be performed as a substudy. The OCT will be performed following the
OCT substudy protocol. 
6.2
DURATION OF STUDY PARTICIPATION
6.2.1
Duration of study participation for each patient
The study consists of a 36-week open-label treatment period including the evaluation IVUS 
imaging (Week 36 ± 2 weeks) starting within 4 weeks after ACS diagnosis and appropriate PCI.
The evaluation IVUS imaging is allowed to be performed between Week 34 and Week 38
depending on the Investigators/sub-Investigators’ decision (36 weeks [EOT] ± 2 weeks). 
Therefore, the study period per patient will be up to 38 weeks.
Patients who experience ongoing SAE or adverse event of special interest (AESI) at the pre-
specified study end-date should be followed until resolution, stabilization, or death, and related 
data will be collected. The end of study per patient is the last protocol planned visit or the 
resolution/stabilization of all SAEs or AESIs, whichever comes last.
6.2.2
Determination of end of clinical trial (all patients)
The end of study is defined as being the last patient last on-site visit as scheduled by the protocol
(including visit for the evaluation IVUS imaging), or the resolution/stabilization of all SAEs and 
AESIs, whichever comes last.
6.3
INTERIM ANALYSIS
No interim analysis is planned.
6.4
STUDY COMMITTEES
Steering Committee:  
Steering Committee (SC) provides Sponsor and Investigators scientific and strategic advices and 
recommendations about the study design, execution, data analysis, and publication of results.  
Clinical Event Committee:   
Clinical Event Committee (CEC) will be responsible for defining, validating, and classifying pre-
specified CV events (non-fatal myocardial infarction, hospitalization for unstable angina, heart 
failure requiring hospitalization, non-fatal ischemic stroke, coronary revascularization, etc.) and 
other potential CV events such as ventricular arrhythmias requiring hospitalization, as well as 
validating the classification of the cause of all deaths in a blinded fashion. All events for 
adjudication will be defined in the CEC charter.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 32
7
SELECTION OF PATIENTS
7.1
INCLUSION CRITERIA
I 01.
Patients hospitalized for ACS (ST-elevation myocardial infarction [STEMI], non ST-
elevation myocardial infarction [NSTEMI], unstable angina)
Definition of ACS:
A) ST-elevation myocardial infarction (STEMI)
Patients meet all of the following items:
1. A chest symptom (chest pain, shortness of breath, etc.) suggestive of ischemia.
2. At least 1 mm of ST elevation in two or more consecutive chest leads or limb leads on 
ECG or a new left bundle branch block.
3. An elevation in blood test value (positive troponin T or troponin I, or creatine 
phosphokinase (CPK) ≥2 times the upper limit of normal) suggestive of myocardial 
necrosis.
B) Non-ST-elevation myocardial infarction (NSTEMI)
Patients meet all of the following items:
1. A chest symptom (chest pain, shortness of breath, etc.) suggestive of ischemia.
2. ST depression >0.5 mm, negative T-wave (≥3 mm: dynamic T-wave inversion), or 
transient ST elevation ≤0.5 mm.
3. An elevation in blood test value (positive troponin T or troponin I, or CPK ≥2 times the 
upper limit of normal) suggestive of myocardial necrosis.
C) Unstable angina
The definition of unstable angina pectoris requires ‘1’ and either of items ‘2 - 6’ described 
below:
1. A chest symptom (chest pain, shortness of breath, etc.) suggestive of ischemia.
2. ST depression ≥0.5 mm or T-wave negative conversion ≥3 mm.
3. An elevation in troponin T.
4. Confirmation of the coronary lesion responsible for acute coronary syndrome by 
diagnostic imaging (coronary angiography, multiple detector computed tomography, etc.).
5. New decrease in wall motion by echocardiogram.
6. Reversible decrease in myocardial blood perfusion induced by drug, exercise, or thallium 
scintigraphy.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 33
I 02.
LDL-C ≥100 mg/dL at ACS diagnosis (either by Friedewald method or direct methods 
measured at each study site):
a)
Patients who have already been on any statin therapy at ACS onset. If the statin is not 
atorvastatin or rosuvastatin, statin will be changed to either atorvastatin ≥10 mg/day or 
rosuvastatin ≥5 mg/day immediately after the ACS diagnosis based on Investigators’
medical judgment. 
b)
If patients have not been on any statin therapy at ACS onset, either atorvastatin 
10 mg/day or rosuvastatin 5 mg/day is started immediately after the ACS diagnosis, 
and LDL-C is not adequately controlled with statin at 2 to 4 weeks after the ACS 
diagnosis (in principle, LDL-C target level ≥100 mg/dL, but this may not apply if the
responsible physician considers the LDL-C level inadequate on statin. Patients who 
have LDL-C <70 mg/dL cannot be enrolled).
I 03.
Patients who has stenosis of at least >50% on coronary angiography within 1 week after 
the ACS onset, and has analyzable coronary IVUS image. The evaluated segment of IVUS 
is a segment where a physician considers the IVUS imaging is possible (regardless of 
culprit vessels or not culprit vessels) other than the culprit lesions.
I 04.
Patients aged ≥20 years old at ACS diagnosis.
I 05.
Patients who meet any of the following conditions.
-
Negative hepatitis B virus surface antigen, negative total hepatitis B virus core 
antibody, and negative hepatitis C virus antibody. 
-
Negative hepatitis B virus surface antigen, positive total hepatitis B virus core 
antibody, negative hepatitis B virus DNA and negative hepatitis C virus antibody.
I 06.
Written informed consent.
7.2
EXCLUSION CRITERIA
Patients who will have met all the above inclusion criteria listed in Section 7.1 will be screened 
for the following exclusion criteria which are described in the following 3 subsections: 
7.2.1
Exclusion criteria related to study methodology
E 01. Patients who have been previously treated with at least one dose of any anti-PCSK9 
monoclonal antibody.
E 02. Uncontrolled hypertension (multiple reading with systolic blood pressure [SBP]
>180 mmHg or diastolic blood pressure [DBP] >110 mmHg) between the ACS diagnosis
and randomization visit.
E 03. Known history of hemorrhagic stroke.
E 04. Currently under treatment with anticancer drug.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 34
E 05. Patients on LDL apheresis.
E 06. Conditions/situations such as:

Any clinically significant abnormality identified that in the judgement of the Investigator
or any sub-Investigator would preclude safe completion of the study or constrain endpoint 
assessment such as major systemic diseases, patients with short life expectancy.

Considered by the Investigator or any sub-Investigator as inappropriate for this study for 
any reason, e.g.:
-
Those deemed unable to meet specific protocol requirements, such as scheduled visits.
-
Investigator or any sub-Investigator, pharmacist, study coordinator, other study staff or 
relative thereof directly involved in the conduct of the protocol, etc.
-
Presence of any other condition (e.g., geographic, social, etc.) actual or anticipated, 
that the Investigator or sub-Investigator feels would restrict or limit the patient’s 
participation for the duration of the study
E 07. Laboratory findings measured before the randomization visit within 4 weeks after the ACS 
diagnosis.

Positive serum or urine pregnancy test in women of childbearing potential.
7.2.2
Exclusion criteria related to background therapies 
E 08. Any contraindications or warning/precaution of use to statin or other LMTs as displayed in 
the respective Package Insert for these treatments.
7.2.3
Exclusion criteria related to the current knowledge of Praluent®
E 09. Any contraindications to Praluent® as displayed in the respective Package Insert for these 
treatments.
E 10. Known hypersensitivity to monoclonal antibody or any component of the drug product
used in the current study.
E 11. Pregnant or breast-feeding women.
E 12. Women of childbearing potential not protected by highly-effective method(s) of birth 
control and/or who are unwilling or unable to be tested for pregnancy.
Note: Women of childbearing potential must have a confirmed negative serum pregnancy test 
before randomization visit measured at each study site and urine pregnancy test during the pre-
treatment period. They must use an effective contraceptive method throughout the entire 
duration of the study treatment and for 10 weeks following the last injection of study treatment 
and agree to repeat urine pregnancy test at designated visits. The applied methods of 
contraception have to meet the criteria for a highly effective method of birth control according 
to the ‘Note for guidance on non-clinical safety studies for the conduct of human clinical 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 35
trials for pharmaceuticals (CPMP/ICH/286/95’). Postmenopausal women must be amenorrheic 
for at least 12 months.
7.2.4
Additional exclusion criteria before randomization
E 13. Patient who has withdrawn consent before enrollment/randomization (starting from signed 
informed consent form).
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 36
8
STUDY TREATMENTS
8.1
INVESTIGATIONAL MEDICINAL PRODUCT(S): SUBCUTANEOUS INJECTION
Formulation

Alirocumab, an active ingredient of Praluent®, is a fully human monoclonal antibody that 
binds PCSK9.  

Praluent® will be supplied in a 1 mL autoinjector as an injectable drug with pH 6.0, 
containing histidine, polisorbate 20 and sucrose with alirocumab concentration of 
75 mg/mL or 150 mg/mL.

The IMP will be supplied by the Sponsor to study sites during the study period. 
Administration of IMP will be performed at the study sites or by self-injection at home. 
Route of administration

Subcutaneous administration to the abdomen, thighs, or outer area of the upper arms.
Dose regimen

75 mg Q2W with up-titration to 150 mg Q2W if LDL-C <100 mg/dL is not achieved.
8.2
NONINVESTIGATIONAL MEDICINAL PRODUCT(S): ORAL ADMINISTRATION

Atorvastatin

Rosuvastatin

Cholesterol absorption inhibitor (ezetimibe)

Fibrates (fenofibrate, bezafibrate)

Anti-platelets (aspirin, clopidogrel, etc.)

Warfarin, and other oral anticoagulants approved in Japan (edoxaban, rivaroxaban, 
apixaban, etc.) 
The noninvestigational medicinal products (NIMPs) will be prescribed by the Investigators as
the standard treatment. Other medications/medical products not described above can be 
prescribed as needed. 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 37
8.3
BLINDING PROCEDURES
8.3.1
Methods of blinding
This study is an open-label design and the IMP administration during the study period will be 
under un-blinded manner. Despite the un-blinded IMP administration, assessment for the primary 
and key secondary efficacy endpoints will be conducted in the central reading laboratory based on 
objectively collected imaging data blinded to study treatment arms.
The study team or delegate must not summarize the primary efficacy endpoint by treatment arm, 
but may review the descriptive statistics of the primary efficacy endpoint by pooling the data from 
both arms.
8.4
METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP
Sponsor will provide the randomization scheme to the registration center. Then, the registration 
center will generate the patient randomization list.
The IMP (i.e., Praluent®) is provided in open-label boxes. 
Patient identification (patient number) is composed of 9-digit number containing the 3-digit 
country code, the 3-digit study site code, and the 3-digit patient chronological number.
Before randomizing a patient, the Investigator/sub-Investigator or designee will have to contact 
the registration center. A randomized patient is defined as a patient who has been allocated to a 
randomized treatment and recorded in the registration center database, regardless of whether a
study drug is used or not. A patient cannot be randomized more than once in the study. If the IMP 
is used without contacting the registration center, patient will be considered as not randomized 
and withdrawn from the study.
At the randomization visit, patients will be randomized to either alirocumab arm or SoC arm at a 
ratio of 1:1 with permuted-block randomization using the registration center. Randomization will 
be stratified by ‘statin therapy’ or ‘not on statin therapy’ at the ACS onset. 
8.5
PACKAGING AND LABELING
Packaging of IMPs is in accordance with the administration schedule. The content of the labeling 
is in accordance with the local regulatory specifications and requirements.
Each treatment kit containing Praluent® autoinjector will be prepared. Written details of packing 
and labeling of Praluent® will be provided as a pharmacy manual. 
NIMPs will be provided at each study site through Investigator’s prescription.  
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 38
8.6
STORAGE CONDITIONS AND SHELF LIFE
The hospital pharmacists, or heads of the study sites, are responsible for storing the IMP
(Praluent®) in a secure and safe place in accordance with local regulations, labeling specifications, 
policies, and procedures. 
Control of IMP storage conditions, especially control of temperature (e.g., refrigerated storage) 
and information on in-use stability and instructions for handling the Sanofi compound should be 
managed according to the rules provided by the Sponsor.
8.7
RESPONSIBILITIES
The hospital pharmacist, or head of the study site, will be responsible for ensuring that the IMP 
used in the clinical trial is securely maintained in accordance with the pharmacy manual provided
by the Sponsor.
All IMP/NIMP will be dispensed in accordance with the Investigator/sub-Investigator's 
prescription and the hospital pharmacist will ensure that an accurate record of IMP/NIMP issued 
and returned is maintained.
Any quality issue noticed with the receipt or use of an IMP (deficiency in condition, appearance, 
pertaining documentation, labeling, expiration date, etc) should be promptly notified to the 
Sponsor. Some deficiencies may be recorded through a complaint procedure.
A potential defect in the quality of IMP may be subject to initiation of a recall procedure by the 
Sponsor. In this case, the study site (Investigator, hospital pharmacist, etc.) will be responsible for 
promptly addressing any request made by the Sponsor, in order to recall the IMP and eliminate 
potential hazards.
Under no circumstances will the study site (Investigator, hospital pharmacist, etc.) supply IMP to 
a third party, allow the IMP to be used other than as directed by this clinical trial protocol, or 
dispose of IMP in any other manner.
8.7.1
Treatment accountability and compliance
Measures taken to ensure and document IMP compliance and accountability are described below:

The Investigator/sub-Investigator or designee will issue treatment number kits to patients 
and record their issued treatment numbers.

The Investigator/sub-Investigator, the hospital pharmacist or designee will complete the 
corresponding treatment log form. 

The Investigator/sub-Investigator or study coordinator will enter data in the appropriate 
electronic Case Report Form (e-CRF) pages, according to data recorded in the treatment 
log form.

The monitor will check the data consistency between e-CRF pages, treatment log forms, 
and returned unused autoinjectors of corresponding kits.  
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 39
8.7.2
Return and/or destruction of treatments

A detailed treatment log of the retrieved/destroyed IMP will be established with the 
hospital pharmacist and countersigned by the hospital pharmacist and the monitoring team.

The Investigator will not destroy the unused IMP unless the Sponsor provides written 
authorization.

The used IMP will be destroyed on study site according to the standard practices of the 
site.

For NIMPs, which will not be provided by the Sponsor, tracking and reconciliation has to 
be achieved by the Investigator (or hospital pharmacist if appropriate) according to the 
system provide by the Sponsor. 
8.8
CONCOMITANT MEDICATION
A concomitant medication is any treatment received by the patient concomitantly with IMP/NIMP 
during the study period.
Concomitant medications should be kept to minimum during the study. However, if these are 
considered beneficial to the patient’s welfare and unlikely to interfere with the IMP/NIMP, they 
may be given at the discretion of the Investigator, at stable dose (if possible). Daily administration 
doses of the concomitant medications will be recorded in the e-CRF and source data. 
For background LMTs, including statin, Investigators must follow the Package Insert and manage 
with safety monitoring.
Nutraceutical products including specified health food or over-the-counter therapies that may 
affect lipids are allowed only if they have been used at a stable dose before the study, but in 
general should be avoided unless these products are required for medical reasons. Example of 
such nutraceutical products or over-the-counter therapies include omega-3 fatty acids at doses 
<1000 mg/day, plant stanols such as found in Benecol (US and Europe), flaxseed oil, psyllium, 
and/or herbal medicines. 
Note: Use of other anti-PCSK9 monoclonal inhibitors is prohibited during the study.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 40
9
ASSESSMENT OF INVESTIGATIONAL MEDICINAL PRODUCT
9.1
EFFICACY ENDPOINT
9.1.1
Primary efficacy endpoint
The primary efficacy endpoint is the percent change in normalized TAV from baseline to 
Week 36, which is defined as: 100 x (normalized TAV value at Week 36 - normalized TAV value 
at baseline) / normalized TAV value at baseline, and calculated by Sponsor or delegate.
The baseline normalized TAV value will be the normalized TAV obtained before the 
randomization.
The normalized TAV at Week 36 will be the normalized TAV obtained after ≥24 weeks of 
treatment after randomization.
9.1.2
Secondary endpoints
9.1.2.1
Key secondary efficacy endpoint
The key secondary efficacy endpoint is:

Absolute change in PAV from baseline to Week 36.
9.1.2.2
Other secondary efficacy endpoints
The other secondary efficacy endpoints are:

Absolute change in normalized TAV from baseline to Week 36.

Absolute and percent changes in external elastic membrane (EEM) volume from baseline 
to Week 36.

Absolute and percent changes in lumen volume from baseline to Week 36.

Absolute and percent changes in calculated LDL-C from baseline to Week 12, and 
Week 36.

Absolute and percent changes in Apo B from baseline to Week 36.

Absolute and percent changes in non-HDL-C from baseline to Week 36.

Absolute and percent changes in TC from baseline to Week 36.

Absolute and percent changes in Lp(a) from baseline to Week 36.

Absolute and percent changes in HDL-C from baseline to Week 36.

Absolute and percent changes in fasting TGs from baseline to Week 36.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 41

Absolute and percent change in Apo A-1 from baseline to Week 36.
9.1.3
Efficacy assessment method
9.1.3.1
IVUS parameters
The EEM volume, lumen volume, TAV, normalized TAV, and PAV will be calculated by the 
Sponsor or delegate. These IVUS parameters will be calculated using the following equations 
defined using EEMCSA and LumenCSA taken at pre-determined interval between each image 
(=0.5 mm):
TAV (mm3)= 
)
(
CSA
CSA
Lumen
EEM


,
normalized TAV (mm3)=TAV
n
C

,
where is the summation over all the analyzed frames, n is the number of analyzed frames per 
patient , C is the median of the number of analyzed frames in patients with available baseline 
TAV within randomized population. EEMCSA is the cross-sectional area inside the EEM border,
the LumenCSA is the cross-sectional area inside the lumen border, and both parameters are 
measured by the central reading laboratory. Besides,
PAV (%)=
100
(










CSA
CSA
CSA
EEM
Lumen
EEM
,
EEM volume (mm3)= 
)
(

CSA
EEM
,
Lumen volume (mm3)= 
)
(
CSA
Lumen

,
where is the summation over all the analyzed frames.
The detailed procedures of IVUS image analysis and calculation of the parameters will be 
specified in the procedure manual of IVUS image analysis. 
The detailed procedures of IVUS imaging will be described in the specific manual, which will be 
provided to study sites (see Section 10).
9.1.3.2
Lipid parameters
The TC, HDL-C, TG, Apo B, Apo A-1, and Lp(a) will be measured by the central laboratory as 
per the schedule in Section 1.2. The LDL-C will be calculated using the Friedewald formula (35).
If TG values exceed 400 mg/dL (4.52 mmol/L), LDL-C level will not be calculated using the 
Friedewald formula, but will be provided using the direct method. Non-HDL-C will be calculated 
by subtracting HDL-C from TC. Apo B/Apo A-1 ratio will be calculated. Detailed procedures of 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 42
sample preparation, storage, and shipment will be described in the laboratory manual which will 
be provided to each study site.
Efficacy endpoints will not be considered as adverse events (AEs), such as those related to
abnormalities in lipid parameters, unless meeting the criteria in Section 10.4.1.
9.2
SAFETY ENDPOINTS
Safety endpoints are as follows:

Safety parameters (adverse events including CV events, laboratory data, and vital signs) 
will be assessed throughout the study.
Note: CV events include CHD death, non-fatal MI, fatal and non-fatal ischemic/hemorrhagic 
stroke, congestive heart failure requiring hospitalization, ischemia-driven coronary 
revascularization procedure.
The observation period of safety data is defined in Section 11.4.3.
9.2.1
Adverse events
All AEs diagnosed by the Investigator/sub-Investigator, irrespective of the result of the 
adjudication for CV events, will be reported and described. 

All AEs will be coded to “Lowest Level Term (LLT)”, “Preferred Term (PT)”, “High 
Level Term (HLT)”, “High Level Group Term (HLGT)”, and associated primary “System 
Organ Class (SOC)” using the version of Medical Dictionary for Regulatory Activities
(MedDRA) currently in effect at Sponsor or delegate at the time of the considered 
database lock. 

AESIs include events as the following:
-
General allergic events (refer to Section 10.6.2)
-
Local injection site reactions (using specific e-CRF pages, refer to Section 10.6.1 and 
Section 17, Appendix I)
-
Hemolytic anemia (using specific e-CRF pages, refer to Section 10.4.4.1 and Section
17, Appendix H)
-
Neurologic and Neurocognitive adverse events (refer to Section 10.4.4.1 and Section
17, Appendix F)
-
Ophthalmologic adverse events (using specific e-CRF pages, refer to Section 10.4.4.1
and Section 17, Appendix F)
-
Skeletal muscle-related adverse event (using specific e-CRF pages, refer to Section 17, 
Appendix F)
-
Symptomatic overdose with IMP (refer to Section 10.4.4.1 and Section 17, Appendix F
and G)
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 43
-
Pregnancy (including male patient’s partner) (refer to Section 10.4.4.1 and Section 17, 
Appendices A and F)
-
Elevation of ALT (refer to Section 10.4.5 and Section 17, Appendices F and G)
Adverse event observation period is as per observation period of safety data defined in 
Section 11.4.3.
Adjudicated CV events include all CV AEs and coronary revascularization positively adjudicated 
(refer to Section 10.6.3) occurring after obtaining the informed consent for study participation
until the end of study. The adjudication classifications are the following:

CHD death

Non-fatal MI

Fatal and non-fatal ischemic and/or hemorrhagic stroke

Unstable angina requiring hospitalization

Ischemia-driven coronary revascularization procedure
In addition, all deaths will be classified.
Note: Observation period for death are as per the adverse event observation period. In addition, 
“post-study” death includes all deaths reported after the end of the study (refer to definition of 
end of study per patient in Section 6.2.2).
9.2.2
Laboratory safety variables
The clinical laboratory data consist of hematology (red blood cell count, hematocrit, hemoglobin, 
white blood cell count with differential count, platelet count), blood chemistry (glucose, sodium, 
potassium, chloride, creatinine, uric acid, lactate dehydrogenase [LDH], total protein, albumin, 
gamma-glutamyl transpeptidase [γGT], CPK, alanine aminotransferase [ALT], aspartate 
aminotransferase [AST], alkaline phosphatase [ALP] and total bilirubin), and hepatitis C virus 
antibody (refer to Section 1.2).
Additional safety laboratory parameters may be reflexively measured based on the resultant 
laboratory data (refer to Section 10.4.5 and Section 17, Appendix F).
Clinical laboratory values will be analyzed after conversion into standard international units. 
International units will be used in all listings and tables.
9.2.3
Vital signs
Vital signs include heart rate, and systolic/diastolic blood pressure in the sitting position.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 44
9.3
OTHER ENDPOINTS
9.3.1
Hemoglobin A1c 
The absolute change in hemoglobin A1c (HbA1c) (%) from the baseline (Week 0) to Week 12, 
Week 24, and Week 36 (EOT visit) will be assessed. 
9.3.2
High sensitivity C-reactive protein
The percent change in high sensitivity C-reactive protein (hs-CRP) from baseline (Week 0) to 
Week 36 (EOT visit) will be assessed.
9.3.3
EQ-5D Patient Questionnaire
EQ-5D is a standardized measure of health status developed by the EuroQol Group in order to 
provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D as a 
measure of health-related quality of life, defines health in terms of 5 dimensions: mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension can take one 
of three responses (3 ordinal levels of severity): “no problem” (1); “some problems” (2); “severe 
problems” (3). Overall health state is defined as a 5-digit number. Health states defined by the 
5-dimensional classification can be converted into corresponding index scores that quantify health 
status, where 0 represents “death” and 1 represents “perfect health” (see Section 17, Appendix J)
(36). If response to one or more dimension is missing, the index score will be missing.
EQ-5D variables include response of each EQ-5D items, index score, and absolute change of 
index score from the randomization visit (Week 0) (36).
9.4
APPROPRIATENESS OF MEASUREMENTS 
The efficacy and safety endpoints used in this study are standard for the evaluation of post-ACS 
patients with hypercholesterolemia (refer to Section 4 for details).
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 45
10
STUDY PROCEDURES
For all study site visits except the randomization visit (Visit 1/Week 0), a time frame of 7 days
before and after the scheduled study site visit will be allowed. For all study site visits after the 
randomization visit (Visit 1/Week 0), if a visit date is not kept, the next visit is scheduled 
according to the original schedule as outlined in Section 1.2.
Evaluation IVUS imaging:
The evaluation IVUS imaging will be performed in the same vessels of the initial IVUS imaging 
at the ACS diagnosis. The Investigator can schedule the evaluation IVUS imaging within 2 weeks 
before and after the EOT (Week 36; between Week 34 and Week 38). The detailed procedures of 
IVUS imaging are described in the specific manual. If the evaluation IVUS study cannot be 
performed by the EOT visit (Week 36) in patients of the alirocumab arm, Praluent® will be 
administered at Week 36 after data collection listed in the EOT visit (see Section 10.1.1.1.5), and 
the evaluation IVUS imaging can be performed before Week 38, while the effect of alirocumab 
remains. For patients in the SoC arm, the evaluation IVUS imaging should be performed between 
Week 34 and Week 36 as in the alirocumab arm. If patients cannot undergo the evaluation IVUS 
imaging by Week 36, all efforts should be made to perform the evaluation IVUS imaging by 
Week 38. 
Blood sampling: 
The blood sampling has to be performed in the morning under fasting conditions, which is defined 
as an overnight fast no less than 8 hours that consist of no food or liquid intake other than water 
with exception of to do so otherwise by Investigator/sub-Investigator’s medical judgment, 
throughout the study. 
The blood sample will be used to measure lipid parameters [TC, LDL-C, HDL-C, TG, non-HDL-
C, Apo B, Apo A-1, Apo B/Apo A-1 ratio, Lp(a)], hematology (red blood cell count, hemoglobin, 
hematocrit, white blood cell count and differential count, platelet count), blood chemistry, HbA1c, 
hs-CRP, hepatitis B virus antibody, hepatitis C virus antibody, etc (see also Section 1.2). 
Alcohol consumption within 48 hours and intense physical activities within 24 hours preceding 
the blood sampling are discouraged. 
Note: If a patient is not in fasting conditions, the blood sampling will be postponed and a new 
appointment will be given the day after (or as close as possible to this date) to the patients with 
instruction to fast.
Laboratory tests:
The laboratory data are collected in accordance with the study schedule described in Section 1.2.
It is noted that the lipid panels 1, 2, hepatitis C virus antibody, hepatitis B total core antibody
(HBc-ab), hs-CRP, and HbA1c will be measured by the central laboratory (and at each study site 
if necessary). 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 46

Hematology

Chemistry including liver function enzymes, LDH, and CPK

Lipid panel 1: TC, calculated and directly measured LDL-C, HDL-C, TG, and non-HDL-C

Lipid panel 2: Apo B, Apo A-1, Apo B/Apo A-1, and Lp(a)

Hepatitis C virus antibody: positive test will be confirmed with reflexive testing at each 
study site

Hepatitis B virus surface antigen, surface antibody, and total core antibody: positive test
that suggests active infection (positive surface antigen and antibody) or viral carrier
(positive total core antibody) will be confirmed with reflexive testing at each study site.
Note: The results of hepatitis B virus surface antigen and antibody results will be collected 
from each study site. Hepatitis B virus total core antibody will be measured by the central 
laboratory at the randomization visit (Week 0). Hepatitis B virus DNA will be measured 
immediately if positive hepatitis B virus total core antibody results.

HbA1c

hs-CRP

Urine pregnancy test

Serum pregnancy test
Decision trees for the management of certain laboratory abnormalities by Sponsor are provided in 
Section 17, Appendix F, and Appendix G, and should be followed by Investigators/sub-
Investigators. 
Other endpoint assessment methods:
All other blood parameters will also be measured at each study site during the study (as per the 
schedule in Section 1.2, on blood samples taken preferably in the morning in fasting conditions
described above [see Section 10.1.1]). Alcohol consumption within 48 hours and intense physical 
activities within 24 hours preceding the blood sampling are discouraged. 
Physical examination:
A physical examination should be performed at the time points indicated in the study schedule 
flowchart of Section 1.2. If a new clinically significant abnormality or worsening from baseline is 
detected after randomization, as should be reported as AE and further clinical investigations 
and/or specialist consultation should be considered as per the Investigator/sub-Investigator’s 
medical judgment. 
Blood pressure / heart rate:
It is recommended that blood pressure is measured in the sitting position under the same 
conditions each time, approximately at the same time of the day, on the same arm, with the same 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 47
apparatus (after the patient has rested in sitting position for at least 5 minutes). Both systolic and 
diastolic blood pressure should be recorded. It should be noted that blood pressure should be 
measured in both arms at the randomization visit (Week 0). The arm with the highest diastolic 
blood pressure will be used to measure the blood pressure throughout the study. The highest blood 
pressure value will be recorded in the e-CRF. 
The heart rate will also be measured at the time of blood pressure measurement. 
Note: In cases with hypertension (high blood pressure values) (within 4 weeks prior to the 
randomization or after ACS onset and prior to the randomization) the Investigator/sub-
Investigators is responsible for the optimization of the patient’s treatment to achieve blood 
pressure target as defined by local guidelines (Japanese Society of Hypertension) or the Seventh 
Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure (JNC7).
Body weight and height: 
Body weight should be obtained with the patient wearing undergarments or very light clothing 
and no shoes, and with an empty bladder. The same scale should be used throughout the study. 
The use of calibrated balance scales is mandatory. Self-reported weights are not accepted. Patients 
must not read the scale themselves. Height should be measured and self-reported heights are not 
accepted. 
EQ-5D patient questionnaire:
Collection of EQ-5D patient questionnaire will be carried out in all patients at each scheduled 
visit (5 visits) by Investigator, or a person designated by the Investigator. 
10.1
VISIT SCHEDULE
Patients with hypercholesterolemia, who develop ACS and undergo successful therapeutic 
intervention such as PCI (stent placement), and IVUS imaging, are the target subjects of the 
current study. All patients have to have been received stable statin therapy with either atorvastatin 
≥10 mg/day or rosuvastatin ≥5 mg/day for at least 2 weeks prior to the randomization visit 
(Visit 1).
Between the onset of ACS and the randomization visit (within 4 weeks prior to the randomization 
visit), the patient will receive verbal information concerning the aims and methods of the study, 
its constraints and risks, and the study duration, and will be provided of a written summary. The 
written informed consent must be signed by the patient and the Investigator prior to any study 
activity. Only patients who meet the inclusion/exclusion criteria as noted in Section 7 will be 
enrolled to the study. Women of childbearing potential will be instructed to use a medically 
approved contraceptive method throughout the entire study period. 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 48
10.1.1 Open-label treatment period
For each on-site visit, the patient should visit the study site in the morning under fasting 
conditions, which is defined as an overnight fasting no less than 8 hours that consist of no food or 
liquid intake other than water with the exception made by Investigator's medical judgment. 
During the open-label treatment period, the patient will have 5 on-site visits, and 14 Praluent®
administration visits§ for patients in the alirocumab arm or 5 phone-call interviews for patient in 
the SoC arm. Data on IMP/NIMP compliance and any AE/SAE including CV events will be 
recorded in both study arms after the randomization visit (Week 0) to the EOT visit (Week 36). 

5 on-site visits: Weeks 0, 4, 12, 24, and 36.

14 Praluent® administration visits (alirocumab arm only)§: Weeks 2, 6, 8, 10, 14, 16, 18, 
20, 22, 26, 28, 30, 32, and 34.
§: If the evaluation IVUS imaging cannot be performed by Week 36, patients will receive 
an additional Praluent® dose at Week 36. The evaluation IVUS imaging must be 
performed within 2 weeks of Week 36 on-site visit.  

If patients perform self-injection of Praluent® at home, they must visit the study site at 
least every 4 weeks, and at Weeks 0, 4, 12, 14, 24, and 36 regardless of the timing of the 
first self-injection.

5 phone-call interviews (SoC arm only); Weeks 8, 16, 20, 28, and 32.
10.1.1.1 Study site visit
10.1.1.1.1Randomization visit (Visit 1 / Week 0 / D1)
Blood sampling should be completed before IMP administration. 
This visit includes:

On-site visit.

Complete and collect written informed consent for the study by the randomization visit.
Patient number will be allocated by the registration center. The patient number is 
composed of a 9-digit number containing the 3-digit country code, the 3-digit center code, 
and the 3-digit patient chronological number (3-digit patient chronological number is 001 
for the first patient screened in a center, 002 for the second patient screened in the same 
center).
Note: The written informed consent can be obtained any time between ACS diagnosis and 
the randomization visit (see Section 1.2).

Confirm inclusion and exclusion criteria.

Collect information about therapeutic intervention such as ACS culprit vessels, IVUS 
imaging locations (refer to Section 17, Appendix D for vessel locations), and types of stent 
placed at the PCI (BMS or DES).
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 49

Contact the registration center to notify the patient enrollment. After the final confirmation 
of inclusion and exclusion criteria at the registration center, the arm to which the patient 
randomized to is communicated.

Demographics (age, gender, race, ethnicity).

Collect contact information (address, email, home and cell phone numbers) of the patient, 
patient's family members, and patient's primary care physician / cardiologist.

Patient's medical and surgical history (including menopausal status, and family history), 
alcohol habits, smoking habits, lipid parameters including LDL-C used for the study 
eligibility, and HbA1c.

Collect patient's history of CV disease.

Record use of LMT including statins and prescription or over-the-counter non-statin 
LMTs within 1 month prior to Visit 1.

Record of all concomitant medications including CV medications.

Collection of adverse events including CV events (if any).

Collection of results of hepatitis B virus surface antigen and antibody tested at the time of 
ACS diagnosis and PCI.
Note: If the hepatitis B virus surface antigen and antibody titers are not checked, they 
must be measured prior to the randomization visit and the results must be recorded at the 
randomization visit (see Section 7.1).  

Physical examination including vital signs: heart rate and sitting SBP and DBP.

Body weight and height.

EQ-5D patient questionnaire.

Serum and urine pregnancy tests (women of childbearing potential [WOCBP]).

Confirm and record compliance with background LMT regimen including NIMPs. 

Fasting blood sample listed below will be collected and measured. 

Hematology and chemistry.
-
TC, calculated and directly measured LDL-C, HDL-C, TG, non-HDL-C (central 
laboratory).
-
Apo B, Apo A-1, Apo B/Apo A-1, Lp(a) (central laboratory).
-
HbA1c (central laboratory).
-
hs-CRP (central laboratory).
-
Hepatitis B virus antibody (Hepatitis B virus total core antibody is tested at the central 
laboratory).
-
Hepatitis C virus antibody titer (central laboratory).
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 50
Note: Additional blood samples can be obtained for measurement of above listed items 
and others at the study site by Investigator’s judgment as needed.

If the patient’s eligibility (and fasting status) is confirmed, contact the registration center 
for randomization. The Investigator/sub-Investigator must not administer IMP without 
notifying the registration center.

When the Investigator confirms the patient is randomized to the alirocumab arm and has 
completed fasting blood sample collection and assessments of all evaluations planned at 
this randomization visit (Visit 1), the first Praluent® injection will be performed at the 
study site following the patient injection instruction. 

The patient should be observed for at least 30 minutes after Praluent® administration.   

If patient is randomized to the SoC arm, ongoing LMTs will be continued unless 
modification of LMTs is made by the Investigator’s medical judgment. 

For the patient who is randomized to the alirocumab arm, an appointment will be given for 
next Praluent® administration visit (Week 2 / D15).

For the patient who is randomized to the SoC arm, an appointment will be given for next 
on-site visit (Visit 2 / Week 4 / D29). The patient should be instructed to visit the study 
site in the morning under fasting conditions, which is defined as an overnight fasting no 
less than 8 hours that consist of no food or liquid intake, other than water unless exception 
made by Investigator's medical judgment. 

Transfer IVUS imaging data to the central reading laboratory. 
10.1.1.1.2Study Site Visit 2 (Week 4 / D29 ± 7 days)
This visit includes:

On-site visit.

EQ-5D patient questionnaire

IMP/NIMP compliance check including diet therapy (Patients should be on a diet 
following JAS guideline or equivalent).

Vital signs: heart rate and sitting SBP and DBP.

Record of all concomitant medications including CV medications.

Collection of adverse events including CV events (if any).

Fasting blood sample listed below will be collected and measured. 
-
Hematology and chemistry.
-
TC, calculated and directly measured LDL-C, HDL-C, TG, non-HDL-C (central 
laboratory).
Note: Additional blood samples can be obtained for measurement of above listed items 
and others at the study site by Investigator’s judgment as needed.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 51

When the Investigator or the site medical staff confirms all required measurements are 
completed, the patient in the alirocumab arm will receive Praluent® administration.

The patient should be observed for at least 30 minutes after Praluent® administration.  

If patient is in the SoC arm, ongoing LMTs will be continued unless modification of 
LMTs is made by the Investigator’s medical judgment. 

For the patient in the alirocumab arm, an appointment will be given for next Praluent®
administration visit (Week 6 / D43). 

For the patient in the SoC arm, an appointment will be given for the first phone-call 
interview (Week 8 / D57). 
10.1.1.1.3Study Site Visit 3 (Week 12 / D85 ± 7 days)
This visit includes:

On-site visit.

EQ-5D patient questionnaire.

IMP/NIMP compliance check including diet therapy (Patients should be on a diet 
following JAS guideline or equivalent).

Body weight.

Vital signs: heart rate and sitting SBP and DBP.

Record of all concomitant medications including CV medications.

Collection of adverse events including CV events (if any).

Fasting blood sample listed below will be collected and measured. 
-
Hematology and chemistry.
-
TC, calculated and directly measured LDL-C, HDL-C, TG, non-HDL-C (central 
laboratory).
-
HbA1c (central laboratory).
Note: Additional blood samples can be obtained for measurement of above listed items 
and others at the study site by Investigator’s judgment as needed.

When the Investigator or the site medical staff confirms all required measurements are 
completed, the patient in the alirocumab arm will receive Praluent® administration.

The patient should be observed for at least 30 minutes after Praluent® administration.   

If patient is in the SoC arm, ongoing LMTs will be continued unless modification of 
LMTs is made by the Investigator’s medical judgment. 

For the patient in the alirocumab arm, an appointment will be given for next Praluent®
administration visit (Week 14 / D99). 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 52

For the patient in the SoC arm, an appointment will be given for next phone-call interview
(Week 16 / D113).
10.1.1.1.4Study Site Visit 4 (Week 24 / D169 ± 7 days)
This visit includes:

On-site visit.

EQ-5D patient questionnaire.

IMP/NIMP compliance check including diet therapy (Patients should be on a diet 
following JAS guideline or equivalent).

Body weight.

Vital signs: heart rate and sitting SBP and DBP.

Record of all concomitant medications including CV medications.

Collection of adverse events including CV events (if any).

Fasting blood sample listed below will be collected and measured. 
-
Hematology and chemistry.
-
TC, calculated and directly measured LDL-C, HDL-C, TG, non-HDL-C (central 
laboratory).
-
HbA1c (central laboratory).
Note: Additional blood samples can be obtained for measurement of above listed items 
and others at the study site by Investigator’s judgment as needed.

When the Investigator or the site medical staff confirms all required measurements are 
completed, the patient in the alirocumab arm will receive Praluent® administration.

The patient should be observed for at least 30 minutes after Praluent® administration.   

If patient is in the SoC arm, ongoing LMTs will be continued unless modification of 
LMTs is made by the Investigator’s medical judgment. 

For the patient in the alirocumab arm, an appointment will be given for next Praluent®
administration visit (Week 26 / D183). 

For the patient in the SoC arm, an appointment will be given for next phone-call interview
(Week 28 / D197).

The Investigator should make a schedule with the patient for the evaluation IVUS study at 
the EOT (Week 36 ± 2 weeks) by this on-site study visit if possible. 
10.1.1.1.5Study Site Visit 5 (End of Treatment Visit, Week 36 / D253 ± 14 days)
This study visit includes:

On-site visit.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 53

Contact the registration center to document the end of study.
Note: If the evaluation IVUS imaging is completed in this visit, EOT will be the end of 
study. If the evaluation IVUS imaging is scheduled after this visit, the contact with the 
registration center will be made when the evaluation IVUS imaging has been completed
and this point is considered the end of study.  

EQ-5D patient questionnaire.

IMP/NIMP compliance check including diet therapy (Patients should be on a diet 
following JAS guideline or equivalent).

Body weight.

Vital signs: heart rate and sitting SBP and DBP.

Record of all concomitant medications including CV medications.

Collection of adverse events including CV events (if any).

Urine pregnancy tests (WOCBP).

Fasting blood sample listed below will be collected and measured. 
-
Hematology and chemistry.
-
TC, calculated and directly measured LDL-C, HDL-C, TG, non-HDL-C (central 
laboratory).
-
Apo B, Apo A-1, Apo B/Apo A-1, Lp(a) (central laboratory).
-
HbA1c (central laboratory).
-
hs-CRP (central laboratory).
-
Hepatitis C virus antibody levels (central laboratory).
Note: Additional blood samples can be obtained for measurement of above listed items 
and others at the study site by Investigator’s judgment as needed.

If patient is in the SoC arm, ongoing LMTs will be continued unless modification of 
LMTs is made by the Investigator’s medical judgment. 

Evaluation IVUS study should performed out by this visit ± 14 days and the IVUS images
are transferred to the central reading laboratory immediately after the IVUS study. 

The notification of the end of study should be communicated to the registration center.
10.1.1.2 Praluent® administration visit (alirocumab arm only)
When patients are randomized to the alirocumab arm, they have to visit the study sites every 
2 weeks for Praluent® administration in addition to on-site visits as indicated below:

Week 2 / D15 ± 7 days

Week 6 / D43±7 days
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 54

Week 8 / D57 ±7 days: IMP/NIMP compliance recording including diet therapy (based 
on JAS guideline or the equivalent)

Week 10 / D71 ±7 days

Week 14 / D99 ±7 days

Week 16 / D113 ±7 days: IMP/NIMP compliance recording including diet therapy (based 
on JAS guideline or the equivalent)

Week 18 / D127 ±7 days

Week 20 / D141 ±7 days: IMP/NIMP compliance recording including diet therapy (based 
on JAS guideline or the equivalent)

Week 22 / D155 ±7 days

Week 26 / D183 ±7 days

Week 28 / D197 ±7 days: IMP/NIMP compliance recording including diet therapy (based 
on JAS guideline or the equivalent)

Week 30 / D211 ±7 days

Week 32 / D225 ±7 days: IMP/NIMP compliance recording including diet therapy (based 
on JAS guideline or the equivalent)

Week 34 / D239 ±7 days
Note: IMP/NIMP compliance, diet therapy and AE/SAE will be assessed and recorded at 
Week 8, Week 16, Week 20, Week 28, and Week 32 as indicated above. 
Note 2: During Praluent® injection visits at Week 2, Week 10, Week 22, and Week 34, the 
appointment will be given for next on-site visits (Week 4, Week 12, Week 24, and Week 
36, respectively). The patient should be instructed to visit the study site in the morning 
under fasting conditions, which is defined as an overnight fasting no less than 8 hours 
that consist of no food or liquid intake, other than water unless exception made by 
Investigator’s medical judgment.
10.1.1.3 Phone-call interview (SoC arm only)
When patients are randomized to the SoC arm, they will have phone-call interview every 4 weeks
for NIMPs compliance including diet therapy, CV medications, and AE/SAE recording in 
addition to on-site visits as indicated below:

Week 8 / D57 ± 7 days

Week 16 / D113 ±7 days

Week 20 / D141 ±7 days

Week 28 / D197 ±7 days
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 55

Week 32 / D225 ±7 days
Note:  During the phone-call interviews at Week 8, Week 20, and Week 32, the 
appointment will be given for next on-site visits (Week 12, Week 24, and Week 36, 
respectively). The patient should be instructed to visit the study site in the morning under 
fasting conditions, which is defined as an overnight fasting no less than 8 hours that 
consist of no food or liquid intake, other than water unless exception made by 
Investigator’s medical judgment.
10.2
DEFINITION OF SOURCE DATA
Evaluations that are reported in the e-CRF must be supported by appropriately signed identified
source documentation related but not limited to the following:

Agreement, date, and signature of informed consent mentioning the study identification.

Patient identification, last participation in a clinical trial, medical history, associated
disease, and data related to the studied pathology.

Contraception methods for women of childbearing potential.

Previous and concomitant medication (including the LMT).

Study identification.

Treatment number, dates of administration.

Dates of visit and assessments including the examination report.

Vital signs, height, body weight.

Central laboratory reports (dated and signed by the Investigator or sub-Investigator).

Laboratory values at study site (dated and signed by the Investigator or sub-Investigator)

The registration center confirmation reports (randomization, discontinuation, and the end 
of the study).

ECG records with physician’s signature and dated.

AEs and follow-up:
-
In case of SAE, the study site should file as the source document at least copies of the
hospitalization reports and any relevant examination reports documenting the follow
up of the SAE.

Date of premature study discontinuation (if any) and reasons.
Source documentation may be found in the followings:

Patient’s identity.

Medical history.

Hospital records.

Nursing notes.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 56

Physician’s notes.

Laboratory reports.
10.3
HANDLING OF PATIENT TEMPORARY OR PERAMANENT TREATMENT
DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION
Study treatment should be continued whenever possible. In case the treatment is discontinued, it 
should be determined whether the discontinuation can be made temporarily; permanent treatment 
discontinuation should be a last resort. Any treatment discontinuation should be fully documented 
in the Case Report Form (CRF). In any case, the patient should remain in the study as long as 
possible.
10.3.1 Temporary treatment discontinuation
Temporary treatment discontinuation may be considered by the Investigator/sub-Investigator
because of suspected AEs. Reinitiation of treatment will be done under close and appropriate 
clinical/and or laboratory monitoring once the Investigator/sub-Investigator will have considered 
according to his/her best medical judgment that the responsibility of the study treatment in the 
occurrence of the concerned event was unlikely and if the selection criteria for the study are still 
met (refer to Sections 7.1 and 7.2).
All treatment interruption duration should be recorded by the Investigator/sub-Investigator in the 
appropriate e-CRF screens when considered as confirmed.
Treatment interruption is defined as one or more scheduled injections that are not administered to 
the patient as decided by the Investigator/sub-Investigator.
10.3.2 Permanent treatment discontinuation with investigational medicinal product(s)
Permanent treatment discontinuation is any treatment discontinuation associated with the 
definitive decision from the Investigator or the patient not to re-expose the patient to the IMP at 
any time.
10.3.3 List of criteria for permanent treatment discontinuation (SoC or IMP)
The patients may withdraw from study treatment if they decide to do so, at any time and
irrespective of the reason, or this may be the Investigator’s decision. Patient withdrawal from the
study treatment or study should be avoided as much as possible. All efforts should be made to
document the reasons for treatment discontinuation and this should be documented in the e-CRF.
Patients should discontinue the study treatment for the following reasons:

Pregnancy, intention for pregnancy, or no longer taking an effective contraceptive method 
(in female patients).

Acute injection-site reaction of clinical concern.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 57

SAE (or non-serious but severe in intensity) of hypersensitivity reaction considered to be 
related to study treatment.

At patient’s request.

If, in the Investigator/sub-Investigator’s opinion, continuation of the study treatment is
detrimental to the patient’s well-being.

Condition that requires discontinuation of study treatment (e.g., laboratory abnormalities, 
refer to decision tree Appendix F).

At the specific request of the Sponsor.

At the specific request of the Investigator with Sponsor’s agreement.
Criteria of permanent treatment discontinuation due to insufficient adherence to medications are 
defined as followed:

Alirocumab arm: IMP administration compliance is less than 50% for 12 weeks (3 months 
from the randomization visit). 

SoC arm: NIMP administration compliance is less than 50% for 6 months from the 
randomization visit.
Note for SoC arm: If patients exhibit their NIMP administration compliance is less than 
50% for the first 3 months after the randomization visit, Investigators/sub-Investigator can 
terminate the study based on their judgment considering patients’ safety. 
10.3.4 Handling of patients after permanent treatment discontinuation (SoC or IMP)

All definitive discontinuation of study treatment should be recorded by the Investigator in
the appropriate screens of the e-CRF and in the patient’s medical records when considered 
as confirmed. The registration center should be notified when a patient prematurely 
discontinues the study. Patients should be asked to stick to the visit schedule for measuring 
laboratory test values until the end of study (Week 36).

When patients permanently discontinue the study (regardless of the reasons) before 
Week 24 (6 months), they will have an unscheduled on-site visit as soon as possible 
(preferably within 7 days from treatment discontinuation) with assessments originally 
planned at the EOT visit (Week 36). 

When patients in the alirocumab arm permanently discontinue the study (regardless of the
reasons) on Week 24 (6 months) or after, the Investigator should make the best effort to 
schedule the evaluation IVUS imaging with assessments originally planned at the EOT
visit (Week 36) within 2 weeks from the last IMP administration (the earliest last IMP 
administration occurs on Week 22). If the patients decline the evaluation IVUS imaging 
after the study discontinuation, they will have an unscheduled on-site visit as soon as 
possible (preferably within 7 days from treatment discontinuation) with assessments 
originally planned at the EOT visit (Week 36). 

When patients in the SoC arm permanently discontinue the study (regardless of the 
reasons) on Week 24 (6 months) or after, the Investigator should make the best effort to 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 58
schedule the evaluation IVUS imaging with assessments originally planned at the EOT
visit (Week 36) within 2 weeks from the determination date of the study discontinuation.
If the patients decline the evaluation IVUS imaging after the study discontinuation, they 
will have an unscheduled on-site visit as soon as possible (preferably within 7 days from 
treatment discontinuation) with assessments originally planned at the EOT visit (Week 36).

When patients, who develop AEs including AESIs and/or SAEs and need to be followed 
up as specified in this protocol, permanently discontinue the study, they will be followed 
up until recovery or stabilization of the AEs. 
Note: If the evaluation IVUS imaging cannot be performed within 2 weeks from the last
Praluent® administration in the alirocumab arm or 2 weeks after the day when the study 
discontinuation is determined in the SoC arm, lipid values measured at the study site 
should be recorded at the evaluation IVUS imaging. 
10.3.5 Procedure and consequence for patient withdrawal from study
The patients may withdraw from the study, before study completion if they decide to do so, at any
time and irrespective of the reason. 
If possible, the patients should be assessed using the usual scheduled procedure on the visit day of 
the end of study.
For patients who fail to return to the site, the Investigator/sub-Investigator should make the best 
effort to re-contact the patient (e.g., contacting patient’s family or private physician, review 
available registries or health care database), and to determine his/her health status, including at 
least his/her vital status. Attempts to contact such patients must be documented in the patient’s 
records (e.g., number of times and dates of attempted telephone contact, receipt for sending a 
registered letter).
Patients who have withdrawn from the study cannot be re-randomized (treated) in the study. Their
patient number and treatment number must not be reused.
10.4
OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING
10.4.1 Definitions of adverse events 
10.4.1.1 Adverse event

An adverse event (AE) is any untoward medical occurrence in a patient or clinical
investigation patient administered a pharmaceutical product and which does not 
necessarily have to have a causal relationship with this treatment.

All AE diagnosed by the Investigator, irrespective of the results of the adjudication for CV 
events, will be reported and described. 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 59

All AEs will be coded to “LLT”, “PT”, “HLT”, “HLGT”, and associated primary “SOC”
using the version of MedDRA currently in effect at Sponsor or delegate at the time of the 
considered database lock. 
10.4.1.2 Serious adverse event
A serious adverse event (SAE) is any untoward medical occurrence that at any dose:

Results in death

Life-threatening
Note: The term “life-threatening” in the definition of “serious” refers to an event in 
which the patient was at risk of death at the time of the event; it does not refer to an event 
which hypothetically might have caused death if it were more severe.

Requires inpatient hospitalization or prolongation of existing hospitalization

Results in persistent or significant disability/incapacity

Congenital anomalies/birth defects, or

Other medically important event
Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
appropriate in other situations, such as important medical events that may not be immediately life-
threatening or result in death or hospitalization but may jeopardize the patient or may require 
medical or surgical intervention (i.e., specific measures or corrective treatment) to prevent one of 
the other outcomes listed in the definition above.
Note: The following list of medically important events is intended to serve as a guideline for 
determining which condition has to be considered a medically important event. The list is not 
intended to be exhaustive:

Intensive treatment in an emergency room or at home for:
-
Allergic bronchospasm,
-
Blood dyscrasias (i.e., agranulocytosis, aplastic anemia, bone marrow aplasia, 
myelodysplasia, pancytopenia, etc.), 
-
Convulsions (seizures, epilepsy, epileptic fit, absence, etc.).

Development of drug dependence or drug abuse.

ALT >3 x upper limit of normal range (ULN) + total bilirubin >2 x ULN or asymptomatic 
ALT increase >10 x ULN.

Suicide attempt or any event suggestive of suicidality.

Syncope, loss of consciousness (except if documented as a consequence of blood 
sampling).

Bullous cutaneous eruptions.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 60

Cancers diagnosed during the study.

Chronic neurodegenerative diseases (newly diagnosed) or aggravated during the study.
10.4.1.3 Adverse event of special interest
An adverse event of special interest (AESI) is an AE (serious or non-serious) that need to be 
monitored, documented, and managed in a pre-specified manner described in the protocol. Please 
see Section 10.4.6 and Section 17, Appendix F for additional information. 
10.4.2 General guidelines for reporting adverse events
All AEs, regardless of seriousness or relationship to study treatment, spanning from the signature 
of the informed consent form until the end of the study as defined by the protocol for that patient, 
are to be recorded on the corresponding page(s) or screen(s) of the e-CRF.
Whenever possible, diagnosis or single syndrome should be reported instead of symptoms. The 
Investigator/sub-Investigator should specify the date of onset, intensity, action taken with respect 
to study treatment, corrective treatment/therapy given, additional investigations performed, 
outcome, and his/her opinion as to whether there is a reasonable possibility that the AE was 
caused by the study treatment or by the study procedure(s). 
The Investigator/sub-Investigator should take appropriate measures to follow all AEs until clinical 
recovery is complete and laboratory results have returned to normal, or until progression has been 
stabilized, or until death, in order to ensure the safety of the patients. This may imply that 
observations will continue beyond the last planned visit per protocol, and that additional 
investigations may be requested by the monitoring team up to as noticed by the Sponsor. When 
treatment is prematurely discontinued, the patient’s observations will continue until the end of the 
study as defined by the protocol for that patient.
Laboratory and vital signs are recorded as AEs only if: 

Symptomatic and/or 

Requiring either corrective treatment or consultation, and/or 

Leading to study treatment discontinuation or modification of dosing, and/or 

Fulfilling a seriousness criterion, and/or 

Defined as an AESI
See Section 17, Appendix F for summary of AE reporting guidelines.
10.4.3 Instructions for reporting serious adverse events
In the case of occurrence of an SAE, the Investigator/sub-Investigator must immediately:

ENTER (within 24 hours) the information related to the SAE in the appropriate screens of 
the e-CRF; the system will automatically send a notification to the Sponsor after approval
of the Investigator/sub-Investigator within the e-CRF or after standard delay.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 61

SEND (within 24 hours, preferably by fax or e-mail) the signed and dated corresponding 
page(s) from the CRF to the representative of the monitoring team whose name, fax 
number, and e-mail address appear in the clinical trial protocol. Care must be taken to 
ensure that the patient’s identify is protected and the Patient’s identifiers in the study are 
properly mentioned on any copy of a source document provided to the Sponsor. For 
laboratory results, include the laboratory normal ranges.

ATTACH a clear photocopy of all examinations carried out and the dates on which these 
examinations were performed. Care should be taken to ensure that the patient's identity is 
protected and the patient's identifiers in the clinical trial are properly mentioned on any 
copy of a source document provided to the Sponsor. For laboratory results, include the 
laboratory normal ranges.

All further data updates should be recorded in the e-CRF as appropriate, and further 
documentation as well as additional information (for laboratory data, concomitant 
medications, patient status, etc) should be sent (by fax or e-mail) to the monitoring team 
within 24 hours of knowledge of the SAE. In addition, every effort should be made to 
further document any SAE that is fatal or life-threatening within a week (7 days) of the 
initial notification.

A back-up plan (using a paper CRF process) will be used when the e-CRF system does not 
work. 

REPORT to head of the study site by document immediately.
Any SAE brought to the attention of the Investigator at any time after the end of study for the 
patient and considered by Investigator to be caused by the IMP with a reasonable possibility, 
should be reported to the Sponsor.
10.4.4 Guidelines for reporting adverse events of special interest 
10.4.4.1 Reporting of adverse events of special interest (AESI)
For AESIs, the Sponsor must be informed immediately (i.e., within 24 hours), as per SAE 
notification described in Section 10.4.3 and Section 17, Appendix F even if not fulfilling a 
seriousness criterion, using the corresponding screens in the e-CRF.

Allergic events: 
-
General allergic drug reactions and/or local injection site reactions deemed to be
allergic (or have an allergic component) that require consultation with other
physician(s) for further evaluation of hypersensitivity/allergy, as per the 
Investigator/sub-Investigator’s medical judgement or as per Section 10.6.2, should be 
reported as an AESI with immediate notification.
-
All general allergic events, and all injection site reactions having an allergic
component or deemed to be allergic, require completion of the specific e-CRF screen
(see Section 10.6.2), regardless of requirements for immediate reporting.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 62

Hemolytic anemia (see Section 17, Appendix H):
-
If there is a decrease in hemoglobin and reflexive testing as per Section 17, Appendix
H suggesting hemolysis, then report this as AESI with immediate notification. Special
e-CRF screen will need to be completed.

Pregnancy
-
Pregnancy occurring in a female patient or the partner of a male patient included in the
clinical trial. Pregnancy will be recorded as an AESI with immediate notification in all
cases. It will be qualified as an SAE only if it fulfills the SAE criteria.
-
In the event of pregnancy of a female patient included in the clinical trial, study 
treatment should be discontinued.
-
The follow-up of the pregnancy will be mandatory until the outcome has been
determined.

Overdose with IMP/NIMP
-
Only the symptomatic overdoses with IMP/NIMP are defined as AESI in the study. 
-
An overdose (accidental or intentional) with the IMP/NIMP is an event suspected by
the Investigator/sub-Investigator or spontaneously notified by the patient (not based on 
systematic injection counts).
-
An overdose with the IMP/NIMP is defined as at least twice of the intended dose
within the intended therapeutic interval.
-
The overdose events should be reported using the corresponding screens in the e-CRF 
using the term “symptomatic overdose (accidental or intentional)”. The circumstances 
of the overdose should be clearly specified in the verbatim and symptoms, if any, 
entered on separate AE forms.
Of note, asymptomatic overdose should be reported using the corresponding screens in the 
e-CRF using the term “asymptomatic overdose (accidental or intentional)”. The 
circumstances of the overdose (i.e., accidental or intentional) and asymptomatic condition 
should be clearly specified. 
-
The patient should be monitored and receive appropriate corrective treatment.

Neurological events: 
-
Neurologic events that require additional examinations / procedures and/or referral to a 
specialist should be reported as an AESI with immediate notification (see Section 17, 
Appendix F).

Neurocognitive events:
-
All neurocognitive events will be considered as AESI (see Section 17, Appendix F)

Ophthalmologic events: 
-
Ophthalmologic events that require additional examinations/procedures and/or referral
to a specialist should be reported as an AESI with immediate notification.

ALT >3 x ULN (see Section 17, Appendices F and G, Increase in ALT).
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 63

Local injection site reaction as non-allergic event (see Section 10.6.1)
-
Local injection site reactions that are considered as non-allergic events should be
further characterized by evaluation of the related symptoms comprising injection site
reactions such as but not limited to redness, pain, etc. (see Section 17, Appendix I).
Specific e-CRF screens will need to be completed. If such AEs do not occur, then do
not report the individual components of the reaction but rather the term “local injection
site reactions”, the individual components being described in the specific e-CRF screen.

Skeletal muscle-related events:
-
Any AEs related to skeletal muscle abnormalities, including myalgia, muscle spasms
and stiffness, musculoskeletal discomfort and stiffness, back pain, muscular weakness,
and muscle fatigue.
10.4.4.2 Device deficiency
A device deficiency is any inadequacy related to the identity, quality, durability, reliability, safety, 
or performance of the medical device including malfunctions, use errors, and inadequate labeling. 
Product complaints:

A product complaint is defined as any written, electronic, or oral communication that 
alleges deficiencies related to the identity, durability, reliability, safety, efficacy, or 
performance of a product after it is released for distribution. 

All product complaints must be reported on a product complaint form when there is a 
reason to suspect a problem with the device. 

In case of a product complaint associated with the occurrence of an AE, the AE must be 
documented on an AE page in the CRF. 

In the case of a product complaint associated with the occurrence of a SAE, the SAE must 
be reported in accordance with the SAE reporting procedure (see Section 10.4.1.2 and 
Section 10.4.2).

All product complaints require reporting within 24 hours
10.4.5 Guidelines for management of specific laboratory abnormalities
Laboratory abnormalities with pre-specified monitoring should be monitored, documented, and 
managed according to the flowchart shown in Section 17, Appendices G and H.

Neutropenia

Thrombocytopenia

Increase in ALT

Acute renal insufficiency

Increase CPK and suspicion of rhabdomyolysis

Decrease in hemoglobin (defined as ≥1.5 g/dL)
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 64
10.4.6 Summary of adverse event reporting instructions
Section 17, Appendix F shows the summary of the reporting instructions of adverse events. 
10.5
OBLIGATIONS OF THE SPONSOR
During the course of the study, the Sponsor will report in an expedited manner;

All SAEs that are both unexpected and at least reasonably related to the IMP (Suspected 
Unexpected Serious Adverse Reaction, SUSAR), to the Health Authorities, independent 
ethics committees (IECs) / institutional review board (IRB) as appropriate and to the 
Investigators.

All SAEs that are expected and at least reasonably related to the IMP to the Health 
Authorities, according to local regulations.
Any AE not listed as an expected event in the Package Insert will be considered unexpected. 
The Sponsor will report all safety observations made during the conduct of the study in the CSR. 
10.6
SAFETY INSTRUCTIONS
10.6.1 Local tolerability (local injection site reactions)
In case the Investigator/sub-Investigator or the patient recognize any sign of local intolerability, 
then this should be treated and followed up as per the Investigator/sub-Investigator’s medical 
judgment. See Section 17, Appendix I for further information. 
AEs that are obviously not of allergic origin (e.g., local injection site reactions) should only be 
recorded on the Local Injection Site Reaction Complementary Form. However, injection site 
reactions which progress/expand/worsen/etc., should be evaluated and General Allergic Reaction 
Complementary Form should be completed.  
10.6.2 Allergic adverse events
Specific e-CRF screen are to be filled in to access allergic reactions or allergic-like reactions that 
may occur during the study conducted with Praluent®. Sometimes transient injection site reactions, 
irritant in nature, may occur, requiring no intervention and being of dubious significance. These 
reactions would not be considered to be allergic reactions. Adverse events that may constitute an 
allergic reaction (e.g., generalized itch, nasal itch, swelling at injection site, flushing, hives, 
swelling at lips, eyes, face, tongue, hands, feet, lump in throat, difficulty in swallowing, 
hoarseness, change in pitch of voice, incapacity to speak, wheezing, chest tightness, stridor, etc.) 
should be considered to be reported on the General Allergic Reaction and/or Local Injection Site 
Reaction Complementary Form. 
Adverse events that are obviously not of allergic origin (e.g., local injection site reactions related 
to mechanics of injection) should only be recorded on the Local Injection Site Reaction 
Complementary Form. However, injection site reactions that progress/expand/worsen/etc. should 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 65
be evaluated as recommended in Section 10.6.2 and the General Allergic Reaction 
Complementary Form should be completed. 
The IMP should be immediately interrupted (temporarily discontinued) if there is a suspicion of 
an allergic event related to IMP. See Section 10.3.1 for further information on treatment 
interruption and Section 10.3.3 for criteria for permanent treatment discontinuation.
10.6.2.1 Allergic adverse events with cutaneous involvement
AEs with cutaneous involvement which are obviously of allergic origin or injection site reactions 
which progress/expand/worsen/etc. should be evaluated by dermatologist as soon as possible, and 
preferably within one week of the study site first becoming aware of the event. 
The Investigator/sub-Investigator should evaluate the patient for possible etiologies (new 
medications, etc.) and extra-cutaneous symptoms and signs. If possible, the Investigator/sub-
Investigator will take pictures of skin lesions in order to provide the patient with the abnormal 
skin images for the dermatologist’s visit. If the photographs of skin lesions are obtained, then 
photocopies should be kept as source documents which may be collected by the Sponsor later. 
The Investigator/sub-Investigator will provide summary of the patient’s case, reason for 
consultation, and information being requested to the consulting dermatologist. 
A full consultation report should be sent by the dermatologist to the Investigator. The full report 
should contain, at a minimum, the following instruction; 1) A detailed description of the rash 
(such as the morphology [lesion type], shape of individual lesions, arrangement of multiple 
lesions [e.g., scattered, grouped, linear, etc.], distribution, color, consistency, presence of pruritus 
or pain, and other clinical signs); 2) Findings of skin biopsy (including histopathology and 
immunofluorescence) if it was deemed necessary as per the dermatologist’s or Investigator/sub-
Investigator’s medical judgment; and 3) The results of this investigation with, if applicable, a 
specific diagnosis of the AE. The Investigator/sub-Investigator will fax the full report and the 
corrected AE form if necessary, to the Sponsor within 24 hours. 
10.6.2.2 Acute allergic reactions of IMP injection
See also Section 10.4.
Acute allergic reactions of IMP (which is considered under the category of general allergic 
reactions) is defined as any AE that occurs during or shortly after injection of Praluent®
(characterized by but not limited to hypotension, bronchoconstriction, urticaria, edema, 
angioedema, nausea, vomiting). Emergency equipment and medication for the treatment of these 
potential adverse effects (e.g., antihistamines, bronchodilators, saline, corticosteroids, 
acetaminophen, and epinephrine) must be available for immediate use of the injections at the 
study site. 
Patients will be observed at the investigational site for at least 30 minutes following the injection
that takes place at the randomization visit. Patients should be treated symptomatically if any AE is 
observed. Patients are to remain at the study site until any acute injection reaction is assessed as 
stable, per the Investigator/sub-Investigator’s discretion. 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 66
General Allergic Reaction and/or Local Injection Site Reaction Complementary Form will have to 
be completed.  
10.6.3 Cardiovascular events and all deaths 
The following suspected or confirmed CV events that occur from randomization until end of the 
study visit should be reported in a corresponding specific e-CRF. The Investigator will submit the
adjudication materials to the CEC through the Sponsor as needed:

MI.

Congestive heart failure requiring hospitalization.

Cerebrovascular events (e.g., stroke, transient ischemic attack, intracranial hemorrhage, 
ischemia or bleeding of spine or retina).

Unstable angina requiring an emergency room visit or requiring / prolonging 
hospitalization.

All coronary revascularization procedures (e.g., PCI, coronary artery bypass graft).

All death (including CHD death).
All suspected or confirmed CV events should be reported as SAEs. For coronary revascularization 
procedures, medical or surgical procedure should not be reported as an adverse event, but rather,
the reason for the procedure should be reported as the adverse event (e.g., unstable angina leading 
to PCI should be reported as “unstable angina” instead of “PCI”).
10.6.4 Laboratory alert related to calculated LDL-C <25 mg/dL (0.65 mmol/L)    
The process includes specific assessment and monitoring in all patients, who has the calculated
LDL-C values <25 mg/dL (0.65 mmol/L) any time after the randomization:

The patient will continue study treatment (both alirocumab and SoC arms).

The Investigator closely monitors the patient and collects any AE including AEs 
potentially associated with low LDL-C. 

The Investigator/sub-Investigator decides whether patient should be immediately request 
to have an unscheduled on-site visit, or patient assessment could be done at the next 
scheduled on-site visit.

At the on-site visit, plan for the following, based on the Investigator/sub-Investigator’s 
medical judgment:
-
Assess the need for conducting clinical investigations, arranging specialist 
consultation(s) as needed, and any relevant additional work-up.    

Assess the need for temporary or permanent discontinuation of study treatment, or 
continuation of the study treatment. Regardless of the action taken regarding study 
treatment, the patient should continue the study as per Section 10.3.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 67
11
STATISTICAL CONSIDERATIONS
11.1
DETERMINATION OF SAMPLE SIZE
The study is expected to enroll approximately 200 patients. The sample size calculations are based 
on the primary efficacy variable of percent change in normalized TAV from baseline to Week 36.
Based on the results of ZEUS (1) and PRECISE-IVUS (2) studies, it is assumed that difference in 
percent change in normalized TAV from baseline between alirocumab arm and SoC arm is 8%, 
and the common standard deviation of percent change in normalized TAV is 15%.
Under the assumption, a sample size of 150 patients (75 in the alirocumab arm and 75 in the SoC 
arm) will have 90% power to detect the treatment difference with two-sided significance level of 
5%. Assuming that proportion of non-evaluable primary endpoint is 25%, it is considered that 
200 patients (100 in the alirocumab arm, 100 in the SoC arm) will be needed.
As the ANCOVA model will be used for primary analysis, the power should be somewhat higher 
due to reduced estimate variability versus the two-sample t-test.
Calculations were made using SAS 9.4
11.2
DISPOSITION OF PATIENTS
Patients who signed the informed consent are defined as the patients who signed the informed 
consent. 
Randomized patients consist of all patients who have been allocated to a randomized treatment 
and recorded in the registration center database, regardless of whether a study drug was used or 
not.
Patients treated without being randomized will not be considered as randomized and will not be 
included in any analysis population.
For any patient randomized more than once, only the data associated with the first randomization 
will be used in any analysis population. The safety experience associated with any later 
randomization will be assessed separately.
The safety experience of patients treated and not randomized will be reported separately.
11.3
ANALYSIS POPULATIONS
The randomized population includes all randomized patients defined in Section 11.2.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 68
11.3.1 Efficacy populations
The primary efficacy analysis population will be the modified intent-to-treat (mITT) population, 
as defined below.
11.3.1.1 Modified intent-to-treat population
The modified intent-to-treat population is the randomized population which takes at least one dose 
or part of dose of study drug and has an available value of normalized TAV before randomization, 
and after 24 weeks of treatment. Patients will be analyzed in the treatment arm to which they are 
randomized.
11.3.2 Safety population
The safety population is defined as the randomized population which actually received at least 
1 dose or part of a dose of the study drug, and analyzed according to the treatment actually 
received.
In addition: 

Non-randomized but treated patients will not be part of the safety population, but their 
safety data will be presented separately. 

Randomized patients for whom it is unclear whether they took the study drug will be 
included in the safety population as randomized.

The treatment arm allocation for “as-treated analysis” will defined as follows:
-
Alirocumab arm if proportion of IMP injection is ≥50%.
-
SoC arm if proportion of IMP injection is <50%.

Proportion of IMP injection (%) is defined as 100 x (Number of IMP injection)/[(Date of 
end of treatment - Date of randomization)/14 + 1]  
11.3.3 Quality-of-life (QOL) population
The analyses of QOL will be performed on all randomized and treated patients (safety population) 
with a baseline and at least 1 matching post-baseline evaluation for any of the 5 dimensions.
11.4
STATISTICAL METHODS
Statistical methods are briefly described here and will be detailed in the statistical analysis plan 
(SAP) of the study.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 69
11.4.1 Extent of study treatment exposure and compliance
The extent of study treatment exposure and compliance will be assessed and summarized within 
the safety population. The extent of IMP exposure and compliance will be summarized for 
alirocumab arm (actual treatment received). Regarding to NIMP, it will be detailed in the SAP. 
11.4.1.1 Extent of investigational medicinal product exposure
The total exposure will be assessed by:

Duration of IMP exposure in weeks regardless of intermittent treatment is defined as: (last 
dose of IMP injection date – first dose of IMP injection date + 14 days)/7. 

Number (%) of patients with an up-titration from Praluent® 75 mg Q2W to Praluent®
150 mg Q2W.
11.4.1.2 Compliance of investigational medicinal product exposure
Compliance will be assessed using the injection frequency defined for each patient as the average
number of days between 2 injections, that is: (last injection date - first injection date) / (number of
injections - 1) and will be summarized descriptively (N, Mean, SD, Median, Min and Max).
11.4.2 Analyses of efficacy endpoints
11.4.2.1 Analysis of primary efficacy endpoint
The primary efficacy endpoint, percent change in normalized TAV from baseline to Week 36
defined in Section 9.1.1 will be analyzed in the mITT population using an analysis of covariance 
(ANCOVA) model with treatment arm (SoC arm, alirocumab arm) and randomization strata
(statin at ACS onset [Yes / No]), as fixed effects, and the baseline normalized TAV as covariate.
Throughout the ANCOVA model run using SAS Mixed procedure, alirocumab arm will be 
compared to SoC arm at the two-sided 0.05 level for superiority and providing baseline adjusted 
least squares means (LS means) estimates at Week 36 for each treatment arm with their 
corresponding standard errors (SEs) and the 95% confidence interval (CI) of the difference
between the arms. 
Let μ0 and μ1 be the population means of the percent change in normalized TAV from baseline to 
Week 36 under SoC arm and alirocumab arm, respectively. The null hypothesis that will be tested 
is “
1
0
0 :


H
” versus “
1
0
1 :


H
”.
Robustness of this method will be also assessed via sensitivity analyses detailed in the SAP, 
including for handling of missing data.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 70
11.4.2.2 Analyses of secondary efficacy endpoints
Method for controlling the overall type-I error rate when testing the key secondary efficacy
endpoint is described in Section 11.4.2.3.
For the key secondary efficacy endpoint (defined in Section 9.1.2.1) and the other secondary
efficacy endpoints (described in Section 9.1.2.2), descriptive summaries and analyses will be
performed in the mITT population.
For descriptive summaries, percentage change (except ratio) and absolute change from baseline in 
calculated LDL-C, TC, HDL-C, TGs, non-HDL-C, Apo B, Apo A-1, Apo B/Apo A-1 ratio, and 
Lp(a) will be provided at each time point for each treatment arm. For lipids, all measurements, 
scheduled or unscheduled will be assigned to analysis windows defined in the SAP in order to 
provide an assessment for time points. Laboratory assessments other than the ones provided by 
the central laboratory will be excluded. For TGs, measurements on non-fasting patients will be 
excluded. The time profile of each parameter will be plotted by treatment arm with the 
corresponding SEs. 
Continuous endpoints related to IVUS anticipated having a normal distribution
Continuous secondary endpoints related to IVUS anticipated having a normal distribution will be 
analyzed using the same ANCOVA model as for the primary endpoint with the continuous fixed 
covariates of corresponding baseline value.
Continuous endpoints of lipids anticipated having a normal distribution and collected at 
Week 0, Week 4, Week 12, Week 24 and Week 36
Continuous secondary endpoints of lipids defined in Section 9.1.2 are anticipated having a normal 
distribution and collected at Week 0, Week 4 Week 12, Week 24, and Week 36 (i.e., calculated 
LDL-C, TC, HDL-C, non-HDL-C) will be analyzed in the in the mITT population using a mixed-
effect model with repeated measures (MMRM) approach. All post-baseline data available within 
Week 4, Week 12, Week 24, and Week 36 analysis windows will be used and missing data will be 
accounted for by the MMRM model. The model will include the fixed categorical effects of
treatment arm (SoC arm, alirocumab arm), time point (Week 4, Week 12, Week 24, and Week 36), 
randomization strata (statin at ACS onset [Yes / No]), treatment-by-time point interaction,
randomization strata-by-time point interaction, as well as, the continuous fixed covariates of 
corresponding baseline value and baseline value-by-time point interaction.
Continuous endpoints of lipids anticipated having a normal distribution and collected at 
Week 0 and Week 36 
Continuous secondary endpoints of lipids defined in Section 9.1.2 are anticipated having a normal 
distribution and collected at Week 0 and Week 36 (i.e., Apo B, Apo A-1, Apo B/Apo A-1 ratio)
will be analyzed using the same ANCOVA model as for the primary endpoint with the continuous 
fixed covariates of corresponding baseline value.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 71
Continuous endpoints of lipids anticipated having a non-normal distribution
Continuous secondary efficacy endpoints of lipids defined in Section 9.1.2 are anticipated having 
a non-normal distribution (i.e., TGs and Lp(a)), will be analyzed in the mITT population using a 
robust regression model (37) (i.e., ROBUSTREG SAS procedure with M-estimation option) with
treatment arm, and randomization strata (statin at ACS onset [Yes / No]) as main effect and 
corresponding baseline value(s) as covariate. Missing values will be addressed using a multiple 
imputation approach, which will be described in the SAP. The variables in the multiple imputation
model will at least include the same variables as used in the robust regression model. The 
treatment arm combined means will be provided with respective SE estimates. The combined 
mean difference between the treatment arms will be provided with the SE, 95% confidence 
interval and p-value.
11.4.2.3 Multiplicity considerations
In order to handle the key secondary efficacy endpoint in addition to the primary efficacy 
endpoint, the overall type-I error will be controlled by the use of a sequential inferential approach. 
Statistical significance of the primary efficacy endpoint at the 0.05 alpha level is required before 
drawing inferential conclusions about the key secondary efficacy endpoint. This fixed hierarchical 
approach will ensure a strong control of the overall type-I error rate at the 0.05 level.
No further adjustments will be made for other secondary endpoints other than key secondary 
endpoints for which p-values will be provided for exploratory purpose only (no claim).
11.4.3 Analyses of safety data
The summary of safety results will be presented by treatment arm. No formal inferential testing
will be performed. Summaries will be descriptive in nature.
Observation period 
The observation period of safety data will be as follows:

Pre-treatment period is defined as the time from the signed informed consent date up to 
the day of randomization.

TEAE period is defined as the time from the day of randomization up to the last 
administration + 14 days (+ 7 days), or end of study, whichever comes first.

Post-treatment period is defined as the time starting the day after the end of the TEAE 
period up to the end of the study (see definition in Section 6.2.1).

On-study observation period is defined as the time from the day of randomization up to
the end of the study (see definition in Section 6.2.1).
All safety analyses will be performed on the safety population using the following common rules:

The potentially clinically significant abnormality (PCSA) values are defined as abnormal 
values considered medically important by the Sponsor according to predefined 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 72
criteria/thresholds based on literature review and defined by the Sponsor for clinical 
laboratory tests and vital signs. 

PCSA criteria will be determined which patients had at least 1 PCSA during the TEAE
period, taking into account all evaluations performed during the TEAE period, including 
unscheduled or repeated evaluations. The number of all such patients will be the 
numerator for the PCSA percentage. 
Drug-induced liver injury
The liver function tests, namely ALT, AST, alkaline phosphatase, and total bilirubin, are used to 
assess possible drug-induced liver toxicity. The proportion of patients with PCSA values at any 
post-baseline visit by baseline status will be displayed by treatment arm for each parameter.
A graph of distribution of peak values of ALT versus peak values of total bilirubin will also be 
presented. Note that the ALT and total bilirubin values are presented on a logarithmic scale. The 
graph will be divided into 4 quadrants with a vertical line corresponding to 3 x ULN for ALT and 
a horizontal line corresponding to 2 x ULN for total bilirubin.
The incidence of liver-related AEs will be summarized by treatment arm. The selection of 
preferred terms will be based on standardized MedDRA query (SMQ) “Hepatic disorder.”
11.4.3.1 Adverse events
The adverse events are defined as follows:

Pre-treatment AEs are AEs that develop, worsen, or become serious during the pre-
treatment period

TEAEs are AEs that develop, worsen, or become serious during the TEAE period

Post-treatment AEs are AEs that develop, worsen, or become serious during the post-
treatment period
AE incidence tables will be presented by SOC (sorted by internationally agreed order), HLGT, 
HLT, and PT sorted in alphabetical order for each treatment arm, and the number (n) and 
percentage (%) of patients experiencing an AE. Multiple occurrences of the same event in the 
same patient will be counted only once in the tables within a treatment phase. The denominator 
for computation of percentages is the safety population within each treatment group.
AE incidence table will be provided by treatment arm for all types of TEAEs: all TEAEs, all 
treatment emergent AESI (defined with a PT or a prespecified grouping), all treatment emerged 
SAEs, and all TEAEs leading to permanent treatment discontinuation.
Deaths
The following deaths summaries will be generated:

Number (%) of patients who die during study period (TEAE, on-study, post-study) 
summarized on the safety population by treatment received
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 73

Death in non-randomized patients or randomized and not treated patients 

TEAE leading to death (death as an outcome on the AE CRF page as reported by the 
Investigator/sub-Investigator) by primary SOC , HLGT, HLT, and PT showing number 
(%) of patients sorted by internationally agreed order of SOC and alphabetic order of 
HLGT, HLT, and PT. 
Adjudicated CV events
The number and percentage of patients experiencing a positively adjudicated CV event will be
presented by treatment arm overall and by category of adjudication.
11.4.3.2 Laboratory data and vital signs
See also Section 9.2.2 and Section 9.2.3.
The descriptive statistics (including mean, median, Q1, Q3, SE, minimum and maximum) of all
laboratory variables and all vital signs parameters (raw data and changes from baseline) will be
calculated for each time point, last and worst values assessed during the treatment period and
presented by treatment arm. For selected parameters, mean changes from baseline with the
corresponding SE will be plotted over time (at same time points) in each treatment arm. The 
incidence of PCSAs at any time during the TEAE period (on-treatment PCSAs) will be
summarized by treatment arm regardless of the baseline level and/or according to the following
baseline categories:

Normal / missing.

Abnormal according to PCSA criterion or criteria.
For laboratory parameters for which PCSA criterion are not defined, similar table(s) using the
normal range could be provided.
Hepatitis C virus test:
The number and percentage of patients with an observed seroconversion of Hepatitis C virus test 
will be provided by treatment arm. 
11.4.4 Analyses of other endpoints
All analyses for other endpoints will be performed on the safety population. The baseline value is 
defined as the last available value before randomization.
The number and percentage of patients with 2 consecutive calculated LDL-C <25 mg/dL and
calculated LDL-C <15 mg/dL, respectively, will be provided by treatment arm. The time interval 
between 2 consecutive calculated LDL-C should be spaced out by at least 21 days.
Exploratory variables defined in Section 9.3 will be summarized by time points for each treatment
arm. For hs-CRP, the incidence of PCSA at any time during the TEAE period will be also 
summarized by treatment arm using descriptive statistics.  
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 74
11.4.5 Analyses of quality of life/health economics variables
The analysis of QOL data will be performed on the QOL population. Baseline is defined as the 
visit 1 (week 0) evaluation.
Data on the 5 items
The responses of each EQ-5D items will be presented by visit for each treatment arm using tables. 
The tables will contain information on the frequency and proportion of the population reporting 
level 1 (no problems), level 2 (some problems) and level 3 (extreme problems) per item, by 
treatment arm.
Scoring the EQ-5D health states
The 5 dimensional 3-level system will be converted into a single index utility score: values for the 
243 theoretically possible health states defined by the EuroQol classification are calculated using 
a regression model (36). The single index utility score will be described by visit and treatment 
arm.
Absolute change from Baseline to the following time points
The absolute change of health-related QOL (single index utility score) from baseline to following 
time points will be described in the QOL population for each treatment arm using the same 
MMRM model as for the continuous secondary efficacy endpoints of lipids anticipated to have a 
normal distribution and collected at Week 0, Week 4, Week12, Week 24 and Week 36 with 
corresponding baseline value as covariate.
11.5
INTERIM ANALYSIS
No interim analysis is planned.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 75
12
ETHICAL AND REGULATORY CONSIDERATIONS
12.1
ETHICAL AND REGULATORY STANDARDS
This clinical trial will be conducted by the Sponsor, the Investigator, and delegated Investigator
staff and sub-Investigator, in accordance with consensus ethics principles derived from 
international ethics guidelines, including the Declaration of Helsinki, and the ICH guidelines for 
Good Clinical Practice (GCP), all applicable laws, rules and regulations.
This clinical trial will be recorded in a free, publicly accessible, internet-based registry, no later 
than 21 days after the first patient enrollment, in compliance with applicable regulatory 
requirements and with Sanofi public disclosure commitments. 
12.2
INFORMED CONSENT
The Investigator (according to applicable regulatory requirements), or a person designated by the 
Investigator, and under the Investigator's responsibility, should fully inform the patient of all 
pertinent aspects of the clinical trial including the written information giving approval/favorable 
opinion by the ethics committee (IRB/IEC). All participants should be informed to the fullest 
extent possible about the study, in language and terms they are able to understand.
Prior to a patient’s participation in the clinical trial, the written informed consent form should be 
signed, name filled in and personally dated by the patient or by the patient’s legally acceptable 
representative, and by the person who conducted the informed consent discussion. A copy of the 
signed and dated written informed consent form will be provided to the patient. 
If informed consent is obtained under special circumstances (emergency, from a guardian, minor, 
etc.), the method should be specified following the ICH requirements. 
The informed consent form used by the Investigator for obtaining the patient's informed consent 
must be reviewed and approved by the Sponsor prior to submission to the appropriate ethics 
committee (IRB/IEC) for approval/favorable opinion.
The Investigator (according to applicable regulatory requirements), or a person designated by the 
Investigator, should fully inform the patient of all pertinent aspects of the clinical trial including 
the written information given approval/favorable opinion by the ethics committee (IRB/IEC). All 
participants should be informed to the fullest extent possible about the study in language and 
terms they are able to understand.
12.3
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
As required by local regulation, the Investigator or the Sponsor must submit this clinical trial 
protocol to the appropriate IRB/IEC, and is required to forward to the respective other party a 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 76
copy of the written and dated approval/favorable opinion signed by the chairman with IRB/IEC 
composition.
The clinical trial (study number, clinical trial protocol title and version number), the documents 
reviewed (clinical trial protocol, informed consent form, Package Insert, Investigator’s curriculum 
vitae [CV], etc.) and the date of the review should be clearly stated on the written (IRB/IEC) 
approval/favorable opinion.
The IMP will not be released at the study site and the Investigator will not start the study before 
the written and dated approval/favorable opinion is received by the Investigator and the Sponsor.
During the clinical trial, any amendment or modification to the clinical trial protocol should be 
submitted to the health authorities (competent regulatory authority), as required by local 
regulation, in addition to the IRB/IEC before implementation, unless the change is necessary to 
eliminate an immediate hazard to the patients, in which case the health authorities (competent 
regulatory authority) and the IRB/IEC should be informed as soon as possible. They should also 
be informed of any event likely to affect the safety of patients or the continued conduct of the 
clinical trial, in particular any change in safety. All updates to the Investigator’s Brochure or 
labeling information, will be sent to the IRB/IEC and to health authorities (competent regulatory 
authority), as required by local regulation.
A progress report is sent to the IRB/IEC at least annually and a summary of the clinical trial’s 
outcome at the end of the clinical trial. 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 77
13
STUDY MONITORING
13.1
RESPONSIBILITIES OF THE INVESTIGATOR(S)
The Investigator is required to ensure compliance with all procedures required by the clinical trial 
protocol and with all study procedures provided by the Sponsor (including security rules). The 
Investigator agrees to provide reliable data and all information requested by the clinical trial 
protocol (with the help of the CRF, Discrepancy Resolution Form [DRF] or other appropriate 
instrument) in an accurate and legible manner according to the instructions provided and to ensure 
direct access to source documents by Sponsor representatives.
If any circuit includes transfer of data particular attention should be paid to the confidentiality of
the patient's data to be transferred.
The Investigator may appoint such other individuals as he/she may deem appropriate as sub-
Investigators to assist in the conduct of the clinical trial in accordance with the clinical trial 
protocol. All sub-Investigators shall be appointed and listed in a timely manner. The sub-
Investigators will be supervised by and work under the responsibility of the Investigator. The 
Investigator will provide them with a copy of the clinical trial protocol and all necessary 
information.
13.2
RESPONSIBILITIES OF THE SPONSOR
The Sponsor of this clinical trial is responsible to regulatory authorities for taking all reasonable 
steps to ensure the proper conduct of the clinical trial as regards ethics, clinical trial protocol 
compliance, and integrity and validity of the data recorded on the CRFs. Thus, the main duty of 
the monitoring team is to help the Investigator and the Sponsor maintain a high level of ethical, 
scientific, technical and regulatory quality in all aspects of the clinical trial.
At regular intervals during the clinical trial, the site will be contacted, through monitoring visits, 
letters or telephone calls, by a representative of the monitoring team to review study progress, 
Investigator and patient compliance with clinical trial protocol requirements and any emergent 
problems. These monitoring visits will include but not be limited to review of the following 
aspects: patient informed consent, patient recruitment and follow-up, SAE documentation and 
reporting, AESI documentation and reporting, AE documentation, IMP allocation, patient 
compliance with the IMP regimen, IMP accountability, concomitant therapy use and quality of 
data.
13.3
SOURCE DOCUMENT REQUIREMENTS
According to the ICH GCP, the monitoring team must check the CRF entries against the source 
documents, except for the pre-identified source data directly recorded in the CRF. The informed 
consent form will include a statement by which the patient allows the Sponsor’s duly authorized 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 78
personnel, the ethics committee (IRB/IEC), and the regulatory authorities to have direct access to 
original medical records which support the data on the CRFs (eg, patient's medical file, 
appointment books, original laboratory records, etc). These personnel, bound by professional 
secrecy, must maintain the confidentiality of all personal identity or personal medical information 
(according to confidentiality and personal data protection rules).
13.4
USE AND COMPLETION OF CASE REPORT FORMS (CRFS) AND ADDITIONAL 
REQUEST
It is the responsibility of the Investigator to maintain adequate and accurate CRFs (according to 
the technology used) designed by the Sponsor to record (according to Sponsor instructions) all 
observations and other data pertinent to the clinical investigation in a timely manner. All CRFs 
should be completed in their entirety in a neat, legible manner to ensure accurate interpretation of 
data.
Should a correction be made, the information will be entered in the e-CRF overwriting the initial 
information. An audit trail allows identifying the modification. 
Data are available within the system to the Sponsor as soon as they are entered in the e-CRF. 
The computerized handling of the data by the Sponsor may generate additional requests 
(discrepancy resolution forms [DRF]) to which the Investigator is obliged to respond by 
confirming or modifying the data questioned. The requests with their responses will be managed 
through the e-CRFs by the Investigator and the Sponsor.
13.5
USE OF COMPUTERIZED SYSTEMS
The complete list of computerized systems used for the study is provided in a separate document 
which is maintained in the Sponsor study files.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 79
14
ADDITIONAL REQUIREMENTS
14.1
CURRICULUM VITAE
A current copy of the curriculum vitae describing the experience, qualification and training of 
each Investigator and sub-Investigator will be signed, dated and provided to the Sponsor prior to 
the beginning of the clinical trial.
14.2
RECORD RETENTION IN STUDY SITES
The Investigator must maintain confidential all study documentation, and take measures to 
prevent accidental or premature destruction of these documents.
The Investigator should retain the study documents at least 15 years after the completion or 
discontinuation of the clinical trial.
However, applicable regulatory requirements should be taken into account in the event that a 
longer period is required.
The Investigator must notify the Sponsor prior to destroying any study essential documents 
following the clinical trial completion or discontinuation.
If the Investigator's personal situation is such that archiving can no longer be ensured by him/her, 
the Investigator shall inform the Sponsor and the relevant records shall be transferred to a 
mutually agreed upon designee. 
14.3
CONFIDENTIALITY
All information disclosed or provided by the Sponsor (or any company/institution acting on their 
behalf), or produced during the clinical trial, including, but not limited to, the clinical trial 
protocol, personal data in relation to the patients, the CRFs, the Investigator's Brochure and the 
results obtained during the course of the clinical trial, is confidential, prior to the publication of 
results. The Investigator and any person under his/her authority agree to undertake to keep 
confidential and not to disclose the information to any third party without the prior written 
approval of the Sponsor.
However, the submission of this clinical trial protocol and other necessary documentation to the 
ethics committee (IRB/IEC) is expressly permitted, the IRB/IEC members having the same 
obligation of confidentiality.
The sub-Investigators shall be bound by the same obligation as the Investigator. The Investigator
shall inform the sub-Investigators of the confidential nature of the clinical trial.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 80
The Investigator and the sub-Investigators shall use the information solely for the purposes of the 
clinical trial, to the exclusion of any use for their own or for a third party's account.
14.4
PROPERTY RIGHTS
All information, documents and IMP provided by the Sponsor or its designee are and remain the 
sole property of the Sponsor.
The Investigator shall not and shall cause the delegated Investigator staff /sub-Investigator not to 
mention any information or the Product in any application for a patent or for any other intellectual 
property rights.
All the results, data, documents and inventions, which arise directly or indirectly from the clinical 
trial in any form, shall be the immediate and exclusive property of the Sponsor.
The Sponsor may use or exploit all the results at its own discretion, without any limitation to its 
property right (territory, field, continuance). The Sponsor shall be under no obligation to patent, 
develop, market or otherwise use the results of the clinical trial.
As the case may be, the Investigator and/or the sub-Investigators shall provide all assistance 
required by the Sponsor, at the Sponsor's expense, for obtaining and defending any patent, 
including signature of legal documents.
14.5
DATA PROTECTION
The patient's personal data, which are included in the Sponsor database, shall be treated in 
compliance with all applicable laws and regulations
When archiving or processing personal data pertaining to the Investigator and/or to the patients, 
the Sponsor shall take all appropriate measures to safeguard and prevent access to this data by any 
unauthorized third party
The Sponsor also collects specific data regarding Investigator as well as personal data from any 
person involved in the study which may be included in the Sponsor’s databases, shall be treated 
by both the Sponsor and the Investigator in compliance with all applicable laws and regulations
The data collected in this study will only be used for the purpose(s) of the study and to document 
the evaluation of the benefit/risk ratio, efficacy, and safety of the product(s). They may be further 
processed if they have been anonymized.
14.6
INSURANCE COMPENSATION
The Sponsor certifies that it has taken out a liability insurance policy covering all clinical trials 
under its sponsorship. This insurance policy is in accordance with local laws and requirements. 
The insurance of the Sponsor does not relieve the Investigator and the collaborators from any 
obligation to maintain their own liability insurance policy. An insurance certificate will be 
provided to the IECs/IRBs or regulatory authorities in countries requiring this document. 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 81
14.7
SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES
For the purpose of ensuring compliance with the clinical trial protocol, good clinical practice, and 
applicable regulatory requirements, the Investigator should permit auditing by or on the behalf of 
the Sponsor and inspection by regulatory authorities.
The Investigator agrees to allow the auditors/inspectors to have direct access to his/her study 
records for review, being understood that these personnel is bound by professional secrecy, and as 
such will not disclose any personal identity or personal medical information.
The Investigator will make every effort to help with the performance of the audits and inspections, 
giving access to all necessary facilities, data, and documents.
As soon as the Investigator is notified of a planned inspection by the authorities, he will inform 
the Sponsor and authorize the Sponsor to participate in this inspection.
The confidentiality of the data verified and the protection of the patients should be respected 
during these inspections.
Any result and information arising from the inspections by the regulatory authorities will be 
immediately communicated by the Investigator to the Sponsor.
The Investigator shall take appropriate measures required by the Sponsor to take corrective 
actions for all problems found during the audit or inspections.
14.8
PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE-OUT OF 
A SITE
14.8.1 By the Sponsor 
The Sponsor has the right to terminate the participation of either an individual site or the study at 
any time, for any reason, including but not limited to the following: 

The information on the product leads to doubt as to the benefit/risk ratio

Patient enrollment is unsatisfactory

The Investigator has received from the Sponsor all IMP, means, and information necessary 
to perform the clinical trial and has not included any patient after a reasonable period of 
time mutually agreed upon

Noncompliance of the Investigator or sub-Investigator, delegated staff with any provision 
of the clinical trial protocol, and breach of the applicable laws and regulations or breach of 
the ICH GCP

The total number of patients are included earlier than expected
In any case the Sponsor will notify the Investigator of its decision by written notice.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 82
14.8.2 By the Investigator
The Investigator may terminate his/her participation upon thirty (30) days' prior written notice if 
the study site or the Investigator for any reason becomes unable to perform or complete the 
clinical trial. 
In the event of premature discontinuation of the study or premature close-out of a site, for any 
reason whatsoever, the appropriate IRB/IEC and regulatory authorities should be informed 
according to applicable regulatory requirements.
14.9
CLINICAL TRIAL RESULTS
The Sponsor will be responsible for preparing a clinical study report and to provide a summary of 
study results to the Investigator.
14.10 PUBLICATIONS AND COMMUNICATIONS
The Investigator undertakes not to make any publication or release pertaining to the study and/or 
results of the study prior to the Sponsor’s written consent, being understood that the Sponsor will 
not unreasonably withhold its approval.
As the study is being conducted at multiple sites, the Sponsor agrees that, consistent with 
scientific standards, a primary presentation or publication of the study results based on global 
study outcomes shall be sought. However, if no multicenter publication is submitted, underway, 
or planned within twelve (12) months of the completion of this study at all sites, the Investigator
shall have the right to publish or present independently the results of this study in agreement with 
other Investigators and stakeholders. The Investigator shall provide the Sponsor with a copy of 
any such presentation or publication for review and comment at least 30 days in advance of any 
presentation or submission for publication. In addition, if requested by the Sponsor, any 
presentation or submission for publication shall be delayed for a limited time, not to exceed 
90 days, to allow for filing of a patent application or such other justified measures as the Sponsor 
deems appropriate to establish and preserve its proprietary rights. 
The Investigator shall not use the name(s) of the Sponsor and/or its employees in advertising or 
promotional material or publication without the prior written consent of the Sponsor. The Sponsor 
shall not use the name(s) of the Investigator and/or the collaborators in advertising or promotional 
material or publication without having received his/her and/or their prior written consent(s).
The Sponsor has the right at any time to publish the results of the study.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 83
15
CLINICAL TRIAL PROTOCOL AMENDMENTS
All appendices attached hereto and referred to herein are made part of this clinical trial protocol.
The Investigator should not implement any deviation from, or changes to the clinical trial protocol 
without agreement by the Sponsor and prior review and documented approval/favorable opinion 
from the IRB/IEC and/or notification/approval of health authorities (competent regulatory 
authority) of an amendment, as required by local regulation, except where necessary to eliminate 
an immediate hazard(s) to clinical trial patients, or when the change(s) involves only logistical or 
administrative aspects of the trial. Any change agreed upon will be recorded in writing, the 
written amendment will be signed by the Investigator and by the Sponsor and the signed 
amendment will be filed with this clinical trial protocol.
Any amendment to the clinical trial protocol requires written approval/favorable opinion by the 
IRB/IEC prior to its implementation, unless there are overriding safety reasons.
In case of substantial amendment to the clinical trial protocol, approval from the health authorities 
(competent regulatory authority) will be sought before implementation.
In some instances, an amendment may require a change to the informed consent form. The 
Investigator must receive an IRB/IEC approval/favorable opinion concerning the revised informed 
consent form prior to implementation of the change and patient signature should be re-collected if 
necessary.
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 84
16
BIBLIOGRAPHIC REFERENCES
1. Nakajima N, Miyauchi K, Yokoyama T, Ogita M, Miyazaki T, Tamura T, et al. Effect of 
combination of ezetimibe and a statin on coronary plaque regression in patients with acute 
coronary syndrome: ZEUS trial (eZEtimibe Ultrasound Study). IJC Metabolic & Endocrine. 
2014;3:8–13.
2. Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, et al. Impact of 
Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque 
Regression in Patients With Percutaneous Coronary Intervention: The Multicenter 
Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol. 2015;66(5):495–507. 
3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel 
in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. 
N Engl J Med. 2001;345(7):494–502. 
4. Canadian Cardiovascular Society, American Academy of Family Physicians, American 
College of Cardiology, American Heart Association, Antman EM, Hand M, et al. 2007 
focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-
elevation myocardial infarction: a report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;51(2):210–47.
5. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, et al. ACC/AHA 
2007 guidelines for the management of patients with unstable angina/non-ST-Elevation 
myocardial infarction: a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 
Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation 
Myocardial Infarction) developed in collaboration with the American College of Emergency 
Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of 
Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary 
Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 
2007;50(7):e1–157.
6. Krumholz HM, Anderson JL, Bachelder BL, Fesmire FM, Fihn SD, Foody JM, et al. 
ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation 
myocardial infarction: a report of the American College of Cardiology/American Heart 
Association Task Force on Performance Measures (Writing Committee to Develop 
Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) 
Developed in Collaboration With the American Academy of Family Physicians and American 
College of Emergency Physicians Endorsed by the American Association of Cardiovascular 
and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and 
Society of Hospital Medicine. J Am Coll Cardiol. 2008;52(24):2046–99. 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 85
7. Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg 
versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 
2006;97(1):61–7. 
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 
Executive Summary of The Third Report of The National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In 
Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97. 
9. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, et al. 
Implications of recent clinical trials for the National Cholesterol Education Program Adult 
Treatment Panel III guidelines. Circulation. 2004;110(2):227–39. 
10.European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, 
De Backer G, Graham I, Taskinen M-R, et al. ESC/EAS Guidelines for the management of 
dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society 
of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 
2011;32(14):1769–818. 
11. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe 
Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 
2015;372(25):2387–97. 
12. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative 
determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with 
atherothrombosis. JAMA. 2010;304(12):1350–7.
13. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al. American 
College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, 
Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the 
American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am 
Coll Cardiol. 2001;37(5):1478–92. 
14. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of 
intensive compared with moderate lipid-lowering therapy on progression of coronary 
atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071–80. 
15. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, 
LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005 Jan 
6;352(1):29–38.
16. Ballantyne CM, Raichlen JS, Nicholls SJ, Erbel R, Tardif J-C, Brener SJ, et al. Effect of 
rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary 
angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived 
coronary atheroma burden. Circulation. 2008;117(19):2458–66. 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 86
17. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two 
intensive statin regimens on progression of coronary disease. N Engl J Med. 
2011;365(22):2078–87. 
18. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin 
treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on 
atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year 
after coronary event: the ESTABLISH Study. Circulation. 2004;110(9):1061–8. 
19. Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, Lavoie A, et al. Intravascular ultrasound-
derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll 
Cardiol. 2010;55(21):2399–407. 
20. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al. Effect of 
intensive statin therapy on regression of coronary atherosclerosis in patients with acute 
coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular 
ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of 
pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 
2009;54(4):293–302. 
21. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, et al. Effect of 
rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary 
atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in 
Japanese subjects (COSMOS). Circ J. 2009;73(11):2110–7. 
22. Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, et al. Antiatherosclerotic 
effects of long-term maximally intensive statin therapy after acute coronary syndrome: 
insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of 
Rosuvastatin Versus Atorvastatin. Arterioscler Thromb Vasc Biol. 2014;34(11):2465–72.
23. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. 
Trends Biochem Sci. 2007;32(2):71–7. 
24. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, et al. NARC-1/PCSK9 
and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) 
receptor and LDL cholesterol. J Biol Chem. 2004;279(47):48865–75.
25. Park SW, Moon Y-A, Horton JD. Post-transcriptional regulation of low density lipoprotein 
receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem. 
2004;279(48):50630–8.
26. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, et al. Decreased plasma 
cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA. 
2005;102(15):5374–9. 
27. Abifadel M, Varret M, Rabès J-P, Allard D, Ouguerram K, Devillers M, et al. Mutations in 
PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–6. 
(electronic 
 
 
 
1.0)


Amended Clinical Trial Protocol No. 3
21-Nov-2017
ALIROL08069 - Alirocumab
Version number: 1
Property of the Sanofi Group - strictly confidential
Page 87
28. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, 
and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–72. 
29. Miyake Y, Kimura R, Kokubo Y, Okayama A, Tomoike H, Yamamura T, et al. Genetic 
variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might 
collectively contribute to plasma LDL cholesterol levels in the general population. 
Atherosclerosis. 2008;196(1):29–36. 
30. Steinberg D, Witztum JL. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL 
cholesterol levels. Proc Natl Acad Sci USA. 2009;106(24):9546–7. 
31. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Executive summary of the 
Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of 
atherosclerotic cardiovascular diseases in Japan -2012 version. J Atheroscler Thromb. 
2013;20(6):517–23. 
32. Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon K-W, Sipahi I, et al. Effect of diabetes 
on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 
intravascular ultrasound trials. J Am Coll Cardiol. 2008;52(4):255–62.
33. Puri R, Nissen SE, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, et al. Factors underlying 
regression of coronary atheroma with potent statin therapy. Eur Heart J. 2013;34(24):1818–25. 
34. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, et al. Statins, high-
density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 
2007;297(5):499–508. 
35. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density 
lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 
1972;18(6):499–502. 
36. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–108. 
37. Mehrotra DV, Li X, Liu J, Lu K. Analysis of longitudinal clinical trials with missing data 
using multiple imputation in conjunction with robust regression. Biometrics. 
2012;68(4):1250–9. 
38. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, et al. A reporting 
system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for 
Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart 
Association. Circulation. 1975;51(4 Suppl):5–40.
39. Habets J, van den Brink RBA, Uijlings R, Spijkerboer AM, Mali WPTM, Chamuleau SAJ, et 
al. Coronary artery assessment by multidetector computed tomography in patients with 
prosthetic heart valves. Eur Radiol. 2012 Jun;22(6):1278–86. 
(electronic 
 
 
 
1.0)

SAP_001.pdf: 
Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of Sanofi (or any of its 
affiliated companies). The use of such confidential information must be restricted to the recipient for the agreed purpose and must not be 
disclosed, published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without the prior written 
consent of Sanofi (or the concerned affiliated company); ‘affiliated company’ means any corporation, partnership or other entity which at the date 
of communication or afterwards (i) controls directly or indirectly Sanofi, (ii) is directly or indirectly controlled by Sanofi, with ‘control’ meaning direct 
or indirect ownership of more than 50% of the capital stock or the voting rights in such corporation, partnership or other entity
According to template: QSD-002643 VERSION 6.0 (06-JUL-2016)
Page 1
STATISTICAL ANALYSIS PLAN
A randomized, open-label, blinded intravascular ultrasound analysis, parallel 
group, multicenter study to evaluate the effect of Praluent® (alirocumab) on 
coronary atheroma volume in Japanese patients hospitalized for acute coronary 
syndrome with hypercholesterolemia not adequately controlled with statin
ALIROL08069
STATISTICIAN: 
DATE OF ISSUE: 11-Oct-2018
Total number of pages:
66
(electronic 2.0)
NCT Number:NCT02984982


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 2
TABLE OF CONTENTS
STATISTICAL ANALYSIS PLAN....................................................................................................................1
TABLE OF CONTENTS..................................................................................................................................2
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ..........................................................................5
1
OVERVIEW AND INVESTIGATIONAL PLAN.................................................................................7
1.1
STUDY DESIGN AND RANDOMIZATION ......................................................................................7
1.2
OBJECTIVES...................................................................................................................................7
1.2.1
Primary objectives............................................................................................................................7
1.2.2
Secondary objectives .......................................................................................................................8
1.3
DETERMINATION OF SAMPLE SIZE.............................................................................................8
1.4
STUDY PLAN...................................................................................................................................9
1.5
MODIFICATIONS TO THE STATISTICAL SECTION OF THE PROTOCOL................................10
1.6
STATISTICAL MODIFICATIONS MADE IN THE STATISTICAL ANALYSIS PLAN......................10
1.7
STATISTICAL ADAPTATIONS MADE IN THE STATISTICAL ANALYSIS PLAN FROM 
THE PROTOCOL BEFORE STUDY START.................................................................................10
2
STATISTICAL AND ANALYTICAL PROCEDURES .....................................................................12
2.1
ANALYSIS ENDPOINTS................................................................................................................12
2.1.1
Demographic and baseline characteristics ....................................................................................12
2.1.2
Prior or concomitant medications...................................................................................................16
2.1.3
Efficacy endpoints ..........................................................................................................................18
2.1.3.1
Primary efficacy endpoint...............................................................................................................19
2.1.3.2
Secondary efficacy endpoint(s)......................................................................................................19
2.1.4
Safety endpoints.............................................................................................................................20
2.1.4.1
Adverse events variables ...............................................................................................................21
2.1.4.2
Deaths............................................................................................................................................23
2.1.4.3
Laboratory safety variables ............................................................................................................23
2.1.4.4
Vital signs variables........................................................................................................................24
2.1.5
Other endpoints..............................................................................................................................24
2.1.5.1
HbA1c.............................................................................................................................................24
2.1.5.2
hs-CRP...........................................................................................................................................24
2.1.5.3
Patients with LDL-C <25 mg/dL (0.65 mmol/L)..............................................................................24
2.1.6
Quality-of-life endpoints..................................................................................................................24
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 3
2.2
DISPOSITION OF PATIENTS .......................................................................................................25
2.2.1
Randomization irregularities...........................................................................................................26
2.3
ANALYSIS POPULATIONS ...........................................................................................................26
2.3.1
Efficacy populations .......................................................................................................................27
2.3.1.1
Modified intent-to-treat population..................................................................................................27
2.3.1.2
Per-protocol population ..................................................................................................................27
2.3.2
Safety population............................................................................................................................28
2.3.3
Quality-of-life population.................................................................................................................28
2.4
STATISTICAL METHODS .............................................................................................................28
2.4.1
Demographics and baseline characteristics ..................................................................................28
2.4.2
Prior, concomitant or post-treatment medications .........................................................................29
2.4.3
Extent of study treatment exposure and compliance .....................................................................30
2.4.3.1
Extent of investigational medicinal product exposure ....................................................................30
2.4.3.2
Compliance of investigational medicinal product exposure ...........................................................30
2.4.3.3
Extent of non-investigational medicinal product exposure.............................................................31
2.4.3.4
Compliance of non-investigational medicinal product exposure ....................................................32
2.4.4
Analyses of efficacy endpoints.......................................................................................................32
2.4.4.1
Analysis of primary efficacy endpoint.............................................................................................32
2.4.4.2
Analyses of secondary efficacy endpoints .....................................................................................35
2.4.4.3
Multiplicity issues............................................................................................................................39
2.4.5
Analyses of safety data ..................................................................................................................39
2.4.5.1
Analyses of adverse events ...........................................................................................................40
2.4.5.2
Deaths............................................................................................................................................43
2.4.5.3
Analyses of laboratory variables ....................................................................................................43
2.4.5.4
Analyses of vital sign variables ......................................................................................................45
2.4.6
Analysis of other endpoints ............................................................................................................46
2.4.6.1
Analyses of hs-CRP .......................................................................................................................46
2.4.6.2
Analyses of HbA1c.........................................................................................................................46
2.4.6.3
Analyses of patients with LDL-C <25 mg/dL (<0.65 mmol/L).........................................................46
2.4.7
Analyses of quality of life/health economics variables ...................................................................46
2.5
DATA HANDLING CONVENTIONS...............................................................................................47
2.5.1
General conventions ......................................................................................................................47
2.5.2
Data handling conventions for secondary efficacy variables..........................................................49
2.5.3
Missing data ...................................................................................................................................49
2.5.4
Windows for time points.................................................................................................................50
2.5.4.1
Time points for IVUS and OCT variables.......................................................................................50
2.5.4.2
Time points for data except OCT and IVUS variables ...................................................................50
2.5.5
Unscheduled visits .........................................................................................................................51
2.5.6
Pooling of centers for statistical analyses ......................................................................................51
2.5.7
Statistical technical issues .............................................................................................................51
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 4
3
INTERIM ANALYSIS .....................................................................................................................52
4
DATABASE LOCK ........................................................................................................................53
5
SOFTWARE DOCUMENTATION..................................................................................................54
6
REFERENCES...............................................................................................................................55
7
LIST OF APPENDICES .................................................................................................................56
APPENDIX A
POTENTIALLY CLINICALLY SIGNIFICANT ABNORMALITIES CRITERIA .......................57
APPENDIX B
EQ-5D PATIENT QUESTIONNAIRE ...................................................................................62
APPENDIX C
EQ-5D UTILITY SCORE ALGORITHM ...............................................................................63
APPENDIX D
MEDICATION SPECIFIC CODING LIST.............................................................................64
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 5
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS
Ab:
antibody
ACE:
angiotensin converting enzyme
ACS:
acute coronary syndrome
AE:
adverse event
AESI:
adverse event of special interest 
ALT:
alanine aminotransferase 
ANCOVA:
analysis of covariance 
Apo:
apolipoprotein 
AST:
aspartate aminotransferase 
BMI:
body mass index 
CEC:
Clinical Events Committee
CHD:
coronary heart disease 
CKD:
chronic kidney disease
CMQ:
company MedDRA query 
CPK:
creatine phosphokinase 
EEM:
external elastic membrane
eGFR:
estimated glomerular filtration rate 
GFR:
glomerular filtration rate
HbA1c:
Glycated hemoglobin A1c
HCV:
hepatitis C virus
HDL-C:
high-density lipoprotein cholesterol
HLGT:
high-level group term
HLT:
high-level term
hs-CRP:
high-sensitivity C-reactive protein 
IMP:
investigational medical product
IVUS:
intravascular ultrasound
LDH:
lactate dehydrogenase 
LDL-C:
low-density lipoprotein cholesterol
LLN:
lower limit of normal range
LLOQ:
lower limit of quantification
LLT:
lowest-level term
Lp (a):
lipoprotein (a)
MedDRA:
Medical Dictionary for Regulatory Activities
MI:
myocardial infarction 
NIMP:
non-investigational medical product
non-HDL-C:
non-high-density lipoprotein cholesterol 
NSAID:
nonsteroidal anti-inflammatory drug
NSTEMI:
non STsegment elevation myocardial infarction
OCT:
optical coherence tomography
PAV:
percent atheroma volume
PCSA:
potentially clinically significant abnormality(ies) 
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 6
PP:
per-protocol
Q1:
first quartile
Q3:
third quartile
QOL:
quality of life
RNA:
ribonucleic acid
SD:
standard deviation
SE:
standard error
SoC:
Standard of Care
SOC:
system organ class
STEMI:
ST-segment elevation myocardial infarction
TAV:
total atheroma volume
TC:
total cholesterol
TEAE:
treatment-emergent adverse event 
TG:
triglycerides 
UA:
unstable angina
ULN:
upper limit of normal range 
ULOQ:
upper limit of quantification
WHO-DD:
World Health Organization-Drug Dictionary
γGT:
gamma glutamyl transferase
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 7
1
OVERVIEW AND INVESTIGATIONAL PLAN  
1.1
STUDY DESIGN AND RANDOMIZATION
This is a phase IV, open-label, 1:1 randomized, blinded intravascular ultrasound (IVUS) analysis, 
parallel group, multicenter study.
Approximately 200 patients from approximately 40 study sites will be enrolled and randomized 
with a treatment period of 9 months.
These patients will be:
-
Patients who suffer an acute coronary syndrome (ACS) event despite of stable statin 
therapy,
-
Patients who have not been on any statin therapy at the time of ACS onset, but who will 
start either atorvastatin 10 mg/day or rosuvastatin 5 mg/day immediately after the ACS 
diagnosis, and whose LDL-C is not adequately controlled with statin at 2 to 4 weeks after 
the ACS diagnosis (in principal, LDL-C target level ≥100 mg/dL, but this may not apply if 
the responsible physician considers the LDL-C level inadequate on statin. Patients who 
have LDL-C <70 mg/dL cannot be enrolled).
Randomization will be stratified by ‘on statin therapy’ or ‘not on statin therapy’ at the time of 
ACS onset.
After randomization, patients will receive open-label study treatment of alirocumab 75 mg every 
2 weeks (Q2W) over a period of 36 weeks on top of stable daily statin therapy or Standard of Care 
(SoC). A dose up-titration to alirocumab 150 mg Q2W will be performed at Week 14 for patients 
randomized to alirocumab group and whose LDL-C level measured at Week 12 remains ≥100 
mg/dL.
1.2
OBJECTIVES
1.2.1
Primary objectives
To compare the effect of alirocumab with standard of care (SoC) on coronary atheroma 
progression (percent change in normalized total atheroma volume [TAV]) after 9 months of 
treatment in patients who had ACS within 4 weeks prior to randomization, with 
hypercholesterolemia treated with any statin.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 8
1.2.2
Secondary objectives

To compare the effect of alirocumab with SoC on secondary endpoints including absolute 
change in percent atheroma volume (PAV) and normalized TAV after 9 months of 
treatment.

To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C), 
apolipoprotein B (Apo-B), triglycerides (TGs), non-high-density lipoprotein cholesterol 
(non-HDL- C) and Lipoprotein(a) (Lp[a] ) after 9 months treatment.

To evaluate the safety of alirocumab including the occurrence of cardiovascular (CV) 
events [coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and 
non-fatal ischemic stroke, unstable angina requiring hospitalization] throughout the study.
1.3
DETERMINATION OF SAMPLE SIZE
The study is expected to enroll approximately 200 patients. The sample size calculations are based 
on the primary efficacy variable of percent change in normalized TAV from baseline to week 36.
Based on the results of ZEUS (1) and PRECISE-IVUS (2) studies, it is assumed that difference in 
percent change in normalized TAV from baseline between alirocumab arm and SoC arm is 8%, 
the common standard deviation of percent change in normalized TAV is 15%.
Under the assumption, a sample size of 150 patients (75 in alirocumab arm and 75 in SoC arm) 
will have 90% power to detect the treatment difference with two-sided significance level of 5%. 
Assuming that proportion of non-evaluable primary endpoint is 25%, it is considered that 
200 patients (100 in alirocumab arm, 100 in SoC arm) will be needed.
As the analysis of covariance (ANCOVA) model will be used for primary analysis, the power 
should be somewhat higher due to reduced estimate variability versus the two-sample t-test.
Calculations were made using SAS 9.4.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 9
1.4
STUDY PLAN
Abbreviations: ACS, acute coronary syndrome; IC, informed consent; IVUS, intravascular ultrasound; LDL-C, low-density lipoprotein cholesterol; LMT, lipid modifying therapy; Q2W, every 2 weeks; R, randomization; 
SoC, standard of care.
a
If patients have not been on any statin therapy at ACS onset, either atorvastatin 10 mg/day or rosuvastatin 5 mg/day is started immediately after the ACS diagnosis. 
b
At randomization, patients should have already received stable statin therapy with either atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day for at least 2 weeks.  
c
Stable dose statin monotherapy (atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day within a range of approved statin doses by the Health Authority) will be administrated to achieve the LDL-C target level <100
mg/dL. Adjusting of statin will occur based on above rule. Concomitant non-statin LMTs will be considered if patients have already been on them on top of statin monotherapy at the time of ACS diagnosis or if LDL-
C target level <100 mg/dL cannot be achieved by the statin monotherapy.. Adjusting of LMT will occur based on above rule, but not limited.
d
Alirocumab 75mg every 2 weeks on top of dose of atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day ± other LMTs, in accordance with approved doses by the Health Authority.  Concomitant non-statin LMTs will 
be considered if patients already on them on top of statin monotherapy at the time of ACS diagnosis. Background statin and/or non-statin LMT regimens should not be changed as a principle during the entire study 
period.
e
In Alirocumab arm, if LDL-C value at Week 12 visit measured by the Central Laboratory does not reach less than 100 mg/dL, alirocumab dose uptitration to 150 mg Q2W will be carried out at Week 14. 
f
Patients who perform self-injection of alirocumab at home must visit the study site at least every 4 weeks, and at Week 0, Week 4, Week 12, Week 14, Week 24 and Week 36.
Open-Label Treatment Period (36weeks)f
ACS
Diagnosisa
N=100 
N=100
R b
W0
Within 4 weeks
SoC Arm : Standard of Care for LDL-C <100 mg/dLc
Alirocumab Arm: Baseline LMT + Alirocumab 75mgQ2W d
IC
W12
W24
W36
Up-titration to 150 mg Q2W
when LDL-C ≥100 mg/dL e
Baseline
IVUS
Evaluation
IVUS
(electronic 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 10
1.5
MODIFICATIONS TO THE STATISTICAL SECTION OF THE PROTOCOL
The statistical section of the protocol was not changed except that randomization strata of "statin 
at ACS diagnosis" was corrected to "statin at ACS onset" due to erroneous description.
1.6
STATISTICAL MODIFICATIONS MADE IN THE STATISTICAL ANALYSIS PLAN
The SAP version 1 was modified between the study start and database lock (DBL) for the main 
study in order to follow the last amended protocol, to address the further information on IVUS and 
optical coherence tomography (OCT) imaging analysis, to keep a consistency with the study 
objectives, and to correct erroneous descriptions. The changes in the SAP from version 1 to
version 2 are as follows:

Section 2.3.1: In the definition of mITT population, "Another one assessed during the 
efficacy treatment period and within the Week 36 analysis window", which is mentioned in 
the 3rd item of Table 1 in Section 1.7, was changed to "Another one assessed after 24 
weeks of treatment ", since the statement in version 1 was inconsistent with the last 
amended protocol, and IVUS imaging outside the efficacy treatment period could not be 
considered as protocol deviation.

Section 2.3.1.1: In the definition of PP population, the following criteria were changed:
-
"Patients with analyzed vessel length less than 10 mm" was added, since it is 
considered major deviation from IVUS imaging procedure and it may have an impact 
on IVUS parameters.
-
"LDL-C ≥100 mg/dL" was changed to "LDL-C at patient selection ≥100 mg/dL for 
patients enrolled based on the protocol amendment 1; ≥70 mg/dL for patients enrolled 
based on the protocol amendment 2 or later" according to the amended protocol.
-
"Background therapy deviation" was removed, since the study team found that in the 
study protocol the use of background therapy including statin is eventually dependent 
upon the doctor and so deviation related to background therapy cannot be specified.

Several analyses including substudy analyses for optical coherence tomography (OCT), 
additional efficacy analyses (Section 2.4.4.4) were removed, since they are beyond the 
study objectives.
1.7
STATISTICAL ADAPTATIONS MADE IN THE STATISTICAL ANALYSIS PLAN FROM 
THE PROTOCOL BEFORE STUDY START
In this section, summarize major adaptations in statistical analysis features made in approved SAP 
versions, with emphasis on adaptations before study start (before the first patient was enrolled) 
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 11
The table below gives the timing, rationale, and key details of major adaptations made in the SAP
from the protocol.  
The first patient is planned to be enrolled on 16-Nov-2016. There are no planned interim analysis.
Table 1 - Adaptations to statistical analysis plan from protocol before study start
Protocol 
Amendment  
Number
Date 
Approved
Rationale
Description of statistical changes
1
19-Aug-2016
To be detailed. 
The definition of normalized TAV (Median  
number of analyzed frames in the 
population) was detailed. 
To correct the erroneous description 
about calculation of normalized 
TAV.
Normalized TAV will be calculated by Sanofi 
or delegate, not Central Reading.
To be detailed
The definition of primary analysis population, 
modified Intent-to-treat population was 
added to have post-baseline during efficacy 
treatment period
To be detailed
Congestive heart failure will be also 
adjudicated by Clinical Events Committee
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 12
2
STATISTICAL AND ANALYTICAL PROCEDURES
2.1
ANALYSIS ENDPOINTS
2.1.1
Demographic and baseline characteristics
Unless otherwise specified, the baseline value is defined as the last available value before 
randomization.
All baseline safety and efficacy parameters (apart from those listed below) are presented along 
with the on-treatment summary statistics in the safety and efficacy sections (Section 2.4.5 and
Section 2.4.4).
Demographic characteristics
Demographic variables are:

Age in years (quantitative and qualitative variable: <65, ≥65 to <75, and ≥75 years; and 
<65, ≥65 years);

Gender (Male, Female);

Race (Asian);

Ethnicity (Not Hispanic or Latino).
Medical or surgical history
This information will be coded using the version of Medical Dictionary for Regulatory Activities 
(MedDRA) currently in effect at Sanofi or delegate at the time of database lock.
Medical history of specific interest includes:

CHD prior to the index ACS diagnosis; 
-
Myocardial infarction
-
Unstable angina
-
Coronary revascularization procedure
-
Other clinically significant CHD

Ischemic stroke

Peripheral arterial disease

Hypertension

Diabetes
-
Type 1 diabetes
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 13
-
Type 2 diabetes

Chronic kidney disease (CKD)

Impaired glucose tolerance

Hypo HDL cholesterolemia (<40 mg/dL)

Family history of premature coronary artery disease

Family history of Type 2 diabetes mellitus
“Peripheral Arterial Disease” history is defined as follows, using combinations of the 
corresponding pre-listed medical history items of the e-CRF page “Cardiovascular history and 
cardiovascular risk factors”:

Intermittent claudication (linked to PAD) TOGETHER WITH ankle-brachial index ≤0.90
Or

Intermittent claudication (linked to PAD) TOGETHER WITH peripheral revascularization 
procedure (angioplasty, stenting) for PAD or peripheral revascularization surgery (arterial 
bypass) for PAD
Or

Critical limb ischemia TOGETHER WITH peripheral revascularization procedure 
(angioplasty, stenting) for PAD or thrombolysis for PAD or peripheral revascularization 
surgery (arterial bypass) for PAD.
The status of hypertension at baseline will be selected using SMQ “hypertension” (narrow), based 
on terms reported as “ongoing” in Medical history by the investigator.
Efficacy and safety analysis performed according to “diabetic status at baseline” reported in the 
Medical history by the investigator will be done using a company MedDRA query (CMQ), based 
on the following PTs reported in e-CRF Medical History: “diabetes mellitus”, “diabetes mellitus
inadequate control”, “fulminant type 1 diabetes mellitus”, “insulin resistant diabetes”, “insulin-
requiring type 2 diabetes mellitus”, “type 1 diabetes mellitus”, “type 2 diabetes mellitus”,
“diabetes mellitus malnutrition-related”, and “diabetes mellitus management”.
Diabetic status at baseline (Yes, No) will be also summarized. Besides, for diabetic patients at 
baseline, the following items will be summarized.

Insulin use (Yes, No);

Time from diagnosis of diabetes (quantitative [years] and qualitative variable: <Median, ≥
Median years).
Medical or surgical history includes:

Medical history of allergies;

Smoking habits (Never, Former, Current);
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 14

Alcohol habits (Never, Occasional, At least monthly, At least weekly, At least daily).
Disease characteristics at baseline  
Specific disease history includes:

The index ACS subtype (acute ST-segment elevation myocardial infarction [STEMI], 
acute non ST-segment elevation myocardial infarction [NSTEMI], unstable angina [UA])

Time from the index ACS diagnosis to randomization (in weeks), quantitatively and in 
category <2, ≥2 to <4, ≥4 weeks

Revascularization procedure associated with the index ACS event (PCI or CABG)

Time from the revascularization procedure to randomization (in weeks)

Types of stents placed at the PCI (bare metal stent [BMS], drug eluting stent [DES] or 
both).

Location of ACS culprit vessels

Location of analyzed IVUS imaging vessels (RCA, LAD, LCX, Other)

New cardiovascular events occurring after the index ACS diagnosis and before 
randomization, selected using e-CRF specific tick box on the adverse event page.

Type of hypercholesterolemia: 
-
Heterozygous familial hypercholesterolemia (heFH);
-
Non-familial hypercholesterolemia (non-FH);
-
Unknown;

For heFH patients:
-
Time from diagnosis of heFH (years);
-
Diagnosis made by genotyping (Yes, No);

For non-FH patients:
-
Time from diagnosis of hypercholesterolemia (years);
-
Fredrickson classification of hyperlipoproteinemia (IIa, IIb, IV);

The background lipid modifying therapy (LMT) regimen at ACS diagnosis, as reported in 
the “Previous Lipid Modifying Therapy” e-CRF page, will be summarized using the 
following categories:
-
Any LMT
-
Any statin by daily dose
-
Atorvastatin, rosuvastatin, pravastatin, simvastatin, fluvastatin, pitavastatin 
-
LMT other than statin
Ezetimibe
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 15
Fibrate
-
Fenofibrate
-
Bezafibrate
-
Other
-
Other

The background lipid modifying therapy regimen at randomization, as reported in the 
“Previous Lipid Modifying Therapy” e-CRF page, will be summarized as those at ACS 
diagnosis.
Other baseline characteristics
Other baseline characteristics include weight in kilograms (quantitative variable and qualitative 
variable: <Median, ≥Median), body mass index (BMI) in kg/m² (quantitative and qualitative 
variable:  <25, ≥25), and randomization strata (as described in Section 1.1) as per registration 
center.
Lipid parameters and glycated hemoglobin A1c (HbA1c) (quantitative and qualitative variable:  
<5.7 %, ≥5.7 to <6.5%, ≥6.5%), hs-CRP (quantitative [mg/L, mg/dL] and qualitative variable: <2, 
≥2 mg/L [ie, <0.2 mg/dL, ≥0.2 mg/dL]), and eGFR (quantitative and qualitative variable: <15 , 
≥15 to <30 , ≥30 to <60 , ≥60 to <90, ≥90 mL/min/1.73m2, category <30, ≥30, <60, 
≥60 mL/min/1.73m2 will be also displayed) at baseline will be also summarized by treatment 
group. Lipid parameters are total cholesterol (TC), calculated LDL-C, non HDL-C, high-density 
lipoprotein cholesterol (HDL-C), fasting TGs, Apo A-1, Apo B, Lp (a), Apo B/Apo A-1 ratio,
Fasting TGs/HDL-C ratio, and calculated LDL-C/HDL-C ratio. Lipids parameters will be 
summarized using standard international unit and conventional unit. Baseline values of lipid 
parameters are defined as the last available value from central laboratory assessed up to the date 
and time of randomization. eGFR will be calculated using the equation defined in Section 2.5.1.
For lipid parameters, both quantitative and qualitative variables will be considered, with the 
following categories:

Calculated LDL-C:  <70, ≥70 to <80, ≥80 to <100, ≥100 to <130, ≥130 to <160, ≥160 to 
<190, ≥190 mg/dL (ie, <1.81, ≥1.81 to <2.07, ≥2.07 to <2.59, ≥2.59 to <3.37, ≥3.37 to 
<4.14, ≥4.14 to <4.91, ≥4.91 mmol/L), category<100,  ≥100 mg/dL (ie, <2.59,
≥2.59 mmol/L) and  <80, ≥160 mg/dL (<2.07, ≥4.14 mmol/L) will be also displayed,

HDL-C:  <40, ≥40 mg/dL (ie, <1.04, ≥1.04 mmol/L),

Non-HDL-C:  <100, ≥100 to <110, ≥110 to <130, ≥130 to <160, ≥160 to <190, 
≥190 to <220, ≥220 mg/dL (ie, <2.59, ≥2.59 to 2.84, ≥2.84 to <3.37, ≥3.37 to <4.14, 
≥4.14 to <4.91, ≥4.91 to 5.69, ≥5.69 mmol/L) , category <110 , ≥130 mg/dL, (ie, <2.84,  
≥3.37 mmol/L) will be also displayed

Fasting TGs:  <150, ≥150 to <200, ≥200 mg/dL (ie, <1.7, ≥1.7 to <2.3,  ≥2.3 mmol/L), 
category ≥150 mg/dL (ie, ≥1.7 mmol/L [mixed dyslipidemia]) will be also displayed,
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 16

Lp (a):  <30, ≥30 to <50, ≥50 mg/dL (ie, <0.3, ≥0.3 to <0.5,  ≥0.5g/L), category ≥30 , 
<50 mg/dL, (ie, ≥0.3, <0.5 g/L) will be also displayed

Apo B:  <75, ≥75 to <90, ≥90 mg/dL (ie, <0.75, ≥0.75 to <0.9, ≥0.9 g/L)
Lipid parameters at patient selection and HbA1c at ACS diagnosis (quantitative and qualitative 
variable) will be also analyzed as those at baseline. Lipid parameters at patient selection are to be
reported in the case report “Lipid Parameters at Patient Selection” form page:
Note: non-HDL-C will be calculated by subtracting HDL-C from the TC. 
Ratio Apo B/Apo A-1 will be calculated by Apo B divided by Apo A-1. If LDL-C was 
directly measured, LDL-C will be calculated using the Friedwald formula. If TG values 
exceed 400 mg/dL (4.52 mmol/L), then calculated LDL-C will be missing.
IVUS parameters (quantitative variables) and analyzed vessel length at baseline will be 
summarized. IVUS parameters are normalized TAV, PAV, external elastic membrane (EEM)
volume, lumen volume, and TAV. For normalized TAV and PAV, quantitative variables will be
also considered, with the following category (<Median, ≥Median).
Any technical details related to computation, dates, and imputation for missing dates are described 
in Section 2.5. 
2.1.2
Prior or concomitant medications
All LMTs taken within 1 month before Visit 1 and until the end of the study are to be reported in 
the case report form pages. Other concomitant medications taken since informed consent until the 
end of study are to be reported in the case report form page:

Previous Lipid Modifying Therapy
-
Previous lipid modifying therapies are to be reported.

Concomitant Non-Investigational Medicinal Product
-
Concomitant Non-Investigational Medical Product (NIMP) defined in protocol are to 
be reported.

Concomitant Other Medication
-
Concomitant medications except NIMPs are to be reported.
All medications will be coded using the World Health Organization-Drug Dictionary (WHO-DD) 
using the version currently in effect at Sanofi or delegate at the time of database lock.

Prior medications are those the patient used within 1 month prior to randomization. Prior 
medications can be discontinued before randomization or can be ongoing during treatment 
phase;

Concomitant medications are any treatments received by the patient concomitantly to the 
treatment, from randomization to the last study treatment administration + 21 days, or end 
of study, whichever comes first. A given medication can be classified both as a prior 
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 17
medication and as a concomitant medication. Concomitant medications do not include 
medications started during the post-treatment period (as defined in the observation period 
in Section 2.1.4). 

Post-treatment medications are those the patient took in the period starting the day after the 
end of treatment-emergent adverse event period (as defined in the observation period in
Section 2.1.4) up to the end of the study.
For patients randomized but not treated, medications will be categorized as prior medications or 
post-treatment medications according to the date of intake in relation to the date of randomization.
The following medications of specific interest including NIMP defined in protocol will be selected 
using specific coding list specified in Table 5, unless otherwise specified:

Anti-platelets

Aspirin
-
Oral adenosine diphosphate (ADP) receptor antagonists (except aspirin)
- Clopidogrel
- Ticagrelor
- Prasugrel
- Ticlopidine

Anticoagulants
-
Injectable anticoagulants (unfractionated heparin [UFH], low molecular weight heparin
[LMWH], bivalirudin, selective factor Xa inhibitor)
-
Specific oral anticoagulants
- Vitamin K antagonist (VKA)
- Non-vitamin K antagonist oral anticoagulants (NOAC)

Thrombolytic

Anti-diabetic drugs
-
Oral hypoglycemic drugs
- Biguanides/metformin
- Sulfonylurea
- Glinide
- Thiazolidine dione (TZD)
- Alpha-glucosidase inhibitors (α-GI)
- DPP4 inhibitor
- SGLT2 inhibitor
-
Injectable hypoglycemic drugs
- Glucagon-like peptide-1 receptor agonists (GLP-1 RA)
- Insulin

Angiotensin-converting-enzyme (ACE)-inhibitor or angiotensin receptor blocker

Beta blocker
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 18

Calcium channel blocker

Diuretics

Nitrates

Non-steroidal anti-inflammatory drugs (NSAIDs) (excluding aspirin)

Cholesterol absorption inhibitor
-
Ezetimibe

Fibrate
-
Fenofibrate
-
Bezafibrate
Any technical details related to computation, dates, imputation for missing dates are described in 
Section 2.5.
2.1.3
Efficacy endpoints
The EEM volume, lumen volume, TAV, normalized TAV, and PAV will be calculated by the 
Sponsor or delegate. These IVUS parameters will be calculated using the following equations 
defined using EEMCSA and LumenCSA taken at pre-determined interval between each image 
(=0.5 mm):
TAV (mm3) =
)
(
CSA
CSA
Lumen
EEM


,
normalized TAV (mm3)=TAV
n
C

,
where is the summation over all the analyzed frames, n is the number of analyzed frames per 
patient, C is the median of the number of analyzed frames in patients with available baseline 
TAV within randomized population. EEMCSA is the cross-sectional area inside the EEM border,
the LumenCSA is the cross-sectional area inside the lumen border, and both parameters are  
measured by the central reading laboratory. Besides,
PAV (%)=
100
(










CSA
CSA
CSA
EEM
Lumen
EEM
,
EEM volume (mm3)= 
)
(

CSA
EEM
,
Lumen volume (mm3)= 
)
(
CSA
Lumen

,
where is the summation over all the analyzed frames.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 19
The detailed procedures of IVUS image analysis and calculation of the parameters will be 
specified in the procedure manual of IVUS image analysis. 
For post-baseline IVUS parameters, the value used for the analyses at Week 36 is the value 
assessed after the ≥24 weeks of treatment and within the Week 36 analysis window defined in 
Section 2.5.4.1, Table 3.
Efficacy parameters include lipid parameters (i.e. TC, calculated LDL-C, HDL-C, fasting TGs, 
non-HDL-C, Apo B, Apo A-1, Apo B/Apo A-1 ratio, Lp[a], fasting TGs/HDL-C ratio, and 
calculated LDL-C/HDL-C ratio). All these parameters except for fasting TGs/HDL-C ratio, and 
calculated LDL-C/HDL-C ratio are measured or calculated by the central laboratory, for both 
scheduled and unscheduled time points. The LDL-C will be calculated using the Friedewald
formula. If TGs values exceed 400 mg/dL (4.52 mmol/L), the calculated LDL-C levels will not be 
used for any analysis. Non-HDL-C will be calculated by subtracting HDL-C from the TC. 
Apo B/Apo A-1 ratio will be calculated. Fasting TGs/HDL-C ratio, and calculated LDL-C/HDL-C
ratio will be calculated by Sanofi or delegate.
Unless otherwise specified, all lipid values from central laboratory (scheduled or unscheduled, 
fasting or not fasting) will be used to provide a value for the secondary efficacy endpoints. All 
measurements, scheduled or unscheduled, fasting or not fasting (except for TGs), will be assigned 
to analysis windows as defined in Section 2.5.4, Table 4 in order to provide an assessment for 
Week 4 to Week 36 time points. For TGs, only fasting measurements will be used. Measurements 
with missing fasting status will be excluded from the analyses.
For all time points, the value of post-baseline lipid parameters used for the analyses at a given 
time point (eg, at Week 36) is the value assessed and within the corresponding analysis window. 
The baseline value is the last available value from central laboratory assessed up to the date and 
time of randomization.
2.1.3.1
Primary efficacy endpoint
The primary efficacy endpoint is the percent change in normalized TAV from baseline to Week 36, 
which is defined as: 100 (normalized TAV value at Week 36 - normalized TAV value at 
baseline) / normalized TAV value at baseline and calculated by Sponsor or delegate.
The baseline normalized TAV value is the one assessed before the randomization.
The normalized TAV at Week 36 will be the one assessed after the ≥24 weeks of treatment and 
within the Week 36 analysis window, defined in Section 2.1.3.
2.1.3.2
Secondary efficacy endpoint(s)
2.1.3.2.1 Key secondary efficacy endpoint

Absolute change in PAV from baseline to Week 36.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 20
2.1.3.2.2 Other secondary efficacy endpoints

Absolute change in normalized TAV from baseline to Week 36.

Absolute and percent changes in EEM volume from baseline to Week 36.

Absolute and percent changes in lumen volume from baseline to Week 36.

Absolute and percent changes in TAV from baseline to Week 36.

Absolute and percent changes in calculated LDL-C from baseline to Week 12, and 
Week 36.

Absolute and percent changes in Apo B from baseline to Week 36.

Absolute and percent changes in non-HDL-C from baseline to Week 36.

Absolute and percent changes in TC from baseline to Week 36.

Absolute and percent changes in Lp(a) from baseline to Week 36.

Absolute and percent changes in HDL-C from baseline to Week 36.

Absolute and percent changes in fasting TGs from baseline to Week 36.

Absolute and percent change in Apo A-1 from baseline to Week 36.

Absolute change in Apo B/Apo A-1 ratio from baseline to Week 36.

Absolute change in fasting TGs/HDL-C ratio from baseline to Week 36.

Absolute change in calculated LDL-C/HDL-C ratio from baseline to Week 36.

The proportion of patients with calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 36

The proportion of patients with calculated LDL-C <50 mg/dL (3.37 mmol/L) at Week 36

The proportion of patients achieving at least 50% reduction in calculated LDL-C at 
Week 36
2.1.4
Safety endpoints
The safety analysis will be based on the reported adverse events (AEs) and other safety 
information, such as clinical laboratory data and vital signs.
Observation period 
The observation period of safety data will be as follows:

Pre-treatment period is defined as the time from the signed informed consent date up to
the day of randomization. 

Treatment-emergent adverse event (TEAE) period is defined as the time from the day of 
randomization to the last study treatment administration + 21 days, or end of study, 
whichever comes first in both the alirocumab and SoC groups.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 21

Post-treatment period is defined as the time starting the day after the end of the TEAE
period up to the end of the study.

On-study observation period is defined as the time from the day of randomization until 
the end of the study.
2.1.4.1
Adverse events variables
Occurrence of adverse events (including SAEs and adverse events of special interest [AESIs]) are 
recorded from the time of signed informed consent until the end of study.
All AEs (including SAEs and AESIs) will be coded to a lowest-level term (LLT), PT, high-level 
term (HLT), high-level group term (HLGT), and associated primary system organ class (SOC) 
using the version of MedDRA currently in effect at Sanofi or delegate at the time of database lock.
Adverse event observation period 

Pre-treatment AEs are AEs that developed or worsened or became serious during the 
pre-treatment period

TEAEs are AEs that developed or worsened or became serious during the TEAE period

Post-treatment AEs are AEs that developed or worsened or became serious during the 
post-treatment period
Adverse events of special interest
Adverse events of special interest (AESIs) are adverse events (serious or non-serious) that need to 
be monitored, documented, and managed in a pre-specified manner described in the protocol. In 
this study, AESIs are the following (their complete descriptions are provided in the protocol):

General allergic events, selected using SMQ “hypersensitivity” (broad and narrow) 
excluding the following preferred terms linked to local injection site reactions (“infusion 
site dermatitis”, “infusion site hypersensitivity”, “infusion site rash”, “infusion site 
urticaria”, “injection site dermatitis”, “injection site hypersensitivity”, “injection site rash”, 
“injection site urticaria”, and “injection site vasculitis”)

General allergic events and local allergic reactions at IMP injection site, selected based on 
the above selection for general allergic event and on the following selection of PT from the 
symptoms complementary form for local injection site reaction (“Injection site dermatitis”, 
“Injection site hypersensitivity”, “Injection site oedema”, “Injection site rash”, “Injection 
site urticaria”, “Injection site eczema”, “Injection site vasculitis”, “Injection site swelling“, 
“Infusion site dermatitis”, “Infusion site hypersensitivity”, “Infusion site oedema”, 
“Infusion site rash”, “Infusion site urticaria”, “Infusion site swelling“).

Local injection site reactions, selected using e-CRF specific tick box on the adverse event 
page

ALT >3 ULN, selected using laboratory data
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 22

Hemolytic anemia, selected using e-CRF specific tick box on the adverse event page and 
confirmed final diagnosis provided in the adverse event complementary form

Neurologic events selected using a CMQ,  based on SMQs “demyelination” (broad and 
narrow), “peripheral neuropathy” (broad and narrow), and “Guillain-Barre syndrome” 
(broad and narrow) excluding the following preferred terms “acute respiratory distress 
syndrome”, “asthenia”, “respiratory arrest” and “respiratory failure” 

Neurocognitive events selected using a CMQ, based on the following 5 HLGTs:  “deliria 
(including confusion)”, “cognitive and attention disorders and disturbances”, “dementia 
and amnestic conditions”, “disturbances in thinking and perception”, and “mental 
impairment disorders”

Ophthalmologic events selected using SMQs “optic nerve disorders” (broad and narrow), 
“retinal disorders” (narrow), and “corneal disorders” (narrow);

Skeletal muscle-related adverse events using a CMQ based on the following 
PTs ”Myalgia”, ”Muscle contractions involuntary”, ”Muscle spasms”, ”Muscle 
twitching”, ”Muscle fatigue”, ”Muscle tightness”, ”Myofascial spasm”, ”Muscular 
weakness','Limb discomfort”, ”Musculoskeletal discomfort”, ”Musculoskeletal 
pain”, ”Pain in extremity”, ”Back pain”, ”Muscle contracture”, ”Musculoskeletal stiffness”

Overdose of Investigational Medical Product (IMP) (symptomatic), selected using the 
preferred terms "Accidental overdose" and "Intentional overdose" and the tick box 
“Overdose with IMP” and “Symptomatic Overdose” in the adverse event complementary 
e-CRF form

Pregnancy (including partner of a randomized male subject) selected using appropriate 
MedDRA codes
The additional grouping of events will be also provided:

Hepatic disorder events using SMQ “Hepatic disorder”

Diabetes mellitus or diabetic complications using HLGT “diabetes complications” 
(including PTs pertaining to the secondary SOC included in the HLGT), HLT “diabetes 
mellitus”, and HLT “carbohydrate tolerance analyses (incl diabetes)” excluding PTs 
“blood glucose decreased” and “Glycosylated haemoglobin decreased” and including the 
PTs “hyperglycaemia”, “Hyperglycaemic unconsciousness” and “Hyperglycaemic seizure” 
from the HLT "Hyperglyceamic conditions NEC"

Cataract using HLT “Cataract conditions”
Cardiovascular events
Suspected CV events that occur from randomization until the follow up visit will be submitted to 
the Clinical Events Committee (CEC) for adjudication. 
Adjudicated CV events include all CV AEs and CV procedures positively adjudicated as defined 
in the CEC charter. The following categories will be described:
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 23

CV death (including undetermined cause),

MI,

Ischemic stroke,

Unstable angina requiring hospitalization,

Congestive heart failure requiring hospitalization,

Ischemia driven coronary revascularization procedure.
2.1.4.2
Deaths
The deaths observation periods are per the observation periods defined above. 

Death on-study:  deaths occurring during the on-study observation period

Death on-treatment:  deaths occurring during the TEAE period 

Death post-study:  deaths occurring after the end of the study 
2.1.4.3
Laboratory safety variables
Clinical laboratory data consists of blood analysis, including hematology, and clinical chemistry. 
Clinical laboratory values after conversion will be analyzed into standard international units and 
international units will be used in all listings and tables, unless otherwise specified.
Blood samples for clinical laboratories will be taken as described in the study flow chart in the 
protocol. The laboratory parameters will be classified as follows:

Hematology
-
Red blood cells and platelets:  hemoglobin, hematocrit, red blood cell count, platelet 
count;
-
White blood cells:  white blood cell count, neutrophils, lymphocytes, monocytes, 
basophils, eosinophils.

Clinical chemistry
-
Metabolism: fasting plasma glucose, total protein, albumin, creatine 
phosphokinase (CPK);
-
Electrolytes:  sodium, potassium, chloride;
-
Renal function:  creatinine, uric acid, estimated glomerular filtration rate (eGFR);
-
Liver function:  alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
alkaline phosphatase (ALP), gamma glutamyl transferase (γGT), lactate 
dehydrogenase (LDH), total bilirubin;
-
Hepatitis screen: anti-hepatitis-C antibody.
Technical formulas are described in Section 2.5.1.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 24
2.1.4.4
Vital signs variables
Vital signs include: weight, heart rate, systolic and diastolic blood pressure in the sitting position.
2.1.5
Other endpoints
Other assessment endpoints defined below are exploratory.
2.1.5.1
HbA1c
The absolute change in HbA1c (%) from baseline over time: same definitions and rules as for 
normalized TAV (see Section 2.1.3.1).
2.1.5.2
hs-CRP
The percent change in hs-CRP from baseline at Week 36 is defined using same definitions and 
rules as for normalized TAV, when applicable (see Section 2.1.3.1). hs-CRP values greater or 
equal to 10 mg/L will be excluded from analyses in a second approach, since these are suggestive 
of concurrent infections, MI, or other events provoking an acute phase response (3).
PCSA criteria for hs-CRP are defined in Appendix A.
2.1.5.3
Patients with LDL-C <25 mg/dL (0.65 mmol/L)
The assessment will include:

The proportion of patients with two consecutive results, spaced out by at least 21 days, of 
LDL-C <25 mg/dL (<0.65 mmol/L) (respectively LDL-C <15 mg/dL, ie, <0.39 mmol/L) 
during the treatment period

The time to the first LDL-C <25 mg/dL (respectively LDL-C <15 mg/dL) for these 
patients.
Only calculated LDL-C will be used for this endpoint.
2.1.6
Quality-of-life endpoints
EQ-5D is a standardized and generic instrument for measuring the health status and health related 
quality of life (QOL) for clinical and economic assessment (4). EQ-5D instrument includes 
5 items corresponding to the following dimensions:  mobility, self-care, usual activities, 
pain/discomfort, anxiety/depression (Appendix B). Each item can take 1 of 3 responses: (1.) “no 
problem”, (2.) “some problems”, and (3.) “severe problems”. Overall health status is defined as a 
5-digit number and will be converted into a standard utility score ranging between -0.111
(representing severe problems) and 1 (representing no problem): the single index utility score, 
using a regression model (, Appendix C). If response to one or more dimension is missing, the 
utility score will be missing.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 25
QOL parameters include response to each EQ-5D items and change in utility score over time from 
baseline.
2.2
DISPOSITION OF PATIENTS
This section describes patient disposition for both patient study status and the patient analysis 
populations.
Included population consists of the patients who signed the informed consent.
Randomized patients consist of all patients who have been randomly allocated to a treatment 
group and recorded in the registration center, regardless of whether the study drug was used or not. 
Patients treated without being randomized will not be considered as randomized and will not be 
included in any analysis population.
For patient study status, the total number of patients in each of the following categories will be 
presented in the clinical study report using a flowchart diagram or summary table:

Patients who signed the informed consent

Non-randomized patients and reasons for non-randomized, if any;

Non-randomized but treated patients, if any

Randomized patients

Randomized but not treated patients and reason for not being treated; 

Randomized and treated patients

Patients who did not complete the study treatment period as per protocol;

Main reason for permanent treatment discontinuation;

Status at last study contact,
For all categories of patients (except for the non-randomized categories) percentages will be 
calculated using the number of randomized patients as the denominator.
Reasons for treatment discontinuation will be supplied in tables giving numbers and percentages 
by treatment group.
The incidence of premature treatment discontinuation (irrespective of the reason) and premature 
treatment discontinuation due to AEs will be presented graphically by treatment group on 
randomized and treated patients (as randomized), using Kaplan-Meier method.
All critical and major deviations potentially impacting efficacy analyses, randomization, and 
drug-dispensing irregularities, and other major deviations will be summarized in tables giving 
numbers and percentages of deviations by treatment group.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 26
Additionally, the following populations will be summarized by treatment group. Definition of the 
study populations are provided in Section 2.3.

Randomized population

Efficacy population: modified intent-to-treat (mITT) population/per-protocol population

Safety population

QOL population
2.2.1
Randomization irregularities
Randomization irregularities occur whenever:
1. A randomization is not in accordance with the protocol-defined randomization method, 
such as, a) a patient is randomized based on an incorrect stratum, b) a patient is 
randomized twice,
Randomization irregularities will be monitored throughout the study and reviewed on an ongoing 
basis.
All randomization irregularities will be documented in the clinical study report. These
irregularities will be summarized by treatment group on the randomized population. 
Non-randomized, treated patients will be described separately. 
Randomization irregularities to be prospectively identified include but are not limited to: 
Randomization irregularities
Patient randomized twice
Stratification error
2.3
ANALYSIS POPULATIONS
Patients treated without being randomized will not be considered randomized and will not be 
included in any analysis population. The safety experience of patients treated and not randomized 
will be reported separately.
Randomized population: includes all randomized patients as defined in Section 2.2.
For any patient randomized more than once, only the data associated with the first randomization 
will be used in any analysis population. The safety experience associated with any later 
randomization will be assessed separately.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 27
2.3.1
Efficacy populations
2.3.1.1
Modified intent-to-treat population 
The primary efficacy analysis population will be the modified intent-to-treat (mITT) population, 
defined as the randomized population who took at least one dose or part of dose of study drug, and 
has 2 analyzable normalized TAV, as defined below. 

One assessed before randomization

Another one assessed after 24 weeks of treatment.
Patients in the mITT population will be analyzed according to the treatment group allocated by 
randomization.
2.3.1.2
Per-protocol population
The per-protocol (PP) population is a subset of the mITT population excluding patients with any 
major protocol deviations that have significant impact on the primary study objective, analyzed 
according to the treatment actually received.
Major protocol deviations that do not cause exclusion from mITT population, but have significant 
impact on the primary study objective are as follows:

Poor adherence to the study protocol

IVUS not performed from Week 34 to Week 38 during efficacy treatment period, which is 
defined as the time from the day of randomization to the last study treatment 
administration + 21 days.

Patients with analyzed vessel length less than 10 mm.

Patients who do not meet the following inclusion criteria. 
-
Patient hospitalized for any ACS
-
LDL-C at patient selection (either Friedewald method or direct methods measured at 
each study site) ≥100 mg/dL for patients enrolled based on the protocol amendment 1;
≥70 mg/dL for patients enrolled based on the protocol amendment 2 or later.
-
Patient who undergoes IVUS imaging with at least >50% stenosis angiographically 
within 1 week after the ACS onset. The IVUS imaging should be performed in the 
culprit vessels with some levels of atherosclerosis/stenosis.
-
Patients aged ≥20 years old at ACS diagnosis.

Patients who meet the following exclusion criteria. 
-
Patient who has been previously treated with at least one dose of any anti-PCSK9 
monoclonal antibody.
-
Patient on LDL apheresis
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 28
-
Patient who has withdrawn consent before enrolment/randomization (starting from 
signed informed consent form).
2.3.2
Safety population
The safety population considered for the safety analyses will be the randomized population who 
actually received at least 1 dose or part of a dose of the study drug (alirocumab or standard of care). 
Patients will be analyzed according to the treatment actually received (i.e. as-treated treatment 
group, Standard of Care or Alirocumab). 
In addition: 

Non-randomized but treated patients will not be part of the safety population, but their 
safety data will be presented separately.

Randomized patients for whom it is unclear whether they took the study drug will be 
included in the safety population as randomized.

The treatment group allocation for “as-treated analysis” will defined as follows:
-
Alirocumab group if IMP injection proportion is ≥50%.
-
SoC group if IMP injection proportion is <50%.
IMP injection proportion (%) defined as 100 x (Number of IMP injection)/[ (the date of 
last study treatment administration -the date of randomization) /14 + 1]
2.3.3
Quality-of-life population
The analyses of QOL will be performed on all randomized and treated patients (safety population) 
with a baseline and at least 1 matching post-baseline evaluation for any of the 5 dimensions.
Patients will be analyzed according to the treatment actually received.
2.4
STATISTICAL METHODS
2.4.1
Demographics and baseline characteristics
Parameters described in Section 2.1.1 will be summarized by treatment group and overall using 
descriptive statistics.
Continuous data will be summarized using the number of available data, mean, standard 
deviation (SD), median, minimum, and maximum for each treatment group. First quartile (Q1) 
and third quartile (Q3) will be also provided for baseline IVUS parameters, lipid parameters, 
HbA1c, hs-CRP. Categorical and ordinal data will be summarized using the number and 
percentage of patients in each treatment group.
Unless otherwise specified, parameters will be summarized on the randomized population and
mITT population analyzed in the treatment arm to which they were randomized. Similar analyses 
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 29
will be done on the PP population (respectively safety population) in the treatment arm to which 
they are actually received if the size of the PP population (respectively safety population) is 
different (>10%) from the size of the mITT population (respectively randomized population) for 
any treatment group. In the randomized population and mITT population, parameters will also be 
summarized within each randomization strata as per the registration center and within each 
diabetic status at baseline.
All reported patient’s medical and surgical history and all ongoing reported patients’ these
histories at the start of study will be presented by primary SOC and HLT. The tables will be sorted 
by SOC internationally agreed order and decreasing frequency of HLT based on the overall 
incidence across treatment groups. In addition all medical history of specific interest will be 
presented by treatment group.
P-values comparing the 2 treatment groups on demographic characteristics, disease characteristics 
and other baseline characteristic data will be provided for descriptive purpose, as a screening tool, 
using the Fisher exact test for categorical data and Wilcoxon rank sum test for continuous data.
No specific description of the safety parameters will be provided at baseline. If relevant, the 
baseline values will be described along with each safety analysis.
2.4.2
Prior, concomitant or post-treatment medications
The prior, concomitant, and post-treatment medications will be presented for the randomized 
population.
Medications will be summarized by treatment group according to the WHO-DD dictionary, 
considering the first digit of the anatomic category (ATC) class (anatomic category) and the first 
3 digits of the ATC class (therapeutic category). All ATC codes corresponding to a medication 
will be summarized, and patients will be counted once in each ATC category (anatomic or 
therapeutic) linked to the medication. Therefore patients may be counted several categories for the 
same medication. 
The table for prior medications will be sorted by decreasing frequency of ATC followed by all 
other therapeutic classes based on the overall incidence across treatment groups. In case of equal 
frequency regarding ATCs (anatomic or therapeutic categories), alphabetical order will be used.
The tables for concomitant and post-treatment medications will be sorted by decreasing frequency 
of ATC followed by all other therapeutic classes based on the incidence in the alirocumab group.
In case of equal frequency regarding ATCs (anatomic or therapeutic categories), alphabetical order 
will be used. In addition all medications of specific interest will be presented by treatment group.
Details (ie, statin names, doses) for patients who had received at least 2 statins at the day of 
randomization (if any) will be listed.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 30
2.4.3
Extent of study treatment exposure and compliance 
The extent of study treatment exposure and compliance will be assessed and summarized by actual 
treatment within the safety population (Section 2.3.2).
2.4.3.1
Extent of investigational medicinal product exposure
The total exposure will be assessed by:

Duration of IMP exposure in weeks defined as: (last dose of IMP injection date – first dose 
of IMP injection date + 14 days) / 7, regardless of intermittent discontinuations (see 
Section 2.5.3 for calculation in case of missing or incomplete data);

The total number of IMP injections by patient.
These parameters will be summarized descriptively as a quantitative variable (number, mean, SD, 
median, minimum, and maximum). In addition, the durations of treatment exposure will be 
presented according to the following categories:  ≥1day to <4 weeks, ≥4 weeks to <12 weeks, 
≥12 weeks to <24 weeks, ≥24 weeks to <34 weeks, ≥34 weeks.
Titration
The following summaries will be provided in the alirocumab group:

The number (%) of patients with an up-titration to 150 mg at Week 14 as per kit number 
recorded in eCRF page” Praluent Administration”

The number (%) of patients with calculated LDL-C not achieving <100 mg/dL at Week 12
2.4.3.2
Compliance of investigational medicinal product exposure
Compliance of IMP will be assessed using the following parameters:

The mean injection frequency that will be defined for each patient as the average number 
of days between 2 injections, that is: (last dose date – first dose date) / (number of 
injections – 1).

The overall compliance for injections will be defined for each patient as: 100- (%days with 
under-planned dosing + %days with above-planned dosing). Under-planned and 
above-planned dosing will be defined as follows, considering that injections should be
performed every 2 weeks:

The % days with under-planned dosing will be defined for each patient as the number of
days with no injection administered within the previous 17 days divided by the duration of
IMP injection exposure in days. For example if a patient takes a dose 18 days after his/her
previous injection, then 1 day is counted as a day under-planned dosing.

The % days with above-planned dosing will be defined for each patient as the number of
days with more than one injection administered within the 11 days before divided by the
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 31
duration of IMP injection exposure in days. For example if a patient takes a dose 9 days
after his/her previous injection, then 2 days are counted as days above-planned dosing.
These parameters will be summarized descriptively (N, Mean, SD, Median, Minimum and
Maximum). In addition, the parameters will be presented according to the following 
categories:  <80%, ≥80%.
The percentage of patients whose overall compliance for injections is <80% will be also
summarized as well as numbers and percentages of patients with 0%, >0% and ≤5%, >5% and
≤10%, >10% and ≤20%, and >20% days with above-planned dosing and numbers and percentages
of patients with 0%, >0% and ≤5%, >5% and ≤10%, >10% and ≤20%, and >20% days with 
underplanned dosing.
Cases of overdose will be reported in AE e-CRF pages and described in the AE analysis defined in
Section 2.1.4.1.
2.4.3.3
Extent of non-investigational medicinal product exposure
NIMPs are assessed according to the following categories:

Statin (Atorvastatin, Rosuvastatin)

Non-statin LMT (Ezetimibe, Fibrate)

Anti-platelets

Anticoagulants
Statin and Non-statin LMT are selected using the eCRF tick box in Previous lipid modifying
therapy form or “Concomitant Non-investigational Medicinal Product”.
Anti-platelets and anticoagulants are selected using eCRF form “Concomitant Non-investigational 
Medicinal Product” and the specific coding list specified in Table 5.
The total exposure will be assessed by:

Duration of NIMP exposure in weeks defined as: (last NIMP administration date in study –
first NIMP administration date after randomization + 1 days) / 7, regardless of intermittent 
discontinuations (see Section 2.5.3 for calculation in case of missing or incomplete data).

If more than 1 NIMP in a category are taken, duration of exposure will be calculated using 
the earliest start date and the latest end date.
These parameters will be summarized descriptively as a quantitative variable (number, mean, SD, 
median, minimum, and maximum). In addition, the durations of treatment exposure will be 
presented according to the following categories:  ≥1day to <4 weeks, ≥4 weeks to <12 weeks, 
≥12 weeks to <24 weeks, ≥24 weeks to <34 weeks, ≥34 weeks.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 32
2.4.3.4
Compliance of non-investigational medicinal product exposure
Compliance for each NIMP medications is used Compliance/Adherence Rate in eCRF 
Concomitant Non-investigational Medicinal Product form.
For each category of NIMP defined the above, the percentage of patients with <50%, ≥50 % to 
<80%,  ≥80 % , and <80% compliance will be also summarized. If more than 1 NIMP in the 
category are taken or compliance of the medication was changed during the TEAE period, the 
lowest compliance should be used.
Details (i.e., all drug names, duration, compliance) for patients who had received at least 1 NIMP 
with <50% compliance (if any) will be listed.
2.4.4
Analyses of efficacy endpoints
2.4.4.1
Analysis of primary efficacy endpoint
The primary efficacy endpoint, percent change in normalized TAV from baseline to Week 36
defined in Section 2.1.3.1 will be analyzed in the mITT population using an analysis of covariance 
(ANCOVA) model with treatment group (SoC arm, Alirocumab arm) and randomization strata
(statin at ACS onset [Yes / No]), as fixed effects, and the baseline normalized TAV as covariate.
Throughout the ANCOVA model run using SAS Mixed procedure, Alirocumab group will be 
compared to SoC group at the two-sided 0.05 level for superiority, and baseline adjusted least 
squares means (LS means) estimates at Week 36 for each treatment group with their 
corresponding standard errors (SEs) and the 95% confidence interval (CI) of the difference
between treatment groups will be provided. 
Let μ0 and μ1 be the population means of the percent change in normalized TAV from baseline to 
Week 36 under SoC group and alirocumab group, respectively. The null hypothesis that will be 
tested is “
1
0
0 :


H
” versus “
1
0
1 :


H
”.
Main result of this study is the result using the primary analysis.
Model assumption checks
Treatment group-by-statin dose interaction:
A treatment group-by-randomization strata interaction term will be added in the primary 
ANCOVA model, and the Least Square Means Difference versus SoC group of alirocumab group 
will be provided, as well as the corresponding standard error and 95% confidence interval, within 
each randomization strata.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 33
Homogeneity of slope:
Given the low sample sizes in each treatment group, the homogeneity of slopes assumption will be
explored by means of the following outputs:

The treatment group-by-baseline normalized TAV interaction term will be added in the 
primary ANCOVA model and its significance level will be examined.

A separate-slopes model with terms for treatment group, randomization strata, and 
treatment group-by- baseline normalized TAV interaction will be fitted to the data, and the 
graph presenting the observed and predicted values by baseline normalized TAV values
will be provided. Predicted values within a same treatment group and randomization strata
will be joined to form the 2 twins of regression lines of the separate slopes model.

Within the framework of the above separate-slopes model, a graph presenting the Least
Square Means Difference of alirocumab arm versus SoC arm and the corresponding 95% 
confidence interval, by baseline normalized TAV value, will be provided.
Homogeneity of variance:
The homogeneity of variances will be checked by displaying the variance of the residuals within
each level of the treatment group. A scatter plot of predicted versus residual values will be also
provided.
Sensitivity analyses
A sensitivity analysis will be performed on randomized population to explore the potential impact 
of the missing post-baseline normalized TAV. This will include analyses using multiple 
imputation methods. Missing data will be imputed 100 times to generate 100 complete data sets, 
using SAS MI procedure. The MI procedure assumes that the data are from a continuous 
multivariate distribution and contain missing values that can occur on any value. Baseline 
normalized TAV and other baseline characteristics such as age, gender, weight, statin at ACS 
onset as randomization strata and laboratory markers (HDL-C, calculated LDL-C, fasting TGs) at 
baseline, diabetic status at baseline, and treatment group will be used in the imputation procedure. 
The imputation procedure will only be performed on the primary endpoint. The 100 complete data 
sets will be then analyzed using ANCOVA model above. Then the MIANALYZE procedure will 
be used to generate valid statistical inferences by combining results from the 100 analyses using 
Rubin’s formulae (5). Combined means estimates for both treatment groups, as well as the 
differences of these estimates, with their corresponding SEs, 95% CIs and p-value will be 
provided.
Supportive analyses
The primary efficacy endpoint will be analyzed on PP population to assess the effect due to major 
protocol deviation and/or premature discontinuation.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 34
Subgroup analyses (Stratified analyses)
To assess the homogeneity of the treatment effect across various subgroups, 
treatment group-by-subgroup factor interaction terms and a subgroup factor term will be added in 
the primary ANCOVA model. LS means difference versus SoC will be provided, as well as the
corresponding SE and 95% CI, within each subgroup. The significance level of the 
treatment group-by-subgroup factor interaction term will be also provided for each factor for
descriptive purpose. Forest plots will be provided. 
Subgroups of interest are (providing sufficient number of patients per subgroups):

Baseline normalized TAV(<Median, ≥ Median) for this specific subgroup factor, the 
ANCOVA model will include this categorical baseline instead of continuous baseline;

BMI (<25, ≥ 25 kg/m²);

Weight (<Median, ≥Median kg) ;

Gender;

Age (<65, ≥65 years);

Randomization strata as per registration center (With/Without statin at ACS onset);

Diabetic status at baseline (Yes, No);

Diabetic status at baseline relevant to insulin use (No diabetes, diabetes without insulin, 
diabetes with insulin);

Diabetic status at baseline relevant to time from diagnosis of diabetes (No diabetes, 
diabetes for <Median years, diabetes for ≥Median years);

Index ACS event (STEMI, NSTEMI, UA);

Prior ischemic stroke(Yes, No);

eGFR (<60, ≥60 mL/min/1.73m2) ;

eGFR (<30, ≥30 to <60, ≥60 mL/min/1.73m2); if sufficient number of patients in category   
≥ 30 to <60, then combine category  ≥ 30 to <60 and  ≥60; i.e. eGFR(<30, ≥30);

Baseline calculated LDL-C (<80, ≥80 to <100, ≥100 to <130, ≥130 to <160, ≥160 mg/dL)
(ie, <2.07, ≥2.07 to <2.59, ≥2.59 to <3.37, ≥3.37 to <4.14, ≥4.14 mmol/L);

Baseline calculated LDL-C (<100, ≥100 to <130, ≥130 to <160, ≥160 mg/dL) 
(ie, <2.59, ≥2.59 to <3.37, ≥3.37 to <4.14, ≥4.14 mmol/L);

Baseline HDL-C (<40, ≥40 mg/dL) (ie, <1.04, ≥1.04 mmol/L);

Baseline fasting TGs (<150, ≥150 mg/dL) (ie, <1.7, ≥1.7 mmol/L [mixed dyslipidemia]);

Baseline Lp(a) (<30, ≥30 to <50, ≥50 mg/dL) (ie, <0.3, ≥0.3 to <0.5, ≥0.5 g/L);

Baseline Lp(a) (<50, ≥50 mg/dL) (ie, <0.5, ≥0.5 g/L);

Baseline non-HDL-C (<110, ≥110 to <130, ≥130 mg/dL) (ie, <2.84, ≥2.84 to <3.37, 
≥3.37 mmol/L);
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 35

Baseline Apo B (<75, ≥75 to <90, ≥90 mg/dL) (ie, <0.75, ≥0.75 to <0.9, ≥0.9 g/L);

Baseline hs-CRP (<2, ≥2 mg/L);

Baseline HbA1c (<6.5, ≥6.5 %).
2.4.4.2
Analyses of secondary efficacy endpoints
Method for controlling the overall type-I error rate when testing the key secondary efficacy
endpoint is described in Section 2.4.4.3.
For the key secondary efficacy endpoint (defined inSection 2.1.3.2.1) and the other secondary
efficacy endpoints (described in Section 2.1.3.2.2), descriptive summaries and analyses will be
performed in the mITT population. 
For lipids parameters (calculated LDL-C, TC, HDL-C, fasting TGs, non-HDL-C, Apo B, Apo A-1, 
ApoB/Apo A-1 ratio, Lp(a), calculated LDL-C/HDL-C ratio, and fasting TGs/HDL-C ratio), all
measurements, scheduled or unscheduled will be assigned to analysis windows defined in 
Section 2.5.4.2, Table 4 in order to provide an assessment for time points. Laboratory assessments 
other than the ones provided by the central laboratory will be excluded. For TGs, measurements 
on not-fasting patients will be excluded. Analyses will be performed using standard international 
unit and conventional unit.
Continuous endpoints anticipated to have a normal distribution with only 1 post-baseline value 
collected
Continuous secondary endpoints anticipated to have a normal distribution (i.e., normalized TAV, 
PAV, Apo B, Apo A-1, Apo B/Apo A-1 ratio, fasting TGs/HDL-C ratio, calculated LDL-C/HDL-
C ratio) will be analyzed using the same ANCOVA model as for the primary endpoint with the 
continuous fixed covariates of corresponding baseline value.
Continuous endpoints anticipated to have a non-normal distribution with only 1 post-baseline 
value collected
Continuous secondary endpoints anticipated to have a non-normal distribution (i.e., lumen volume, 
EEM volume, TAV, Lp[a]) will be analyzed in the mITT population using a robust regression 
model (6) (i.e., ROBUSTREG SAS procedure with M-estimation option) with treatment group,
and randomization strata (statin at ACS onset [Yes / No]) as main effect and corresponding 
baseline value(s) as covariate. 
Continuous endpoints anticipated to have a normal distribution with multiple post-baseline 
values collected
Continuous secondary endpoints anticipated to have a normal distribution with multiple post-
baseline values collected (i.e., calculated LDL-C, TC, HDL-C, non-HDL-C) will be analyzed in 
the mITT population using a mixed-effect model with repeated measures (MMRM) approach. All 
post-baseline data available within Week 4, Week 12, Week 24, and Week 36 analysis windows 
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 36
will be used and missing data are accounted for by the MMRM model. The model will include the 
fixed categorical effects of treatment group (SoC group, Alirocumab group), time point (Week 4, 
Week 12, Week 24, and Week 36), randomization strata (statin at ACS onset [Yes / No]), 
treatment-by-time point interaction, randomization strata-by-time point interaction, as well as, the
continuous fixed covariates of corresponding baseline value and baseline value-by-time point 
interaction.
Continuous endpoints anticipated to have a non-normal distribution with multiple post-
baseline values collected
Continuous secondary efficacy endpoints anticipated to have a non-normal distribution (ie, TGs), 
will be analyzed in the mITT population using multiple imputation approach described in detail 
for handling of missing values, followed by the testing treatment groups using a robust regression 
model (6). Missing data will be imputed 100 times to generate 100 complete data sets, using the 
MI SAS procedure. The percent change from baseline at time point of interest will be then derived 
from observed and imputed lipid values at this time point. The 100 complete data sets will be then 
analyzed using a robust regression model with endpoint of interest as response variable using 
M-estimation (using SAS ROBUSTREG procedure) with treatment group, randomization strata
(statin at ACS onset [Yes / No]), and corresponding baseline value(s) as effects. Then the
MIANALYZE procedure will be used to generate valid statistical inferences by combining results
from the 100 analyses using Rubin’s formulae (5). Combined means estimates for both treatment
groups, as well as the differences of these estimates, with their corresponding SEs, 95% CIs and
p-value will be provided.
Multiple imputation model
Since in general the missing pattern is anticipated to be non-monotone, a two-step approach will
be used:

Step 1: The MCMC method will be used in conjunction with the IMPUTE=MONOTONE
option to create an imputed data set with a monotone missing pattern;

Step 2: Using the monotone data set from step 1, missing data will be imputed using the
regression method.
The imputation model for step 1 will include the treatment group and the values of the analyzed
parameter at baseline and all pre-specified time-points from baseline up to Week 36.
The imputation model for step 2 will include the same variables as in step 1 with the following
additional variables:

The randomization strata;

Age, BMI, and gender (age and BMI included as continuous variables).
Data will be log-transformed before imputation process and then back-transformed to create the
imputed data sets using the TRANSFORM statement of SAS MI procedure, since the distribution
is assumed non-normal.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 37
Non continuous variables included in the imputer’s model (ie, treatment group, randomization
strata and gender) are not expected to be missing.
Binary endpoints
Binary secondary endpoints defined in Section 2.1.3.2.2 (i.e. The proportion of patients with 
calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 36, The proportion of patients with 
calculated LDL-C <50 mg/dL (3.37 mmol/L) at Week 36., and The proportion of patients 
achieving at least 50% reduction in calculated LDL-C at Week 36) will be analyzed using multiple 
imputation approach for handling of missing values(See above for details about multiple 
imputation). In the imputations, log-transform process planned above will not be done for the lipid 
parameter assuming normal distribution. The binary endpoint at time point of interest will be 
derived from observed and imputed lipid values at this time point. Multiple imputation will be 
followed by stratified logistic regression with treatment group as main effect and corresponding 
baseline value(s) as covariate, stratified by randomization strata (as per registration center, as 
defined in Section 1.1). Combined estimates of odds ratio versus placebo, 95% CI, and p-value 
will be obtained through the SAS MIANALYZE procedure.
In the data dependent case such logistic regression is not applicable (eg, the response rate is zero
in 1 treatment arm and thus the maximum likelihood estimate may not exist), the last observation
carried forward (LOCF) approach would be used for handling of missing values and a stratified
exact conditional logistic regression would be performed to compare treatment effects. The LOCF
imputation method for the endpoints at Week 36 will consist of using the last value obtained up to 
the Week 36 analysis window to impute the missing Week 36 value.
In case of computing issues with exact logistic regression, the baseline level(s) will be entered in
the model as a categorical variable(s) using quartiles. In case the model would not converge with
stratification variables, an unstratified exact logistic regression will be performed. Exact odds
followed by logistic regression. In the data dependent case that the logistic regression method is 
not applicable (e.g., the response rate is zero in 1 treatment arm and thus the maximum likelihood 
estimate may not exist).
Descriptive summaries
For descriptive summaries (N, Mean, SD, Median, Minimum, Maximum, Q1 and Q3), raw value,
percentage change (except for ratio and PAV), and absolute change from baseline in IVUS and 
lipids parameters will be provided at each time point for each treatment group. The time profile of 
each parameter will be plotted by treatment group with the corresponding SDs. For IVUS 
parameters, TG, and Lp(a), the time profile of each parameter will be plotted using box whisker 
plot by treatment group. For calculated LDL-C, the same descriptive summaries will also be 
provided for the following patients:

Patients with up-titration;

Patients without up-titration;
together with the spaghettis plots corresponding to the summaries.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 38
In addition, for calculated LDL-C, TC, HDL-C, non-HDL-C, and fasting TG (in conventional 
(US) and international units), raw value, percent change from baseline, and/or when appropriate 
absolute change from baseline (in conventional and international units), will be summarized in the 
mITT population using:

For calculated LDL-C, TC, HDL-C, non-HDL-C: LS mean and SE for each treatment 
group, obtained from the same MMRM models as used for endpoints above and with raw 
values, absolute change from baseline, or percent change from baseline as response 
variable in the model as appropriate.

For fasting TG: mean and SE for each treatment group obtained from multiple imputation 
approach followed by the robust regression models as used for endpoints above and with 
raw values or percent changes from baseline as response variable in the model as 
appropriate.
Sensitivity analyses of key secondary efficacy endpoint
A sensitivity analysis of key secondary efficacy endpoint will be performed on randomized 
population as the same method as sensitivity analysis of primary efficacy endpoint described in 
Section 2.4.4.1, using the baseline PAV instead of baseline normalized TAV. 
Supportive analyses of secondary efficacy endpoints of IVUS parameters
The secondary efficacy endpoints of IVUS parameters will be analyzed on PP population to assess 
the effect due of major protocol deviation and/or premature discontinuation. Descriptive 
summaries of IVUS parameters will be also performed on PP population.
Analyses of secondary efficacy endpoints by subgroups
Subgroup analyses of the key secondary efficacy endpoint and percent change from baseline in
calculated LDL-C at Week 36 will be performed using the same subgroup factor and in the same 
way as in primary efficacy endpoint described in Section 2.4.4.1.
Subgroup analyses of the secondary efficacy endpoints of interest and subgroups of interest are the 
followings (providing sufficient number of patients per subgroups):

The secondary efficacy endpoint : percent change in Lp(a) from baseline to Week 36
-
Interest subgroup: Baseline Lp(a) (<30, ≥30 to <50, ≥50 mg/dL) (ie, <0.3, ≥0.3 to <0.5, 
≥0.5 g/L));

The secondary efficacy endpoint : percent change in fasting TGs from baseline to Week 36
-
Interest subgroup: Baseline fasting TGs (<150 mg/dL, ≥150 mg/dL) (ie, <1.7, ≥1.7
mmol/L [mixed dyslipidemia]);
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 39
2.4.4.3
Multiplicity issues
In order to handle the key secondary efficacy endpoint, the overall type-I error will be controlled 
by the use of a sequential inferential approach. Statistical significance of the primary efficacy 
endpoint at the 0.05 alpha level is required before drawing inferential conclusions about the key 
secondary efficacy endpoint (defined in Section 2.1.3.2.1). This fixed hierarchical approach will 
ensure a strong control of the overall type-I error rate at the 0.05 level.
No further adjustments will be made for other secondary endpoints other than key secondary 
endpoint for which p-values will be provided for exploratory purpose only (no claim).
2.4.5
Analyses of safety data
The summary of safety results will be presented by treatment group. 
General common rules
All safety analyses will be performed on the safety population as defined in Section 2.3.2, unless 
otherwise specified, using the following common rules:

Safety data in patients who do not belong to the safety population (eg, exposed but not 
randomized) will be listed separately;

The baseline value is defined as the last available value before randomization, unless
otherwise specified;

The potentially clinically significant abnormality (PCSA) values are defined as abnormal 
values considered medically important by the Sponsor according to predefined 
criteria/thresholds based on literature review and defined by the Sponsor for clinical 
laboratory tests, vital signs (PCSA defined in the document “Analysis and reporting safety
data from clinical trials through the Clinical Study Report (CSR) (Version Number: 3.0)”
[Appendix A])

PCSA criteria will determine which patients had at least 1 PCSA during the TEAE period, 
taking into account all evaluations performed during the TEAE period, including 
nonscheduled or repeated evaluations. 

The treatment-emergent PCSA denominator by group for a given parameter will be based 
on the number of patients assessed for that given parameter in the TEAE period by 
treatment group on the safety population.

All measurements, scheduled or unscheduled, fasting or not fasting, will be assigned to 
analysis windows defined in Section 2.5.4.2, Table 4.

For quantitative safety parameters, descriptive statistics will be used to summarize results 
and change from baseline values by visit and treatment group using analysis windows 
defined in Section 2.5.4.2, Table 4. Summaries will include the last on-treatment value and 
the worst on-treatment value. The worst value is defined as the nadir and/or the peak value 
during the treatment period according to the direction (minimum or maximum) of the 
abnormality as defined in the PCSA list.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 40
Analyses performed according to diabetic status will be done using the CMQ definition 
(regardless of the ongoing status) (Section 2.1.1).
2.4.5.1
Analyses of adverse events
Generalities
The primary focus of AE reporting will be on TEAEs. Pre-treatment and post-treatment AEs will 
be described separately.
If an AE date/time of onset (occurrence, worsening, or becoming serious) is incomplete, an 
imputation algorithm will be used to classify the AE as pre-treatment, treatment-emergent, or 
post-treatment. The algorithm for imputing date/time of onset will be conservative and will
classify an AE as treatment-emergent unless there is definitive information to determine it is 
pre-treatment or post-treatment. Details on classification of AEs with missing or partial onset 
dates are provided in Section 2.5.3.
AE incidence tables will present, the number (n) and percentage (%) of patients experiencing an 
AE by SOC, HLGT (when applicable), HLT (when applicable), and PT. Multiple occurrences of 
the same event in the same patient will be counted only once in the tables within a treatment phase.  
The denominator for computation of percentages is the safety population within each treatment 
group.
Sorting within tables ensures the same presentation for the set of all AEs within the observation
period (pre-treatment, TEAE, and post-treatment). For that purpose, the table of all TEAEs
presented by SOC and PT sorted by the internationally agreed SOC order and decreasing
frequency of PTs within SOCs (in the alirocumab group) will define the presentation order for all 
other tables by SOC and PT, unless otherwise specified. The tables of AEs by SOC, HLGT, HLT 
and PT will be sorted by the SOC internationally agreed order and the other levels (HLGT, HLT, 
and PT) will be presented in alphabetical order, unless otherwise specified
Analysis of all treatment-emergent adverse events
The following TEAE summaries will be generated for the safety population.

Overview of TEAEs, summarizing number (%) of patients with any:
-
TEAE;
-
Treatment emergent serious adverse event (SAE);
-
TEAE leading to death;
-
TEAE leading to permanent treatment discontinuation.

All TEAEs by primary SOC, HLGT, HLT, and PT, sorted by the SOC internationally 
agreed order. The other levels (HLGT, HLT, and PT) will be presented in alphabetical 
order;
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 41

All TEAEs regardless of relationship and related to IMP by primary SOC, HLGT, HLT, 
and PT, sorted by the internationally agreed SOC order. The other levels (HLGT, HLT,
and PT) will be presented in alphabetical order;

All TEAEs regardless of relationship and related to LMT-NIMP by primary SOC, HLGT, 
HLT, and PT, sorted by the internationally agreed SOC order. The other levels (HLGT, 
HLT, and PT) will be presented in alphabetical order;
-
AE related to LMT-NIMP is defines all AEs checked “Related” in 
“Atorvastatin/Rosuvastatin?” or “Lipid Modifying Therapy?” on the adverse event 
case report form page. 

All TEAEs regardless of relationship and related to LMTs by primary SOC, HLGT, HLT, 
and PT, sorted by the internationally agreed SOC order.  The other levels (HLGT, HLT, 
PT) will be presented in alphabetical order;
-
AE related to LMTs is defines all AEs checked “Related” in “IMP/Praluent?”,or 
“Atorvastatin/Rosuvastatin?”, or “Lipid Modifying Therapy?” on the adverse event 
case report form page. 

All TEAEs by primary SOC and PT, sorted by the internationally agreed SOC order and by 
decreasing incidence of PTs within each SOC (in the alirocumab group).  This sorting 
order will be applied to all other tables by SOC and PT of TEAEs, unless otherwise 
specified.

The frequency of AEs by SOC/PT and selected AEs over time during TEAE period 
(number of patients experiencing AE and percentage by patient-months) will be provided 
by time intervals defined as: ≤12 weeks, >12 to ≤24 weeks, >24 weeks using the actuarial 
method. Only the first event will be counted. Those intervals will be calculated from the 
randomization.

All TEAEs that occurred with HLT incidence ≥2% in any treatment group, by primary 
SOC, HLT, and PT, sorted by internationally agreed SOC order and by alphabetic order for 
the other levels (HLT and PT);

All TEAEs by maximal intensity (ie, mild, moderate, or severe), presented by primary 
SOC and PT.
Analysis of all treatment emergent serious adverse event(s)

All treatment-emergent SAEs by primary SOC, HLGT, HLT, and PT, sorted by the 
internationally agreed SOC order. The other levels (HLGT, HLT, and PT) will be 
presented in alphabetical order;

All treatment-emergent SAEs regardless of relationship and related to IMP, by primary 
SOC, HLGT, HLT, and PT, sorted by the internationally agreed SOC order.  The other 
levels (HLGT, HLT, and PT) will be presented in alphabetical order.

All treatment-emergent SAEs regardless of relationship and related to LMT-NIMP, by 
primary SOC, HLGT, HLT, and PT, sorted by the internationally agreed SOC order. The 
other levels (HLGT, HLT, and PT) will be presented in alphabetical order.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 42

All treatment-emergent SAEs regardless of relationship and related to LMTs, by primary 
SOC, HLGT, HLT, and PT, sorted by the internationally agreed SOC order. The other 
levels (HLGT, HLT, and PT) will be presented in alphabetical order.

All treatment-emergent SAEs by primary SOC and PT.
Analysis of all treatment-emergent adverse event(s) leading to treatment discontinuation

All TEAEs leading to treatment discontinuation, by primary SOC, HLGT, HLT, and PT, 
sorted by the internationally agreed SOC order.  The other levels (HLGT, HLT, and PT) 
will be presented in alphabetical order.

All TEAEs leading to treatment discontinuation by primary SOC and PT;
Analysis of groupings of adverse events including selected adverse events of special interest
All grouping of TEAEs including adverse events of special interest as listed in Section 2.1.4.1 will
be analyzed using selections defined in Section 2.1.4.1 and will be presented by SMQ and PT 
(when selection is based on SMQs) and by SOC and PT (when selection is based on the e-CRF 
tick box or HLGT/HLT). The summaries will be sorted by decreasing incidence of PT within each 
SOC/SMQ (in the alirocumab group).
Analyses of grouping of AEs for diabetes (Section 2.1.4.1) will be performed overall and 
according to the diabetic status at baseline (Section 2.1.1).
In addition, the following variables will be tabulated for the local injection site reactions TEAEs:

Intensity of the event (mild, moderate, severe);

Number of events divided by the number of IMP injections received;

Time from randomization to first injection site reaction;

Description of the highest intensity of each symptom recorded in the specific e-CRF page 
with table and bar chart.
Besides, description of symptoms and possible etiologies for General Allergic Reaction TEAE 
reported by investigator (using the tick box), will be presented.
Analysis of cardiovascular events
Adjudication results of treatment-emergent CV events will be summarized. 
Analysis of pre-treatment and post-treatment adverse events

All pre-treatment adverse events by primary SOC and PT sorted by the internationally 
agreed SOC order and decreasing incidence of PTs within each SOC;

All pre-treatment adverse events leading to treatment discontinuation (if any) by primary 
SOC and PT, sorted by the internationally agreed SOC order and decreasing incidence of 
PTs within each SOC;
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 43

All post-treatment adverse events by primary SOC and PT, sorted by the internationally 
agreed SOC order and decreasing incidence of PTs within each SOC;

All post-treatment SAEs by primary SOC and PT, sorted by the internationally agreed 
SOC order and decreasing incidence of PTs within each SOC.
Subgroup of patients with 2 consecutive LDL-C <25 mg/dL
If applicable, similar summaries of TEAEs as those described above will be also provided on the 
safety subgroup population of patients with 2 consecutive results of calculated LDL-C <25 mg/dL 
(as defined in Section 2.1.5.3) . Only TEAE for which it will be confirmed or unclear that they 
occurred, worsened or became serious the day or after the first level of calculated LDL-C <25 
mg/dL will be considered.
Analysis of AESI including neurocognitive and neurological events and cataract (see selections in
Section 2.1.4.1) will also be provided on the safety subgroup population of patients with 2 
consecutive results of calculated LDL-C <25 mg/dL (as defined in Section 2.1.5.3).
2.4.5.2
Deaths
The following summaries of deaths will be generated for the safety population.

Number (%) of patients who died by study period (on-study, on-treatment, post-study) and 
reasons for death adjudicated by the CEC

Deaths in non-randomized patients or randomized but not treated patients

Treatment-emergent adverse events leading to death (death as an outcome on the adverse 
event case report form page as reported by the Investigator) by primary SOC , HLGT, 
HLT, and PT showing number (%) of patients sorted by internationally agreed SOC order,
with HLGT, HLT, and PT presented in alphabetical order within each SOC . 
2.4.5.3
Analyses of laboratory variables 
Descriptive statistics over time
The summary statistics (including number, mean, median, Q1, Q3 standard deviation, minimum, 
and maximum) of all laboratory variables (central laboratory values and changes from baseline) 
will be calculated for each visit or study assessment (baseline, each post-baseline time point, last
on-treatment and worst on-treatment value) by treatment group during the treatment period.
For glucose, this summary will be also provided according to the diabetic status at baseline. Only 
fasting samples will be summarized.
In addition, for some parameters of interest, mean changes from baseline with the corresponding 
standard error could be plotted over time in each treatment group.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 44
Potentially clinically significant abnormalities
The incidence of PCSAs (list provided in Appendix A) as well as ALT increase as defined as 
AESI and hemoglobin decrease from baseline ≥15 g/L at any time during the TEAE period will be 
summarized by biological function (specified in Section 2.1.4.3) and treatment group whatever the 
baseline level and/or according to the following baseline status categories:

Normal/missing;

Abnormal according to PCSA criterion or criteria.
For glucose, this summary will also be provided according to the diabetic status at baseline. Only 
fasting samples will be summarized.
For parameters for which no PCSA criteria are defined, similar table(s) using the normal range 
will be provided.
Hepatitis C
The number and percentage of patients with a post-baseline seroconversion for hepatitis C test 
will be provided by treatment group in post-baseline (including the TEAE and post TEAE 
periods). Post-baseline seroconversion is defined for patients with a negative baseline status who 
had either a “positive ribonucleic acid” (RNA) or a “confirmed positive antibody with negative 
RNA” post-baseline status as defined in the table below. Other situations require case by case 
evaluation and will be described individually if relevant.
The status as regards to hepatitis C virus (HCV) for a patient will be defined as follows for all 
evaluations (baseline and post-baseline).
Table 2 - Definition of the patient status regarding hepatitis C virus
Hepatitis C Antibody test result
Negative
Positive
Reflexive testa –
hepatitis C RNA test
Not available or HCV 
RNA not detected
HCV RNA 
detected
HCV RNA not 
detectedb
HCV RNA 
detected
Not available 
Hepatitis C status -
label
Negative
Positive RNA
Negativeb
Positive RNA
Positive Ab – no 
RNA available
a
Test performed at the same time or after the antibody test in the pre-treatment period (for baseline evaluation), or post-baseline, respectively
b
For post-baseline evaluation, a second antibody test with a different type of assay is to be done at the same date or after the first antibody 
test. The result of this test will modify the final hepatitis C status of the patient in some cases (see details in the text below the table)
The baseline evaluation will be based on tests performed during the pre-treatment period.
In case of multiple hepatitis C tests available for the post-baseline evaluation, the positive status of 
the patient will be defined as follows:

“Positive RNA” status if at least 1 post-baseline positive RNA is detected, regardless of 
status of the patient at the end of treatment.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 45

Else “Positive Ab – no RNA available” status if no post-baseline reflexive RNA test is 
available for at least 1 post-baseline positive antibody test.
If no antibody test is available or with “indeterminate” as result pre-treatment or post-baseline, 
respectively, the RNA test (if available) will be used alone to determine the status of the patient. If 
no RNA is available then the hepatitis C status of the patient will be missing.
The post-baseline status “confirmed positive antibody with negative RNA” will replace
“Negative” status as defined above in the case where no RNA was detected post-baseline and the 
2 antibody tests surrounding the same visit (from 2 different types of assay) are positive.
For a conservative approach, the post-baseline status “Positive Ab – no RNA available” will not 
be modified by the availability of a second antibody test from a different assay.
Possible drug-induced liver injury
The liver function tests, namely AST, ALT, alkaline phosphatase, and total bilirubin, are used to 
assess possible drug-induced liver toxicity.  The proportion of patients with PCSA values at any 
post-baseline visit by baseline status will be displayed by treatment group for each parameter.
A graph of distribution of peak values of ALT versus peak values of total bilirubin will also be 
presented. Note that the ALT and total bilirubin values are presented on a logarithmic scale. The 
graph will be divided into 4 quadrants with a vertical line corresponding to 3 x ULN for ALT and 
a horizontal line corresponding to 2 x ULN for total bilirubin.
Graph and listing of possible Hy’s law cases identified by treatment group (eg, patients with any 
elevated ALT>3 x ULN, and associated with an increase in bilirubin ≥2 x ULN) with ALT, AST, 
alkaline phosphatase, total bilirubin, and, if available, direct and indirect bilirubin, will be 
provided.
2.4.5.4
Analyses of vital sign variables
The summary statistics (including number, mean, median, Q1, Q3, standard deviation, minimum,
and maximum) of all vital sign variables (values and changes from baseline) will be calculated for 
each visit or study assessment (baseline, each post-baseline time point, last on-treatment and worst 
on-treatment value) by treatment group during the treatment period.  In addition, for some 
parameters of interest, mean changes from baseline with the corresponding standard error could be 
plotted over time in each treatment group.
Vital signs without position filled in will only be used for the PCSA analysis described below.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 46
The incidence of PCSAs at any time during the TEAE period will be summarized by treatment 
group.
2.4.6
Analysis of other endpoints
All measurements, scheduled or unscheduled, fasting or not fasting, will be assigned to analysis 
windows defined in Section 2.1.5.
2.4.6.1
Analyses of hs-CRP
hs-CRP parameter (values and percent change from baseline) will be summarized on the safety 
population by analysis visit using number of available data, mean, SD, median, Q1, Q3, minimum, 
and maximum for each treatment group during the treatment period. The time profile will be 
plotted by treatment group with the medians, Q1 and Q3. The incidence of PCSA at any time 
during the TEAE period will be summarized by treatment group using descriptive statistics.
hs-CRP values greater or equal to 10 mg/L will be excluded from analyses in a second approach, 
since these are suggestive of concurrent infections.
2.4.6.2
Analyses of HbA1c
HbA1c parameter (values and change from baseline) will be summarized on the safety population 
by analysis visit using number of available data, mean, SD, median, Q1, Q3, minimum, and 
maximum for each treatment during the treatment period. Summary will be also provided 
according to the diabetic status at baseline (see Section 2.1.1). The time profile will be plotted by 
treatment group with the means and the corresponding standard errors (SEs). The incidence of 
PCSA at any time during the TEAE period will be summarized by treatment group using 
descriptive statistics.
2.4.6.3
Analyses of patients with LDL-C <25 mg/dL (<0.65 mmol/L)
The number and percentage of patients with 2 consecutive LDL-C <25 mg/dL (respectively, 
LDL-C <15 mg/dL, ie, 0.39 mmol/L) will be provided by treatment group on the safety 
population. Kaplan-Meier curves will be provided for the time to the first LDL-C <25 mg/dL 
(respectively 15 mg/dL) for these patients. For this analysis, patients without post-baseline LDL-C 
result or with only 1 post-baseline LDL-C result will not be included.
2.4.7
Analyses of quality of life/health economics variables
The analysis of data from EQ-5D instrument will be performed on QOL population. Baseline is 
defined as the visit 1 (Week 0) evaluation. Analysis window for efficacy parameters will be used 
to assign time points (see Section 2.5.4.2, Table 4).
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 47
Individual EQ-5D items
Response for each one of the 5 EQ-5D items will be summarized by visit for each treatment group 
using tables which will contain frequency and proportion of the population reporting level 1 (no 
problems), level 2 (some problems), and level 3 (extreme problems) by item and treatment group.
EQ-5D utility score
The raw value and the absolute change from baseline of the utility score will be summarized using 
mean, median, Q1, Q3, SD, minimum, and maximum for each post-baseline visit. Cumulative 
distribution functions for the absolute change in utility score from baseline will be displayed by 
treatment groups, at Week 4, Week 12, Week 24, and Week 36.
The absolute change from baseline in utility score to Week 4, Week 12, Week 24, and Week 36
will be analyzed using a MMRM model with fixed categorical effects of treatment group, 
randomization strata as per the registration center, treatment-by-time point interaction, 
strata-by-time point interaction, as well as, the continuous fixed covariates of baseline value and 
baseline value-by-time point interaction.
2.5
DATA HANDLING CONVENTIONS
2.5.1
General conventions
The following formulas will be used for computation of parameters.
Time
1 month = 30.4375 days,
1 year = 365.25 days.
Age
Age (years) = (Date of ACS diagnosis – Date of birth) / 365.25.
Age will be rounded using SAS INT function. In case date of ACS diagnosis and date of birth 
have the same month and day, then Age = year of ACS diagnosis – Year of birth.
BMI
BMI (kg/m2) = weight (kg)/ height (m)/ height (m).
For reporting such as Patients Profiles, or Listing of validation, the value will be rounded with 2 
significant digits. But for calculating the summary, it will not be rounded.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 48
Time from index ACS diagnosis to randomization
Time from index ACS diagnosis to randomization (weeks) = (Date of randomization – Date of 
index ACS diagnosis) / 7.
Time from revasculization procedure to randomization
Time from revascularization procedure to randomization (weeks) = (Date of randomization – Date 
of revasculization procedure) / 7.
Time from diagnosis
Time from diagnosis (years) = (Date of informed consent – Date of diagnosis*) / 365.25.
(*):  In case the month of diagnosis would be missing, it will be put equal to JANUARY if the 
year of diagnosis equals the year of informed consent; it will be put equal to JUNE otherwise. In 
case that the day of the date is missing, the day will be put equal to "1st".
Calculated LDL-C using the Friedwald formula
calculated LDL-C(mg/dL) = TC – HDL-C – TGs/5
If TG values exceed 400 mg/dL (4.52 mmol/L), then calculated LDL-C will be missing.
Conversion to standard international unit
Should not be rounded at the time of calculation for conversion to standard international unit.
Date of last administration of study treatment
The date of the last administration is equal to the last date of administration reported on the end-of 
treatment case report form page, or missing if the last administration date is unknown. 
Renal function formulas
eGFR value will be derived using the Japanese equation:
194 x (serum creatinine in mg/dL )-1.094 x (age in years)-0.287 (x 0.739 if female). Serum creatinine
rounded off to two decimal places will be used.
Lipid variables, laboratory safety variables, hs-CRP
For data below the lower limit of quantification (LLOQ)/limit of linearity, half of the lower limit 
value (i.e; LLOQ/2) will be used for quantitative analyses. For data above the upper limit of 
quantification (ULOQ) / limit of linearity, the upper limit value (ie, ULOQ) will be used for 
quantitative analyses.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 49
2.5.2
Data handling conventions for secondary efficacy variables
See Section 2.1.3.
2.5.3
Missing data
For categorical variables, patients with missing data are not included in calculations of 
percentages unless otherwise specified. When relevant, the number of patients with missing data 
is presented.
Handling of computation of treatment duration and compliance if IMP or NIMP first or end of 
treatment date is missing
If the last or first administration date is missing, the exposure duration and compliance will be 
used theoretical date.
Handling of medication missing/partial dates
No imputation of medication start/end dates or times will be performed. If medication date or time 
is missing or partially missing and it cannot be determined whether it was taken prior or 
concomitantly, it will be considered a prior, concomitant, and post-treatment medication, unless 
otherwise specified.
Handling of adverse events with missing or partial date/time of onset
Missing or partial AE onset dates and times will be imputed so that if the partial AE onset 
date/time information does not indicate that the AE started prior to treatment or after the TEAE 
period, the AE will be classified as treatment-emergent.  No imputation of AE end dates/times 
will be performed. These data imputations are for categorization purpose only and will not be used 
in listings.  No imputation is planned for date/time of adverse event resolution.
Handling of adverse events when date and time of first administration is missing
The exposure duration should be kept as missing.
Handling of missing assessment of relationship of adverse events to IMP
If the assessment of the relationship to IMP is missing for an adverse event, the adverse event will 
be considered as related to the IMP in the tables of possibly related adverse events, but no 
imputation will be done at the data level
Handling of missing assessment of relationship of adverse events to LMTs
If the assessment of the relationship to LMTs is missing for an adverse event, the adverse event 
will be considered as related to the LMTs in the tables of possibly related adverse events, but no 
imputation will be done at the data level
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 50
Handling of missing assessment of relationship of adverse events to LMT-NIMP
If the assessment of the relationship to LMT-NIMP is missing for an adverse event, the adverse 
event will be considered as related to the LMT-NIMP in the tables of possibly related adverse 
events, but no imputation will be done at the data level
Handling of potentially clinically significant abnormalities
If a patient has a missing baseline value, he/she will be grouped in the category “normal/missing at 
baseline.”
For PCSAs with 2 conditions, one based on a change from baseline value or a normal range and 
the other on a threshold value, with the first condition being missing, the PCSA will be based only 
on the second condition.
For a PCSA defined on a threshold and/or a normal range, this PCSA will be derived using this 
threshold if the normal range is missing (e.g., “>0.5 GIGA/L” criterion will be used for 
eosinophils for the PCSA “>0.5 GIGA/L or >ULN if ULN ≥0.5 GIGA/L” when ULN is missing.
Measurements flagged as invalid by the laboratory will not be summarized or taken into account 
in the computation of PCSA values.
2.5.4
Windows for time points
2.5.4.1
Time points for IVUS and OCT variables
Data analyzed by time point for IVUS and OCT variables will be summarized using the analysis 
window given in Table 3. This analysis window will be applicable for all analyses, and they are 
defined to provide more homogeneous data for time point-specific analyses.
Table 3 - Analysis windows definition
Time point
Targeted study day
Analysis window in study days
Week 36
253
≥169
Study days are calculated from the day of randomization, the day of randomization being Day 1. 
2.5.4.2
Time points for data except OCT and IVUS variables
Data analyzed by time point for all variables except OCT and IVUS variables will be summarized 
using the analysis windows given in Table 4. These analysis windows will be applicable for all 
analyses, and they are defined to provide more homogeneous data for time point-specific analyses.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 51
Table 4 - Analysis windows definition
Time point
Targeted study day
Analysis window in study days
Week 4
29
15 to 42
Week 12
85
78 to 98
Week 24
169
155 to 182
Week 36
253
239 to 266
Study days are calculated from the day of randomization, the day of randomization being Day 1. 
If multiple valid values of a variable exist within an analysis window, the nearest from the 
targeted study day will be selected. If the difference is a tie, the value after the targeted study day 
will be used. If multiple valid values of a variable exist within a same day, then the first value of 
the day will be selected when time is available, else the scheduled visit will be selected.
2.5.5
Unscheduled visits
For IVUS data, OCT data, lipid data, QOL, safety laboratory data, or vital signs, unscheduled visit 
measurements may be used to provide a measurement for a time window, a baseline, a time point, 
or a worst value, if appropriate according to their definition. The measurements may also be used 
to determine abnormal/PCSA values.
2.5.6
Pooling of centers for statistical analyses
The randomization scheme was not stratified by center because the number of patients in some 
center is expected to be low. Therefore, the center will not be added as factor in the primary 
analysis model.
2.5.7
Statistical technical issues
Not applicable.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 52
3
INTERIM ANALYSIS
No interim analysis is planned.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 53
4
DATABASE LOCK
The database is planned to be locked at 2 months after last patient last visit.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 54
5
SOFTWARE DOCUMENTATION
All summaries and statistical analyses will be generated using SAS version 9.4 or higher.
(electronic 
 
 
 
2.0)


Statistical Analysis Plan
11-Oct-2018
ALIROL08069 - alirocumab
Version number: 2
Property of the Sanofi Group - strictly confidential
Page 55
6
REFERENCES
1. Nakajima N, Miyauchi K, Yokoyama T, Ogita M, Miyazaki T, Tamura H, et al. Effect of
combination of ezetimibe and a statin on coronary plaque regression in patients with acute
coronary syndrome ZEUS trial (eZEtimibe Ultrasound Study). IJC Metabolic & Endocrine
2014;3: 8-13.
2. Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, et al. Impact of
dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in
patients with percutaneous coronary intervention. J Am Coll Cardiol 2015; 66: 495-507.
3. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al.
Markers of inflammation and cardiovascular disease: application to clinical and public health
practice: A statement for healthcare professionals from the Centers for Disease Control and
Prevention and the American Heart Association. Circulation. 2003 Jan 28;107(3):499-511.
4. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997 Nov;35(11):1095-
108.
5. SAS Institute Inc. 2009. SAS/STAT® 9.2 User’s Guide. 2nd Ed. Cary, NC: SAS Institute Inc.
6. Mehrotra DV, Li X, Liu J, Lu K. Analysis of longitudinal clinical trials with missing data
using multiple imputation in conjugation with robust regression. Biometrics. 2012;68(4):1250-
9.
(electronic 2.0)